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Abstract  
Chronic schizophrenia (ScZ) is associated with impaired gamma oscillations, 
reflected by robust alterations in 40 Hz ASSR. Oscillatory deficits may arise from 
changes in the cortical E/I-balance. However, it is unclear whether aberrant 
oscillations and potential underlying mechanisms are present also in early and 
clinical high risk (CHR) stages of psychosis. 
In this thesis, data from a multimodal CHR study were used to explore auditory 
oscillatory alterations in CHR individuals, assessed using MEG-recorded 40 Hz 
Auditory Steady State Response (ASSR) measures, with the aim to establish how 
deficits may account for early alterations in neural circuits in emerging 
psychosis. To further map such changes, a group of first episode of psychosis 
(FEP) participants were also studied, and oscillatory measures were compared 
with H1-MRS measures of neurotransmitter levels as well as with clinical 
measures.  
The thesis first presents a meta-analysis of ASSR findings in ScZ so far, showing 
that the response is impaired in chronic patients. Each of the following four 
chapters respectively present separate data analyses, focusing on baseline ASSR 
data, connectivity analyses, proton magnetic resonance spectroscopy (1H-MRS) 
analyses, and data assessing longitudinal outcomes.  
Through these investigations, the thesis demonstrates impairments in RSMG 40 
Hz spectral power and ITPC in CHR and FEP, with bidirectional connectivity 
impairments present between RSMG and primary auditory cortex in CHR 
participants. In addition, strong beta frequency reductions in power were 
observed in CHR and FEP participants relative to controls. No clear impairments 
were detected in 1H-MRS data, but a trend deficit in right auditory GABA levels 
was seen in FEP patients. Finally, investigations of longitudinal parameters 
revealed that RSMG oscillatory impairments are related to functioning at the 
time of scanning, but not to functioning at the one-year follow-up. Moreover, 
beta frequency power was found to be selectively impaired in individuals with 
sustained CHR symptoms and low GAF scores (at both baseline and 12 months). 
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Combined, the results of this thesis provide evidence for complex, subtle neural 
circuit alterations in emerging psychosis, which can be captured non-invasively 
using the 40 Hz ASSR paradigm.  
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Chapter 1 A General Introduction to 
Schizophrenia and Psychosis Risk States 
1.1 Aim  
Schizophrenia (ScZ) patients show robust impairments in neural oscillations 
(Uhlhaas & Singer, 2011; Uhlhaas & Singer, 2010), thought to reflect changes in 
the cortical excitation/inhibition (E/I) balance. Neural oscillations arise from the 
interaction between excitatory glutamatergic and inhibitory GABAergic signals 
(Bartos, Vida, & Jonas, 2007) and appear to play an important role in both 
cognitive and sensory functions (Fries, 2015; Siegel, Donner, & Engel, 2012; 
Ward, 2003). Thus, the oscillatory impairments in ScZ may reflect a core 
pathophysiological mechanism that could account for the severe cognitive and 
sensory dysfunctions in the disorder (Shin, O’Donnell, Youn, & Kwon, 2011; 
Uhlhaas & Singer, 2010).  
The 40 Hz auditory steady state response (ASSR) is an oscillatory measure 
assessed using electroencephalography (EEG) or magnetoencephalography 
(MEG), which is impaired in chronic ScZ patients (Thuné, Recasens, & Uhlhaas, 
2016). Likewise, magnetic resonance spectroscopy (1H-MRS) measures of 
glutamate and GABA have indicated altered E/I-balance in ScZ patients 
(Wijtenburg, Yang, Fischer, & Rowland, 2015). However, a direct link between 
the 40 Hz ASSR-deficits and alterations in GABAergic/Glutamatergic transmission 
has not been systematically explored. Furthermore, it is still unclear whether 
the 40 Hz ASSR could be a candidate marker for the detection of first-episode 
psychosis (FEP), or even participants at clinical high risk (CHR) for the 
development of ScZ, since it is unknown when 40 Hz ASSR impairments first 
emerge. 
The available data from early-stage psychosis remain limited compared to the 
chronic ScZ literature. So far, one group has explored the 40 Hz ASSR in CHR 
individuals (Koshiyama et al., 2018a; Tada et al., 2016). Moreover, several 
groups have reported measures of GABA and glutamate levels in CHR samples 
(Bossong et al., 2018; Fuente-Sandoval, Leon-Ortiz, Favila, Stephano, & Mamo, 
2011; Fuente-Sandoval et al., 2016; Fusar-Poli et al., 2011; Menschikov et al., 
2016; Modinos, Şimşek, et al., 2018; Natsubori et al., 2014; N. Tandon et al., 
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2013; Wood et al., 2010; Yoo et al., 2009), but to the author’s knowledge 
nobody has yet attempted to look directly at the relationship between these 
measures in CHR. 
Hence, the overarching aim of this thesis is to explore neuromagnetic 40 Hz ASSR 
and 1H-MRS measures of cortical GABA and Glx (Glutamate + Glutamine) in a 
large cohort of CHR individuals, with the objective to identify the nature of 
potential early oscillation and E/I changes. The a priori hypotheses were based 
on findings in ScZ populations: 
1. CHR individuals will show reduced 40 Hz ASSR power and inter-trial phase 
coherence (ITPC) compared to healthy controls.  
2. CHR individuals will show altered network connectivity compared to 
healthy controls. 
3. CHR individuals will show impaired balance between Glx and GABA 
compared to healthy controls.  
In addition, an FEP group was included in the analyses to allow comparisons with 
CHRs and controls, and to replicate previous FEP findings. CHR participant 
measures were hypothesised to be intermediate between controls and FEPs, with 
the FEP patients showing more pronounced impairments. 
Furthermore, the relationship of oscillatory and neurochemical measures with 
psychological and neurocognitive data was explored, with the aim to establish if 
and how cortical oscillatory data may reflect clinical characteristics. 
The following introductory sections serve to provide an overview of ScZ, focusing 
particularly on the postulated role of gamma oscillations and their association 
with the cortical E/I balance.  
1.2 ScZ Prevalence  
ScZ is a severe psychotic disorder with a typical age of onset in late adolescence 
or early adulthood (McGrath et al., 2016). Compared to women, men have an 
Chapter 1 
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earlier onset of approximately 4-5 years (Angermeyer & Kühn, 1988). The life-
time prevalence is estimated to be approximately 1% worldwide (Millan et al., 
2016) with highest prevalence among males, in urban areas and migrant 
communities (McGrath et al., 2004), highlighting the complex influence of social 
and environmental factors on the disorder. 
Psychotic disorders, such as ScZ, are associated with substantial economic costs 
(Gustavsson et al., 2011). In Europe alone, ScZ and other psychotic disorders 
cost € 93.9 billion in 2010 (Gustavsson et al., 2011). These costs are explained by 
the long-term functional impairment experienced by ScZ patients, resulting in 
productivity loss and the need for continuous treatment and healthcare support 
(Jin & Mosweu, 2017).   
Moreover, the personal costs of illness are also high. ScZ contributed 13.4 million 
years of life lived with disability to burden of disease globally in 2016 (Charlson 
et al., 2018) and is associated with a shorter life-span (Rössler, Joachim Salize, 
Van Os, & Riecher-Rössler, 2005) and a high risk of suicide (Gottesman, 1990). 
Furthermore, attempts to measure the quality of life experienced by ScZ 
patients (Bobes, Garcia-Portilla, Bascaran, Saiz, & Bousoño, 2007) suggest that 
patients experience an overall lower life quality not only compared to healthy 
individuals, but also lower than people with other chronic illnesses. Crucially, 
the quality of life declined progressively in relation to the duration of the 
disorder (Bobes et al., 2007), highlighting the importance of developing better 
and earlier treatments and intervention methods. 
1.3 Conceptual Evolution and Clinical Symptoms 
of ScZ  
While diagnostic criteria of ScZ have changed over time, the disorder is widely 
defined as a chronic condition with poor outcome (Schultz, North, & Shields, 
2007; R. Tandon et al., 2013). The condition is associated with three distinct 
symptom groups (R. Tandon et al., 2013), including negative (avolition, 
anhedonia, affective blunting, alogia etc.) (Millan, Fone, Steckler, & Horan, 
2014), positive (hallucinations and delusions) (Schultz et al., 2007), and 
cognitive symptoms (Schaefer, Giangrande, Weinberger, & Dickinson, 2013). 
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The concept of ScZ emerged as the result of early clinical observations 
(Jablensky, 2010). The French physician Morel observed characteristic psychotic 
symptoms in his young patients and labelled the condition démence précoce. 
Kahlbaum and Hecker described the conditions hebephrenia and catatonia which 
also shared features with ScZ (Adityanjee, Aderibigbe, Theodoridis, & Vieweg, 
1999). Eventually, reports were integrated by the German psychiatrist Emil 
Kraeplin to describe a condition called dementia praecox (Jablensky, 2010). 
Kraeplin’s work on dementia praecox formed the foundation for the modern-day 
understanding of ScZ. He put emphasis on the chronic nature of the disorder, 
and highlighted avolition and poor prognosis as key clinical features (Andreasen, 
1997; R. Tandon et al., 2013). In addition, he attempted to map the underlying 
aetiology, including factors such as age of onset, family history and premorbid 
behavioural patterns (Adityanjee et al., 1999). He also proposed a biological 
framework for the condition, involving serious cerebral cortical lesions 
(Adityanjee et al., 1999).  
The term schizophrenia was coined by the Swiss psychiatrist Eugene Bleuler. He 
was influenced by psychoanalytic as well as neurological ideas and aimed to 
understand individual patient experiences of ScZ in the context of an underlying 
disease process (Hoff, 2015). His description of the illness focused primarily on 
four features which he considered fundamental to the disorder: loosening of 
associations, affective flattening, autism and ambivalence. Other symptoms such 
as hallucinations, delusions and changes in speech were considered accessory or 
secondary as they varied between patients (Adityanjee et al., 1999).  
Subsequently, the concept was further advanced by the contributions of Kurt 
Schneider, who like Bleuler strived to identify and classify the main features of 
ScZ (Andreasen, 1997). He acknowledged both long- and short-term features of 
the disorder and introduced a list of “first-rank symptoms”, which allowed for 
more unified diagnostic procedures (Adityanjee et al., 1999). In the symptom 
list, Schneider highlighted hallucination and delusion symptoms which Kraeplin 
and Bleuler had considered of less importance, with the aim to identify the most 
clinically meaningful characteristics (Andreasen, 1997; Jablensky, 2010).  
Chapter 1 
19 
 
Diagnosing ScZ remains a largely subjective process, based on patient reports of 
and clinical consensus (R. Tandon, Keshavan, & Nasrallah, 2008). A diagnosis is 
established using the current versions of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) (DSM-V American Psychiatric Association, 2013) or the 
International Statistical Classification of Diseases and Related Health Problems 
(ICD) (World Health Organization, 2018). In the DSM-V, a patient is diagnosed 
with ScZ if they have experienced two or more positive and/or negative 
symptoms continuously for one month (or shorter if successfully treated), and a 
notable impairment and functional decline for a duration of six months (R. 
Tandon et al., 2013). For an ICD-11 diagnosis of ScZ, persistent symptoms of 
delusions, hallucinations, thought disorder, experiences of influence, passivity, 
or control must have persisted for at least one month (World Health 
Organization, 2018). 
Positive symptoms include hallucinations and delusions (Fletcher & Frith, 2009). 
Hallucinations are false perceptions and can occur in any sensory modality, while 
delusions are beliefs and convictions which are highly unlikely and which cannot 
be explained by the individuals cultural background (Fletcher & Frith, 2009). 
These symptoms are generally improved or fully treated by the administration of 
antipsychotic medication, but patients’ functioning tends to remain low even 
after drug treatment due to the limited effect of medications on the remaining 
two symptom categories (Chue & Lalonde, 2014; Fusar-Poli, Papanastasiou, et 
al., 2015).  
Negative symptoms of psychosis are debilitating and include widespread 
functional impairments, such as social withdrawal, avolition, anhedonia, 
affective flattening, as well as poverty of speech and thought (Andreasen, 1982; 
Crow, 1976). While the symptom features of ScZ are diverse and tend to vary 
between patients, around 40% of patients have been found to have two or more 
negative symptoms (Patel et al., 2015), with symptom severity associated with 
likelihood of hospital admission (Patel et al., 2015) and long-term functional 
outcome (Milev, Ho, Arndt, & Andreasen, 2005). As such, negative symptoms are 
a prominent feature of ScZ and may indicate clinical vulnerability. 
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Figure 1 Overview of the Main Symptom Categories Observed in ScZ 
Cognitive impairments have been recognized as the third core symptomatic 
feature of ScZ since the disorder was first described (Moskowitz & Heim, 2011), 
and are detrimental for patients’ overall functioning, affecting areas such as 
social relationships, work performance and recreational activities (Bowie & 
Harvey, 2006; Green, Kern, Braff, & Mintz, 2000; Milev et al., 2005). 
Neurocognitive abnormalities are widespread, including domains such as 
attention (Luck & Gold, 2008), working memory (McGurk et al., 2004), and 
verbal memory (Bowie & Harvey, 2006; Guimond, Chakravarty, Bergeron-
Gagnon, Patel, & Lepage, 2016).  
In addition, social cognitive functions such as social cue perception, experience 
sharing, inferring other people’s thoughts and emotions and emotional response 
regulation are also affected in ScZ patients (Green, Horan, & Lee, 2015). 
Importantly, cognitive abnormalities are understood to be among the first 
occurring symptoms, typically preceding the onset of psychosis (Fusar-Poli  et 
al., 2012), and tend to be stable over time in contrast to other symptoms of 
psychosis which typically go through periods of improvement and relapses (Bowie 
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& Harvey, 2006). However, current antipsychotic drugs are inadequate for the 
treatment of these symptoms (Bowie & Harvey, 2006).  
Cognitive and social cognitive impairments are thought to be closely linked to 
abnormalities in basic sensory processing (Hamilton et al., 2018). Low level 
sensory processing was previously thought to be intact in ScZ, yet research from 
recent decades has detected sensory processing abnormalities in all sensory 
modalities (Javitt, 2009).  
1.4 Auditory Symptoms in ScZ 
Auditory function is adversely affected in ScZ (Javitt & Sweet, 2015). Auditory 
hallucinations are a prominent feature of ScZ (Shergill, Murray, & McGuire, 
1998), occurring in 60-80% of patients (A. Lim et al., 2016). Moreover, ScZ is 
associated with impaired basic auditory processing mechanisms and deficit 
auditory cognitive functions (Javitt & Sweet, 2015). As such, auditory 
impairments contribute to impairments across all major symptom domains of 
ScZ.  
Auditory dysfunction is reflected by neuroimaging measures, providing empirical 
evidence for impairments in auditory sensory gating mechanisms as well as 
salient stimulus detection and oscillatory steady state response patterns in ScZ 
(Javitt & Sweet, 2015). Deficits in the fundamental sensory processes reflected 
by these measures may be closely linked to cognitive difficulties, possibly 
through faulty information filtering (Hamilton et al., 2018). Hence, auditory 
processing measures may be clinically useful for understanding and detecting 
early impairments in psychosis and could potentially constitute candidate 
biomarkers.  
1.5 The At-Risk State 
The clinical view of psychosis has developed over the past couple of decades to 
now recognize the importance of the pre-psychotic phase (Fusar-Poli  et al., 
2013). Individuals who go on to develop a psychotic disorder typically experience 
a prodromal period during which they begin to experience subtle changes in 
their experience of the world (Parker, 2006). This involves the onset of mild 
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symptoms such as subjective difficulties in concentration, perception, speech 
and thought patterns (basic symptoms) (Schultze-Lutter, 2009), and may 
eventually lead to attenuated psychotic symptoms, including delusions that are 
not held with complete conviction and not fully formed hallucinations (Yung, 
Yuen, Phillips, Francey, & McGorry, 2003).  
 
Figure 2 Psychosis Onset Trajectory, Adopted from Fusar-Poli et al., 2013 
The earliest concept of prodromal psychosis was coined in the early 1900’s and 
marked the start of a large research field focused on the study of individuals at-
risk for psychosis (Fusar-Poli  et al., 2013). Prodromal psychosis refers to 
patients who proceed to transition to psychosis. However, individuals may be 
considered at-risk regardless of later onset of psychosis if they meet a specific 
set of clinical criteria (“clinical high risk” – CHR, or “ultra-high risk” – UHR). In 
addition, individuals who have a first-degree relative suffering from a psychotic 
disorder form a separate high-risk group (“genetic high risk”) (Fusar-Poli  et al., 
2013).  
An important motivation for studying these groups is to map differences and 
similarities compared to psychotic patients, to identify mechanisms underlying 
the disorder, differentiate disorder impairments from side-effects caused by 
long-term medication, and to allow for earlier interventions (Fusar-Poli  et al., 
2013). The latter is thought to be of high importance in light of the observed 
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association between duration of untreated psychosis and poor long-term 
functional outcomes (Marshall et al., 2005).   
 To date, a number of interview measures have been developed with the 
purpose of detecting individuals in the at-risk state: The ScZ Proneness 
Instrument – Adult/Child and Adolescent versions (SPI-A or SPI-CY) was 
developed to detect the subtle subjective basic symptoms which typically 
present first (Schultze-Lutter, 2009), while the Comprehensive Assessment of At-
Risk Mental States (CAARMS) (Yung et al., 2005), the Structured Interview for 
Prodromal Symptoms (SIPS) (including the companion Scale of Prodromal 
Symptoms [SOPS]) (Miller et al., 2003), and the Basel Screening Instrument for 
Psychosis (BSIP) (Riecher-Rössler et al., 2007) are all used to detect the later 
attenuated psychotic symptoms. Furthermore, the latest DSM manual (DSM-V) 
recognizes the at-risk Attenuated Psychosis Syndrome as a clinical state which in 
itself warrants diagnosis and treatment (Fusar-Poli  et al., 2017). However, low 
specificity has limited the clinical use of at-risk measures, with meta-analysis 
results indicating transition in 18-36% of at-risk participants depending on 
duration of follow-up from 6 months to 3 years)(Fusar-Poli et al., 2013). In 
addition, prior to the inclusion of the Attenuated Psychosis Syndrome in the 
DSM-V, experts debated the usefulness and potential harmfulness of such a 
diagnosis (Shrivastava et al., 2011), with some raising concerns about ethical 
issues such as the possibility that the label could lead to unnecessary stigma 
(Yang, Wonpat-Borja, Opler, & Corcoran, 2010) , while others argued that even 
CHR individuals who did not convert were ill and would benefit from treatment 
(Ruhrmann, Schultze-Lutter, & Klosterkötter, 2010). Later evaluations have 
indicated that the clinical recognition of the CHR state can have beneficial 
effects for help-seeking patients (Fusar-Poli  et al., 2017).  
Currently, CHR diagnosis relies on psychological assessments (Fusar-Poli  et al., 
2013), yet identification of objective methods to detect CHR individuals could 
aid early detection and interventions. Since chronic ScZ patients show 
debilitating impairments in cognition, efforts have been made to map whether 
cognitive deficits could serve as a risk-marker. Robust widespread impairments 
were seen in CHR compared to healthy controls across several cognitive domains 
(De Paula, Hallak, Maia-de-Oliveira, Bressan, & Machado-de-Sousa, 2015; Fusar-
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Poli  et al., 2012), with impairments in verbal fluency and memory associated 
with subsequent transition to psychosis (Fusar-Poli  et al., 2012) and normal 
verbal fluency in CHR being predictive of later remission from the at-risk state 
(Simon et al., 2012). Notably, CHR cognitive capacity was intermediate between 
that of healthy controls and psychosis patients (Fusar-Poli  et al., 2013). Thus, 
evidence indicates that cognitive impairments are present but less pronounced 
in CHR and that cognitive performance may be useful for assessments of long-
term outcome. 
Functional neuroimaging methods have been utilized to study aberrant activity 
patterns in CHR. EEG and MEG measures of event-related potentials (ERPs) have 
revealed impaired auditory P50 and N100 sensory gating in chronic and first 
episode ScZ patients (Javitt & Sweet, 2015), with one study also reporting 
deficit P50 but not N100 suppression in CHR (Brockhaus-Dumke et al., 2008). The 
P50 peak is thought to be pre-attentive and linked primarily to stimulus filtering, 
while the N100 is affected by attention and appears to be functionally related to 
passive attention switching (Kisley, Noecker, & Guinther, 2004; Rosburg, 
Trautner, Elger, & Kurthen, 2009), suggesting that basic auditory sensory gating 
but not auditory attention switching is impaired in the CHR state. Another ERP 
implicated in ScZ is the mismatch negativity (MMN) response (Mikanmaa et al., 
2017), elicited by the detection of change (Näätänen & Kähkönen, 2009). The 
MMN has been linked to the framework of predictive coding (Wacongne, 2016), 
and impairments in ScZ indicate a reduced ability to detect and adjust to 
unexpected changes in sensory input (Erickson, Ruffle, & Gold, 2015). However, 
CHR findings have varied, and several reports suggest that the impairment on 
group level is driven specifically by individuals who eventually transition to 
psychosis (Bodatsch, Brockhaus-Dumke, Klosterkotter, & Ruhrmann, 2015).  
Functional EEG and MEG measures have also been used to map neural oscillatory 
patterns in patients. This could provide essential information about disease 
mechanisms, yet the knowledge about neural oscillations in the CHR population 
remains limited. In Chapter 4, new data from an oscillatory ASSR paradigm in a 
large CHR sample are presented, with the aim to shed more light on oscillatory 
changes in this important clinical group. 
Chapter 1 
25 
 
 
Figure 3 The Stress Vulnerability Model of ScZ Assumes that Increased Vulnerability to 
stress Increases the Likelihood of Experiencing a Psychotic Episode 
1.1 Neurobiology of ScZ 
Despite more than a century of research, ScZ is still only partially understood. It 
is thought that the disorder arises through the interplay of genetic risk factors, 
developmental abnormalities and external stressors (Gomes, Rincón-Cortés, & 
Grace, 2016; Howes & McDonald, 2004; Selemon & Zecevic, 2015). ScZ risk has a 
clear genetic component, with over 100 identified risk genes (Ripke et al., 
2014), and high heritability (Hilker et al., 2018). Yet, external disruptions in 
early brain development during gestation and early infancy (for example 
maternal infection or malnutrition), and during later cortical maturation in 
adolescence (such as  cannabis abuse) is also strongly linked to ScZ risk (Selemon 
& Zecevic, 2015). The combination of genetic risk and aberrant neural 
development may render patients more vulnerable to stressors (Figure 3), such 
as early trauma (Howes & McDonald, 2004). This framework is supported by in-
vivo work: Animals exposed to a combination of neonatal excitotoxic lesions of 
the medial prefrontal cortex (mPFC) and cannabis in adolescence showed 
severely impaired social behaviour, similar to social impairments seen in 
psychotic patients (Schneider & Koch, 2005). Similarly, the MAM model is a rat 
stress vulnerability model, created through exposure to the mitotoxin 
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methylazoxymethanol acetate (MAM) during gestational day 17, and results in 
animals showing ScZ like behavioural, neurochemical and anatomical features 
(Gomes et al., 2016).  
Neurochemical models of ScZ provide potential frameworks to explain how 
impairments may be mediated on a neurotransmitter level. For a long time, the 
dominant hypothesis postulated that ScZ emerges from alterations in   
dopaminergic signalling. The dopamine hypothesis stems from the early 
observation that drugs effective for alleviating positive symptoms acted on the 
dopaminergic system by increasing dopamine metabolism (Carlsson & Lindqvist, 
1963; Howes, McCutcheon, & Stone, 2015). Subsequent work demonstrated that 
clinical antipsychotic efficacy was directly related to dopamine receptor binding 
(Creese, Burt, & Snyder, 1976), adding further support for the notion that 
hyperdopaminergic activity caused symptoms of ScZ. However, later post-
mortem, lesion and PET studies indicated more complex alterations, involving 
striatal increases but frontal decreases in dopaminergic activity, proposed to 
each reflect positive and negative symptoms respectively (Howes & Kapur, 
2009). While further research has provided additional evidence for this 
framework, the most recent formulation of the hypothesis highlights that these 
dopamine alterations are mostly presynaptic, may be caused by a range of 
contributing factors including genetic predisposition, environmental stress and 
drug use, and that the result of the dysregulation is psychosis rather than a 
specific diagnosis (such as ScZ) (Howes & Kapur, 2009).  
The link between dopamine and ScZ has guided research and clinical 
approaches, but antipsychotic drugs targeting dopamine impairments are 
inefficient for treatment of negative and cognitive symptoms (Chue & Lalonde, 
2014; Moghaddam & Javitt, 2012). Later work indicates that these symptom 
domains may be more linked to alterations in the glutamatergic system (Chue & 
Lalonde, 2014; Moghaddam & Javitt, 2012). The glutamate hypothesis of ScZ was 
originally formed as drugs of abuse acting on the glutamate system were found 
to trigger psychotic-like symptoms (Lahti, Weiler, Michaelidis, Parwani, & 
Tamminga, 2001; Morris, Cochran, & Pratt, 2005). Empirical evidence for such 
alterations comes from post-mortem, pharmacological and neuroimaging studies 
(Howes et al., 2015). The glutamate system deficits are thought to be related to 
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NMDA receptor dysfunction (Stone, Morrison, & Pilowsky, 2007), and give rise to 
symptoms through effects on the cortical E/I balance (Gonzalez-Burgos & Lewis, 
2012). The proposed mechanism for these abnormalities will be discussed in 
more detail later in this chapter.  
Thus, there is now evidence for both the dopamine and glutamate hypotheses 
(Howes et al., 2015) and there is an overall consensus that both signalling 
pathways are implicated in the disorder and may account for slightly different 
symptoms and patient subtypes. Furthermore, a recent addition to the biological 
understanding of ScZ is the notion that increased oxidative stress plays a role in 
the disorder. Oxidative stress is a disruption of balance between oxidants (rest 
products from aerobic metabolism) and anti-oxidant molecules, in favour of the 
oxidants (Sies, 1996). Higher levels of oxidants have been measured in ScZ 
patients compared to healthy controls (Gonzalez-Liencres et al., 2014), 
suggesting elevated levels of oxidative stress. This alteration could constitute 
one of the factors contributing to disrupted brain development in childhood and 
adolescence (Do, Cuenod, & Hensch, 2015). Intriguingly, recent work has linked 
oxidative stress to N-methyl-D-aspartate (NMDA) glutamate receptor 
impairments, suggesting that oxidative stress could also explain some of the 
glutamate pathway impairments (Hardingham & Do, 2016).  
Another important consideration in understanding the neural underpinnings of 
psychosis, is that most research has been done on medicated patients. While 
medications are still inadequate, with varied and limited cognitive benefits 
(Keefe et al., 2007; Keefe, Silva, Perkins, & Lieberman, 1999; Leucht et al., 
2009), antipsychotic drugs cause significant physiological side-effects, including 
extra-pyramidal motor impairments and sexual dysfunction for first-generation 
antipsychotic drugs, and metabolic changes for newer drug alternatives 
(Rummel-Kluge et al., 2010). Furthermore, meta-analytic data indicate that 
brain volume abnormalities frequently reported in ScZ may result from 
antipsychotic medication treatment (Moncrieff & Leo, 2010), although 
alterations in brain morphology have also been observed in medication naïve 
patients (Cahn et al., 2002; Chua et al., 2007). Thus, the potential effects of 
medication are essential to consider in the interpretation of all ScZ studies.  
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1.1.1 Cortical Excitation and Inhibition 
One proposed neural mechanism for ScZ is an impairment in the balance 
between excitation and inhibition (Gonzalez-Burgos & Lewis, 2012; Lisman, 
2012). Synchronized neural oscillations are fundamental for integrated sensory 
processing and cognition (Siegel et al., 2012) and are generated through the 
interaction between glutamatergic and GABAergic signals (Carlén et al., 2012; 
Shin et al., 2011; Z. Zhang & Sun, 2011). An disturbance in E/I balance could 
underlie some of the cognitive and sensory impairments seen in patients with 
psychosis (Barch & Ceaser, 2012; Uhlhaas & Singer, 2010; Uhlhaas, 2013). 
Glutamate is the primary excitatory neurotransmitter in the central nervous 
system and is involved in a broad spectrum of brain functions (Howes et al., 
2015; Kew & Kemp, 2005). The human cerebral cortex contains excitatory 
glutamatergic pyramidal neurons extending from superficial layers to the deep 
subcortical areas, constituting 70-80% of all cortical neurons (Markram et al., 
2004). These cells communicate with surrounding cells via metabotropic and 
ionotropic synaptic receptors. The latter includes a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) 
receptors (Kew & Kemp, 2005). The NMDA subgroup of receptors is unique as its 
activation requires removal of a voltage gated Mg2+ block in addition to ligand 
binding, providing a further regulatory mechanism. This receptor type is thought 
to be crucial for a range of functions such as neuronal development, synaptic 
plasticity, learning, and cell integrity (K. Hashimoto, 2017) and is involved in the 
maintenance of E/I balance through its presence on inhibitory interneurons, 
allowing the activation of these (Carlén et al., 2012). 
Excessive levels of glutamate result in excitotoxicity and ultimately cell death 
and the synaptic release is therefore tightly regulated (Magistretti & Pellerin, 
1999). Multiple mechanisms are in place for monitoring glutamate, including 
glutamate transport proteins, glial uptake and conversion of glutamate 
(Magistretti & Pellerin, 1999). Moreover, the glutamatergic cells are regulated 
locally by different subtypes of interneurons, releasing the primary inhibitory 
neurotransmitter GABA (Markram et al., 2004). The regular interplay between 
inhibitory GABA and excitatory glutamate neurons is thought to form the 
foundation for the rhythmic neural activity (Carlén et al., 2012; Gonzalez-
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Burgos, Hashimoto, & Lewis, 2010), detected as neural oscillations using MEG or 
EEG (Vohs, Chambers, O’Donnell, Krishnan, & Morzorati, 2012).  
Glutamatergic cells are regulated locally by interneurons (Markram et al., 2004). 
Across cortical regions and layers, the interneurons are molecularly and 
functionally diverse, with the three largest subgroups being neurons expressing 
the Ca2+ binding molecule parvalbumin (PV+), neurons expressing the 
neuropeptide somatostatin (SOM) and neurons expressing the serotonin receptor 
5HT3a (5HT3aR) (Rudy, Fishell, Lee, & Hjerling-Leffler, 2011). Among these, the 
largest proportion of GABAergic interneurons are made up by PV+ cells (Rudy et 
al., 2011), and these have thus been the focus of much of the recent work in ScZ 
(T. Hashimoto et al., 2003; Lewis, 2011; Lewis, Curley, Glausier, & Volk, 2013; 
Taylor & Tso, 2014). However, recent evidence suggests that also SOM GABA 
interneurons play an important and distinct role which may be implicated in the 
maintenance of healthy cortical function (Chen et al., 2017).  
The PV+ GABA interneurons can be divided into two types of fast-spiking cells: 
basket cells and chandelier cells (Rudy et al., 2011). These cell types are 
involved in local cortical circuits and typically do not project across cortical 
layers (Markram et al., 2004). The primary distinguishing feature between the 
cell types is which area of cortical pyramidal cells they project to. Basket cells 
target the proximal dendrites/cell bodies and are therefore able to adjust the 
amplitude of synaptic signals passing through the neuron. In contrast, the 
chandelier cells synapse on the axon initial segments of pyramidal neurons, 
allowing them to edit action potential output (Lewis, 2011; Markram et al., 
2004). The primary SOM interneurons are Martinotti cells (Rudy et al., 2011), 
found in layers 2-6 of the cortex. These are distinct from PV+ neurons as they 
specialise in projecting up to superficial layer 1 of the cortex where they inhibit 
dendrites of the pyramidal cortex in one or several adjacent columns (Markram 
et al., 2004). Separate optogenetic tagging of SOM and PV+ interneurons in mice 
showed that SOM interneurons are preferentially linked to cortical beta (≈12-30 
Hz) oscillations, while stimulation of PV+ interneurons correlated stronger with 
gamma range oscillations (Chen et al., 2017). Thus, distinct inhibitory neuronal 
subtypes appear to play separate but complementary roles in the generation of 
oscillations.  
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There is evidence suggesting that both glutamatergic and GABAergic signalling 
pathways are impaired in psychosis. For instance, studies mapping ScZ risk genes 
have highlighted genes linked to the expression of NMDA receptor subunits 
(Ripke et al., 2014), and revealed altered cortical expression of GABA related 
genes (Hoftman et al., 2015). In line with these data, post-mortem findings have 
shown altered NMDA receptor expression, trafficking, and downstream signalling 
pathways (Hammond, Shan, Meador-Woodruff, & McCullumsmith, 2014), as well 
as deficits in the GABA synthesis pathway (Lewis et al., 2012; Taylor & Tso, 
2014). Furthermore, pharmacological manipulation in-vivo and in humans, using 
NMDA receptor antagonists such as MK-801, phencyclidine and ketamine, has 
been found to result in immediate symptoms resembling psychosis (Howes et al., 
2015; Moghaddam & Javitt, 2012). 
Moreover, NMDA receptor dysfunction may involve GABAergic interneurons 
during neural development, causing impaired interneuron maturation and 
ultimately aberrant regulation of both glutamate and GABA cortical signalling 
(Nakazawa, Jeevakumar, & Nakao, 2017). Combined, such findings have resulted 
in the E/I imbalance hypothesis of ScZ. This notion fits with the well-established 
glutamate hypothesis and could better account for cognitive and negative 
symptoms than the dopamine hypothesis (Howes et al., 2015). 
1.1.2 Neural Oscillations 
Neural oscillations are typically categorized based on frequency, ranging from 
delta (0.5–3 Hz) and theta (3–8 Hz) , to alpha (8-12 Hz), beta (12-30 Hz) and 
gamma (> 30 Hz) frequencies (Bartos et al., 2007). Different frequency bands are 
thought to represent different neural functions (Uhlhaas & Singer, 2010). 
Through synchronised firing at different frequencies, brain regions interact 
locally and over long distances and enable functions such as perception, memory 
and attention (Siegel et al., 2012). The establishment of such large scale 
networks involves the interaction of gamma oscillations which contribute to 
synchronization in local functional brain networks, and beta oscillations (12-30 
Hz) permitting long-range synchronisation (Phillips & Uhlhaas, 2015; Siegel et 
al., 2012). In contrast, the lowest frequency bands, alpha (8-12 Hz), theta (3-
8 Hz) and delta (0.5-3 Hz) are implicated in inhibition of activity during rest and 
sleep states, but are also involved in a range of important processes during 
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waking, such as inhibition, attention and long-range synchronization (Lisman, 
2016; Phillips & Uhlhaas, 2015).  
EEG and MEG techniques allow the non-invasive study of neural oscillations 
through the detection of electrical/magnetic signals from groups of cortical 
neurones (Lopes da Silva, 2010). Neuronal signalling involves electrical action 
potentials, formed by transmembrane currents, travelling down the axons of 
neurones (Lopes da Silva, 2010). As the current moves, a weak magnetic field 
arises around the neuron’s projections, and when groups of neurones fire in 
synchrony, the compound strength from the electrical/magnetic signals is 
sufficient for detection with EEG electrodes/MEG sensors (Lopes da Silva, 2010). 
As the two methods detect different forms of the same signal, they share 
common features. However, EEG measures are more affected by scalp tissue 
thickness and cannot be reconstructed in the source space as easily as MEG 
measures (Ramantani et al., 2006). In contrast, MEG sensors are blind to 
magnetic fields from completely radial neurons and the MEG method is therefore 
inferior at detecting signals from deep brain sources (Ramantani et al., 2006). 
Impaired oscillatory patterns in several frequency bands have been observed in 
ScZ patients (Moran & Hong, 2011). Given that high and low frequency 
oscillations are thought to interact to establish local as well as long range 
networks (Uhlhaas, 2013), changes in multiple frequencies in ScZ support the 
view that the disorder affects large brain systems (Anticevic & Lisman, 2017). 
The gamma band has been studied extensively in ScZ patients, and deficits in 
this frequency range are considered an important feature of ScZ pathology (Shin 
et al., 2011). In the auditory domain, ScZ gamma oscillations have been studied 
using ASSR paradigms (Thuné et al., 2016), and there is consistent evidence for 
impaired 40 Hz ASSR evoked spectral power and ITPC measures of signal phase 
synchrony between trials (Thuné et al., 2016). Moreover, there are data 
indicating that lower frequency ASSRs, such as beta and theta oscillations, may 
also be impaired in ScZ (Kirihara, Rissling, Swerdlow, Braff, & Light, 2013).  
Furthermore, the ASSR paradigm has been used to study induced gamma power 
in ScZ  (Edgar et al., 2014; Hirano et al., 2015; Kirihara et al., 2012; Krishnan et 
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al., 2009; Roach, Ford, Hoffman, & Mathalon, 2013; Teale, Collins, Maharajh, 
Rojas, & Kronberg, 2009). Induced power is a measure of power which, in 
contrast to evoked power, is not phase-locked to the periodic ASSR stimulation 
(Hirano et al., 2015). Two studies reported reduced induced power around 40 Hz 
in ScZ (Roach et al., 2013; Krishnan et al., 2009), while others found no 
difference (Kirihara et al., 2013) or an increase in 40 Hz induced power in ScZ-
patients (Teale et al, 2008). Moreover, broadband evaluations of induced power 
indicated increases in ScZ, both for baselined (Edgar et al., 2014) and non-
baselined data (Hirano et al., 2015), including the pre-stimulus period. The 
discrepancies in findings may be accounted for in part by differences in 
methodology, such as different approaches for computing induced power or 
selection of frequency of interest.  
In line with observed increases in induced power (Edgar et al., 2014; Hirano et 
al., 2015), one group reported elevated left hemisphere baseline power during a 
40 Hz ASSR experiment in ScZ patients compared to controls. The increase 
correlated with ASSR power reductions during the task, suggesting that some of 
the task effect was driven by the underlying baseline difference (Spencer, 2012). 
However, it remains unclear whether the 40 Hz ASSR baseline is affected in ScZ 
as this has not been widely investigated. 
In the visual domain, presentation of moving grating stimuli gives rise to a strong 
gamma response in healthy subjects (Hoogenboom, Schoffelen, Oostenveld, 
Parkes, & Fries, 2006). While presenting such stimuli during MEG recordings, 
colleagues recently found impaired visual gamma power in chronic ScZ patients 
and first-episode psychosis sample (Grent-’t-Jong et al., 2016). This is in line 
with previous visual gamma reports (Spencer, 2008; Wynn et al., 2005) and 
stimulations with more complex visual stimuli, such as Mooney faces (Grützner 
et al., 2013). Furthermore, visual oscillatory impairments were found to coincide 
with behavioural impairments (Grent-’t-Jong et al., 2016; Grützner et al., 2013), 
suggesting a link between visual perceptual processing abnormalities and neural 
oscillatory deficits.  
Oscillatory alterations have also been detected in the lower beta, alpha, theta 
and delta frequency ranges (Moran & Hong, 2011). Reduced alpha and/or beta 
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power and phase-locking was reported in ASSR studies (Brenner, Sporns, Lysaker, 
& O’Donnell, 2003; Krishnan et al., 2009; Vierling-Claassen, Siekmeier, 
Stufflebeam, & Kopell, 2008), while one ASSR study reported intact beta 
(Maharajh, Teale, Rojas, & Reite, 2010). Beta phase-synchrony impairments 
were seen in both a visual steady state task (Riečanskỳ, Kašpárek, Řehulová, 
Katina, & Přikryl, 2010), and a gestalt perception task (Uhlhaas et al., 2006). In 
the alpha range, multiple complex oscillatory alterations have been reported 
(Başar & Güntekin, 2013). Early visual steady state investigations reported 
reductions in alpha-power (Rice et al., 1989), and reduced alpha phase-locking 
has also been observed during visual steady state stimulation (Riečanskỳ et al., 
2010). In addition, alpha-band suppression was impaired in a multisensory 
paradigm in ScZ compared to controls (Roa Romero et al., 2016) and alpha 
amplitude abnormalities in ScZ were observed during an ambiguous visual 
perception task (Basar-Eroglu, Mathes, Khalaidovski, Brand, & Schmiedt-Fehr, 
2016). Furthermore, the topographical pattern of alpha oscillatory responses to 
visually evoked stimulation was  found to be altered in ScZ (Basar-Eroglu, 
Schmiedt-Fehr, Marbach, Brand, & Mathes, 2008). However, others reported 
intact alpha power in ScZ during a visual grating processing task (Grent-’t-Jong 
et al., 2016), in a visual-steady state task (Krishnan et al., 2005) and in a 
resting-state paradigm (Hinkley et al., 2011).  
Increased slow-frequency theta and delta oscillations during wakeful rest has 
been reported as one of the most robust oscillatory alterations in ScZ (Boutros, 
Arfken, Galderisi, Warrick, & Pratt, 2009). In addition, there is evidence that 
delta oscillatory power is decreased during sleep (Keshavan et al., 1998). 
Moreover, delta and theta induced and evoked oscillatory activity was reduced 
in several cognitive and sensory processing tasks (Başar & Güntekin, 2013). In 
contrast, theta range increases in power have been reported from an ASSR task 
(Kirihara et al., 2012), and altered spatial patterns with both local increases and 
decreases in theta were reported from a visual domain task (Basar-Eroglu et al., 
2008). Alterations in the theta range are potentially important as these may 
influence gamma range activity through cross-frequency coupling (Kirihara et 
al., 2012).  
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This section has highlighted that there is empirical evidence for disrupted 
oscillations in ScZ in both the auditory and visual domains, particularly but not 
exclusively, in the gamma range. However, while both visual and auditory steady 
state stimulation approaches provide information about oscillatory neural 
activity, it should be noted that they are not equivalent measures (Zoefel & 
VanRullen, 2017). Visual gamma paradigms tap into the intrinsic synchronised 
oscillatory sampling of sensory neurones in the visual cortex, while the 40 Hz 
ASSR is an evoked response reflecting entrainment of auditory neurones to an 
external stimulus (Lakatos, Gross, & Thut, 2019). As such, both types of 
experiments reflect the capacity of neurones to elicit an oscillatory response, 
but the 40 Hz ASSR is externally driven (Brenner et al., 2009). Nevertheless, the 
ASSR measure could provide important indications about the capacity of auditory 
neurones to entrain to oscillating sources within the brain or body  
1.1.3 Dysconnectivity in ScZ 
Evidence from neuroimaging data suggests that ScZ is a disorder of neural 
dysconnectivity (Stephan, Friston, & Frith, 2009). Neural connectivity measures 
capture structural connectivity, reflected by the white matter axonal 
connections between regions, or functional connectivity assessed through 
statistical estimates of the likelihood of two regions communicating (Bowyer, 
2016). Available evidence indicates that both structural and functional 
connections are impaired in ScZ (Fitzsimmons, Kubicki, & Shenton, 2013).  
Diffusion tensor imaging (DTI) measures have been used to examine structural 
connectivity, while fMRI has frequently been used to evaluate functional 
connectivity (Fitzsimmons et al., 2013; Fornito, Zalesky, Pantelis, & Bullmore, 
2012). However, the high temporal resolution and direct measures of brain 
activity make EEG and MEG data suitable alternatives for functional measures 
and an increasing number of EEG and MEG ScZ studies are therefore reporting 
connectivity measures (Maran et al., 2016). 
Results from a meta-analysis of DTI voxel-based morphometry measures of 
fractional anisotropy (i.e. degree of restriction of diffusion), showed poor 
consistency between studies, yet multiple reports indicate abnormalities in 
several brain regions in psychotic patients (Melonakos et al., 2011). In the 
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context of auditory function it is relevant to note that one study found no 
overall difference in corpus callosum fractional anisotropy between FEP and 
healthy controls, yet patients experiencing complex auditory hallucinations in 
the form of two or more conversing voices showed an increase in fractional 
anisotropy in these tracts compared to patients without severe hallucination 
symptoms (Mulert et al., 2012). 
One longitudinal study exploring DTI measures of fractional anisotropy in 
controls, FEP and UHR participants found differences both at baseline, where 
the FEP patients had the lowest and controls the highest fractional anisotropy 
measures, and at follow-up where fractional anisotropy values declined in UHR 
participants who eventually transitioned to psychosis, but not in non-converters 
(Carletti et al., 2012). Thus, there is some evidence that impaired white matter 
integrity could be a feature associated with psychosis onset.  
Functional connectivity has been widely evaluated using fMRI resting-state 
paradigms (Woodward, 2014). Some inconsistencies in results exist, yet recent 
systematic reviews and alternative methodological approaches have revealed 
robust evidence for dysconnectivity in ScZ (Damaraju et al., 2014; Giraldo-Chica 
& Woodward, 2017). Specifically, patients show reduced prefrontal-thalamic 
connectivity, but increased thalamic-sensorimotor connectivity (Giraldo-Chica & 
Woodward, 2017), as well as abnormalities in the cortico-cerebellar-striatal-
thalamic loop and task specific networks (Sheffield & Barch, 2016). Moreover, 
dynamic connectivity analyses indicate that ScZ patients spend less time overall 
in states of strong large-scale connectivity, and that it is while patients are in 
such states that most abnormal connectivity patterns occur (Damaraju et al., 
2014). However, while it has been speculated that connectivity alterations may 
underly cognitive impairments seen in ScZ, literature reviews have not indicated 
a clear link between connectivity changes and a specific cognitive domain, but 
rather suggest that dysconnectivity results in general functional impairments 
which may affect general cognitive function (Sheffield & Barch, 2016). Thus, 
fMRI has contributed to an emerging awareness of the characteristics of 
dysconnectivity in ScZ, and how such disruptions may relate to clinical 
symptoms.  
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Importantly, the high temporal resolution of connectivity data from EEG and 
MEG studies (Maran, Grent-‘t-Jong, & Uhlhaas, 2016) allow an expansion of the 
current understanding of ScZ connectivity changes. Several groups reported 
increased delta and theta band resting state functional connectivity in ScZ 
patients compared to healthy controls (Andreou, Leicht, et al., 2015; Di Lorenzo 
et al., 2015; Kam, Bolbecker, Donnell, Hetrick, & Brenner, 2013; Lehmann et 
al., 2014). Moreover, CHR subjects were found to have intermediate levels of 
theta-band functional connectivity, falling between the levels seen in ScZ 
patients and controls (Andreou, Leicht, et al., 2015). In the alpha and beta 
bands, both increased (Di Lorenzo et al., 2015; Hinkley et al., 2011; Kam et al., 
2013) and reduced resting-state functional connectivity (Di Lorenzo et al., 2015; 
Hinkley et al., 2011; Kam et al., 2013; Lehmann et al., 2014) has been reported. 
Finally, resting-state gamma range connectivity appears increased in ScZ 
(Andreou, Nolte, et al., 2015; Di Lorenzo et al., 2015), especially in patients 
with long disease duration (Lorenzo et al., 2015).  
Crucially, EEG/MEG data also provide evidence for connectivity disruptions in 
ScZ sensory pathways. Disrupted connectivity measures have been reported 
during both auditory (Henshall, Sergejew, Rance, McKay, & Copolov, 2013; 
Winterer, Coppola, Egan, Goldberg, & Weinberger, 2003; Ying, Zhou, Lin, & Gao, 
2015) and visual tasks (Griesmayr et al., 2014; Krishna, Neill, Sánchez-Morla, & 
Thaker, 2015; Popov, Rockstroh, Popova, Carolus, & Miller, 2014).  
In summary, there is evidence for disruptions in both structural connections and 
functional connectivity patterns in ScZ and to some degree also in FEP and at-
risk individuals. Data from EEG/MEG indicate connectivity abnormalities in ScZ 
both during rest and in tasks, and thus support the ScZ dysconnectivity 
framework.  
1.1.4 Magnetic Resonance Spectroscopy  
Proton magnetic resonance spectroscopy (1H-MRS) provides a non-invasive 
method for measuring levels of brain metabolites, by exploiting the unique 
molecular resonance frequency of different chemical substances. Specifically, 
1H-MRS is a molecular imaging technique which utilises the unique resonance 
frequencies of molecules arising from the magnetic shielding on protons by local 
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electron clouds (Dager, Oskin, Richards, & Posse, 2008), to create a spectrum 
showing the relative concentrations of brain metabolites (Stefan Blüml, 2013). 
Importantly, refined scanning protocols, such as the MEGAPRESS (MEscher–
GArwood Point RESolved Spectroscopy) sequence (Mescher, Merkle, Kirsch, 
Garwood, & Gruetter, 1998; Mescher, Tannus, O’Neil Johnson, & Garwood, 
1996), have enabled the measure of molecules such as GABA and the compound 
Glx (Glutamate + Glutamine), despite the relatively low concentrations of these 
in the brain and the fact that their resonance frequency peaks overlap with 
other metabolites (Edden, Puts, Harris, Barker, & Evans, 2013).  
Early 1H-MRS ScZ studies focused  on high concentration brain metabolites such 
as N-Acetyl aspartic acid (NAA), creatine and choline (Jessen et al., 2006; 
Keshavan, Montrose, Pierri, & Elizabeth, 1997; Wood et al., 2003, 2010; Yoo et 
al., 2009), which can easily be detected and measured in the 1H-MRS spectrum 
(Wijtenburg, Yang, Fischer, & Rowland, 2015). However, more recent efforts 
have been directed primarily at measures of GABA and Glutamate/Glx (Egerton, 
Modinos, Ferrera, & McGuire, 2017; Merritt, Egerton, Kempton, Taylor, & 
Mcguire, 2016; Poels et al., 2014; Wijtenburg et al., 2015), due to the potential 
high relevance of these for ScZ pathology.  The MEGAPRESS sequence allows the 
acquisition of such measures through 1H-MRS spectral editing, whereby 
molecular interactions within the GABA molecule, known as J-couplings, are 
exploited to alter the appearance of the metabolite spectrum (Mullins et al., 
2014). MEGAPRESS collects two spectra through one un-edited and one edited 
scan sequence. The latter utilises radio frequency pulse editing of a coupled 
molecular spin within the GABA molecule, targeting the GABA peak at 1.9ppm to 
shift the peak at 3ppm (Mullins et al., 2014). This allows computation of a 
difference spectrum where only peaks for GABA and Glx (Glutamate+ Glutamine) 
are visible.    
1.9 ppm (those directly affected by the pulses), the GABA signal at 3 ppm 
(coupled to GABA spins at 1.9 ppm), the combined glutamate/ 
glutamine/glutathione (Glx) peaks at 3.75 ppm (coupled to the Glx res- onances 
at approximately 2.1 ppm), 
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As comprehensively reviewed by Poels et al (2014), Wijtenburg et al (2015) and 
Merritt et al (2016), measures of glutamate or Glx in ScZ have resulted in 
inconsistent findings so far. Decreased levels of glutamate or Glx have been 
observed in medial prefrontal cortex and anterior cingulate cortex (Natsubori et 
al., 2014; Rowland et al., 2013; Théberge et al., 2003). However, several studies 
have reported elevated glutamate or Glx concentrations, with significant 
increases observed  in both frontal and temporal regions, the basal ganglia 
(Merritt et al., 2016; Poels et al., 2014) and medial prefrontal cortex (Poels et 
al., 2014). Such increases in glutamate are consistent with findings of NMDA 
receptor hypofunction in-vivo (Nakazawa, Jeevakumar, & Nakao, 2017) and 
human ketamine studies showing that artificial increases in glutamate give rise 
to psychotic-like symptoms. 
Critically, evidence is emerging indicating that impairments are present also in 
the CHR population (Merritt et al., 2016). A recent report highlighted the 
importance of the hippocampus in psychosis pathology and demonstrated that 
CHR subjects who transitioned to psychosis had higher hippocampal glutamate 
levels than the CHR subjects who did not transition (Bossong et al., 2018). 
Furthermore, significant increases were observed in the anterior cingulate 
cortex (Fuente-Sandoval et al., 2016), the pre-commissural dorsal-caudate 
(Fuente-Sandoval et al., 2011), thalamus and caudate (Tandon et al., 2013) in 
CHR. However, contradicting findings have also been reported. Wood et al. did 
not observe glutamate alterations in a UHR sample (Wood et al., 2010) and no 
significant effects were found in high genetic risk groups (Block et al., 2000; 
Capizzano, Toscano, & Ho, 2011; Keshavan et al., 2009).   
1H-MRS studies of GABA in psychotic individuals are inconsistent (Egerton et al., 
2017; Wijtenburg et al., 2015). In ScZ patients, reduced GABA levels were 
reported in dorsal anterior cingulate cortex (Marenco et al., 2016) and bilateral 
calcarine sulci (Yoon et al., 2010). In contrast, increased concentrations were 
observed in medial and dorsolateral prefrontal cortex, anterior cingulate cortex, 
occipital cortex and basal ganglia (Kegeles et al., 2012; Öngür, Prescot, 
McCarthy, Cohen, & Renshaw, 2010; Rowland et al., 2013; Tayoshi et al., 2010). 
In FEP patients, decreased levels of GABA/creatine compared to healthy controls 
have been reported in the left basal ganglia, parietal occipital lobe (Goto et al., 
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2010) and the bilateral calcarine sulci (Kelemen, Kiss, Benedek, & Kéri, 2013), 
but not in the frontal cortex (Goto et al., 2010). 
Similarly, one UHR study found increased GABA in bilateral dorsal caudate and 
medial prefrontal cortex (Fuente-Sandoval, 2016), while another reported 
reduced GABA and GABA/Glx concentrations in the left frontal lobe (Menschikov 
et al., 2016). Moreover, medial prefrontal cortical levels of GABA were found to 
be correlated with left hippocampal cerebral blood flow, and this relationship 
was found to differ between UHR participants who transitioned to psychosis and 
those who did not (Modinos, Şimşek, Azis, et al., 2018). Thus, while the data 
remain limited there is increasing empirical support for the notion that both 
glutamate and GABA may be abnormal already prior to psychosis onset.  
1.2 Disease Detection and Biomarkers 
Psychiatric research has long had low priority, and the lack of knowledge of 
underlying biological mechanisms meant that detection and diagnosis was done 
exclusively using clinical information (McGorry et al., 2014; Singh & Rose, 2009). 
Recent research has improved the understanding of physiological and 
psychological mechanisms involved in psychotic disorders, yet the assessment 
methods remain largely the same and rely primarily on individual clinicians’ 
interpretation of clinical consensus (Jablensky, 2010; McGorry et al., 2014). 
Thus, there is a need to develop new sensitive psychosis detection methods, for 
example through biomarkers.  
A biomarker can be defined as follows: “A characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group, 2001). This concept is challenging for 
aetiologically complex disorders such as ScZ, as the pathophysiology is likely to 
be heterogeneous, involving genetic, neural and social risk factors (Selemon & 
Zecevic, 2015).  
A primary issue in the development of biomarkers for risk- or early stages of 
psychosis is the relative lack of empirical data from FEP and CHR samples. 
Moreover, as highlighted early by Kraemer, a crucial feature of a biomarker is 
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that it should be present prior to the outcome of interest (Kraemer et al., 1997). 
Thus, for the development of biomarkers truly reflecting risk of transition, a 
measure which differs specifically between controls and those CHR individuals 
who do transition to psychosis is required (Gifford et al., 2016). However, an 
important consideration is whether transition is the most relevant outcome 
variable. Thus, biomarkers predicting psychological, cognitive and/or social and 
occupational functioning may be equally important.  
Neuroimaging measures are attractive alternatives to biochemical measures 
(such as serum hormonal and neuromodulator levels (Bičíková et al., 2011)) as 
they are non-invasive and can be collected easily in clinical settings (Bowyer et 
al., 2015). Consequently, neuroimaging measures impaired in ScZ have been 
proposed as potential biomarkers of psychosis, and could aid not only early 
detection, diagnosis and intervention of psychosis, but also the identification of 
better treatment targets (Fusar-Poli  et al., 2013). For instance, machine 
learning algorithms have been applied to MRI data in order to predict transition 
to psychosis in a large CHR project, demonstrating relatively reliable predictions 
especially for the contrast converters vs healthy controls (Koutsouleris et al., 
2012). 
MEG and EEG have been used to study whether evoked potentials such as P50 
and N100 sensory gating (Patterson et al., 2008) or MMN (Erickson et al., 2015) 
could be suitable marker candidates. In particular MMN-studies have yielded 
promising results. While some have failed to detect a difference in MMN 
between CHR and control subjects (Brockhaus-Dumke et al., 2005; Higuchi et 
al., 2013),  MMN impairments have been found to be more severe in CHR 
participants who eventually transition to psychosis (Bodatsch et al., 2015, 2011; 
Lavoie et al., 2018), suggesting that MMN measures may be sensitive to the true 
prodromal state. 
However, MEG and EEG measures of oscillations have not been evaluated 
extensively for psychosis prediction. Recent resting state EEG data suggest that 
oscillations can be used for psychosis prediction in CHR (Ramyead et al., 2016), 
however the potential for using sensory related task measures for assessments of 
clinical prognosis is unknown. One group has published ASSR data from CHR 
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individuals (Koshiyama et al., 2018a; Tada et al., 2016), but have not explored 
the predictive power of the measure. However, data from chronic and first 
episode ScZ patients indicate a moderately robust impairment across studies 
(Thuné et al., 2016), motivating further study of this measure in CHR samples to 
further evaluate its biomarker potential. 
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Chapter 2 Participants and Methods 
2.1 Recruitment  
All data reported in this thesis were collected as part of the longitudinal Youth 
Mental Health Risk and Resilience (YouR) study (Uhlhaas et al., 2017). The study 
was approved by the West of Scotland Research Ethics Committee 5. FEP and 
CHR participants were recruited through clinical referrals from the NHS in the 
Greater Glasgow and Clyde and Mid Lothian districts, as well as from the general 
population in Glasgow and Edinburgh, using the YouR study recruitment website 
(www.your-study.org.uk). Healthy control participants were recruited using the 
University of Glasgow psychology department’s online subject pool.  
Individuals between 16 and 35 years old were invited via advertisements, GP 
recommendations and emails to complete a questionnaire on the study website 
(McDonald et al., 2018), consisting of (a) the 16-item Prodromal Questionnaire 
(PQ-16) (Ising et al., 2012) and (b) a nine-item scale of perceptual and cognitive 
anomalies which was developed to assess basic symptoms. Participants endorsing 
6 or more items on the SPQ and/or 3 on the basic symptom scale were invited 
for screening assessments at the University of Glasgow or the University of 
Edinburgh. Between September 2014 and July 2018 there were 2853 entries on 
the YouR study website. Out of these, 2190 met cut-off criteria for CHR and 382 
participants in Glasgow and 78 in Edinburgh attended screening assessments.  
Further participants entered the study via direct referrals from NHS services 
such as the psychosis early intervention program in Glasgow, Esteem. Until July 
2018, a total of 32 participants in Glasgow and 7 in Edinburgh entered the study 
via this route. Like participants recruited from the website, the referred 
subjects attended initial screening assessments to establish whether they met 
CHR criteria.  
Three FEP patients’ data were recorded as part of a different first-episode of 
psychosis study, with the participants subsequently consenting to the data being 
shared between studies.  
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Inclusion criteria for all groups were: 16-35 years old (inclusive), no 
ferromagnetic implants in body, not pregnant, normal/corrected to normal 
vision, no neurological disorders and no acute suicidality. In addition, control 
participant inclusion required no history of psychiatric illness and no first-degree 
relatives with ScZ.  
Participants were recruited to the CHR-group if they met (a) the SPI-A Cognitive-
Perceptive Basic Symptoms (COPER) or Cognitive Disturbances (COGDIS) criteria; 
(b) CAARMS criteria for the attenuated psychosis group; (c) CAARMS criteria for 
genetic risk and functional deterioration (family history of psychosis plus a 30% 
drop in Global Assessment of Functioning (GAF) scores); or (d) CAARMS criteria 
for Brief Limited Intermittent Psychotic Symptoms (BLIPS). Screened CHR-
participants were excluded if they met criteria for current or past diagnosis with 
Axis I psychotic disorders. Other co-morbid Axis I diagnoses, such as mood or 
anxiety disorders, were not exclusionary (Uhlhaas et al., 2017). 
Participants meeting CAARMS criteria for psychosis threshold and the diagnostic 
criteria for FEP on DSM-IV, assessed using the Structured Clinical Interview for 
DSM-IV-TR AXIS I disorders (SCID-I) (First, 2015) were included in the FEP sample.   
After screenings, 113 participants in Glasgow and 41 participants in Edinburgh 
met CHR inclusion criteria. Furthermore, 15 (Glasgow) and 11 (Edinburgh) 
participants met FEP criteria. 
Following screenings, participants attended additional clinical interviews 
(Appendix 1). CHR and control participants were assessed with the Premorbid 
Assessment Scale (PAS) (Cannon-Spoor, Potkin, & Wyatt, 1982) and the Mini 
International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). FEP 
participants were assessed with the Structured Clinical Interview – Positive and 
Negative Syndrome Scale (SCI-PANSS) (Kay, Fiszbein, & Opler, 1987). Moreover, 
all participants underwent a neuropsychological evaluation, completing the Brief 
Assessment of Cognition in Schizophrenia (BACS) (Keefe et al., 2004). Results 
from the neuropsychological assessments are presented elsewhere (Haining et 
al., 2019).  
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The fourth study visit involved MEG and MRI measurements. MEG data were 
recorded on a 4D Neuroimaging Magnes 3600 Whole Head 248 Channel system. 
The test battery included a resting-state task, and measures of visual gamma 
oscillations, auditory MMN, the 40 Hz ASSR and auditory sensory attenuation. 
MRI data were recorded on a Siemens 3 t scanner. A 10-minute duration 
anatomical T1 weighted magnetic resonance imaging (MRI) scan was recorded 
with parameters: 192 slices, voxel size 1 mm3, FOV=256256 176 mm3, 
TR=2250 ms, TE=2.6 ms, FA=9°. In addition, 1H-MRS measures of GABA and Glx 
were collected using MEGAPRESS (see Chapter 6). 
Following the neuroimaging session, CHR participants were invited for follow-up 
visits every six months for a duration of up to three years. Initial analyses based 
on follow-up data are presented in Chapter 7.  
During the time period considered in this thesis, a total of 107 CHR participants, 
49 healthy control participants and 19 FEP patients underwent scans 
(Appendix 2). Some data were lost due to poor quality or participants’ inability 
to complete the paradigm. Hence, data from a total of 93 CHR, 17 FEP, and 46 
healthy controls are presented in this thesis. At the time of data analysis, 4 of 
the CHR participants had transitioned to FEP.  
2.2 Clinical Characteristics 
This thesis addresses ASSR oscillatory data in CHR individuals (Chapters 3, 4, 5 & 
7). Power calculations for the present analyses were performed based on an 
assumed ASSR Hedge’s g effect size of -0.42 found through meta-analytic 
evaluations of ASSR findings in ScZ (Chapter 3) (Thuné et al., 2016). Assuming an 
effect of -0.42, the current sample sizes and an alpha limit of 0.05, it was 
estimated that a minimum power of 0.75 should be obtained even for the 
smallest group included (FEP). 
A summary of demographic variables is given in Table 1. There was no significant 
difference in overall group age, yet as expected the FEP group had the overall 
highest mean age, while CHR participants had the overall lowest mean age. 
There was a significant difference in GAF scores between groups (Independent-
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Samples Median Test statistic: 64.00, p<0.01, d=2.49), with highest scores in the 
control group (mean 87.62, sd± 6.50), intermediate scores for CHR (59.48, sd± 
12.87) lowest scores in the FEP group (43.31, sd± 14.23).Moreover, there was a 
significant difference in GAF variance (Levene’s stat=6.80, p <0.01), with the 
control group showing least and the FEP group most variance. 
Table 1 YouR Study Sample Demographic Characteristics 
Group [N] 
 
Demographic 
 
Control [46] CHR [93] FEP [17] Test 
statistic 
Sig. (p) Effectd 
Mean Std Mean Std Mean Std 
Age (years) 22.48 3.44 21.62 4.37 23.77 4.69 4.45a 0.11 0.31 (d) 
Education (years) 16.61 3.04 15.01 3.38 14.92 2.97 3.90b 0.02 0.46 (d) 
Mother education (years) 15.31 2.57 14.87 3.30 14.33 2.87 0.47b 0.63 0.18 (d) 
Father education (years) 15.66 2.20 14.20 4.47 15.38 3.66 1.89b 0.16 0.37 (d) 
Total CAARMS severity 0.76 2.42 26.56 16.96 85.00 25.85 64.54a <0.01 0.77 (d) 
Total BACS 0.00 0.99 -0.82 2.12 -2.99 2.51 10.15b <0.01 2.98 (d) 
GAF score 87.62 6.50 59.48 12.87 42.31 14.23 64.00a <0.01 2.49 (d) 
Role Functioning Score 8.57 0.78 7.51 1.07 N/A 37.47b <0.01 -1.08 (d) 
Social Functioning Score 8.84 0.48 7.55 1.08 N/A 54.10b <0.01 -1.39 (d) 
PAS childhood 1.38 1.45 4.02 3.41 N/A 22.04a <0.01 0.91 (d) 
PAS early adolescence 2.30 1.76 6.41 4.32 N/A 37.16a <0.01 1.12 (d) 
PAS late adolescence 2.76 2.53 6.26 4.51 N/A 22.45a <0.01 0.88 (d) 
Gender (male) 15 24 8 3.27c 0.20 0.15 (V) 
Righthanded 39 84 17 3.21c 0.20 0.14 (V) 
Learning disability (N) 1 13 1 5.63c 0.60 0.21 (V) 
First degree relative 
with ScZ (N) 
0 8 1 5.55c 0.06 0.19 (V) 
Medication free (N) 46 44 3 49.45c <0.01 0.56 (V) 
Admission to hospital (N) 0 3 3 14.25c <0.01 0.31 (V) 
Current smoker (N) 6 23 5 4.63c 0.10 0.18 (V) 
Past smoker (N) 5 13 0 2.28c 0.32 0.12 (V) 
a) Independent-Samples Median Test statistic 
b) F statistic 
c) Chi square statistic 
d) Effect sizes reported as Cohen's d or Kraemer's V 
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Gender and handedness were explored as both may potentially affect ASSR 
measures (Melynyte et al., 2018). However, here no significant difference was 
found in proportions of gender and handedness in the three groups. Thus, these 
factors are unlikely to have confounded the analyses presented in Chapters 4-7. 
A total CAARMS severity score was calculated for each participant, by 
multiplying the global score by the frequency score for each of the four symptom 
groups and calculating the sum of these four numbers (as suggested by Morrison 
& French, 2012). There was a significant group effect (Independent-Samples 
Median Test statistic: 64.54, p<0.01, d=0.77), representing lowest CAARMS 
severity scores for controls (mean: 0.76 ±sd 2.42), intermediate scores for CHR 
participants (mean: 26.56,±sd 16.96) and highest scores for the FEPs (mean: 
85.00,±sd 25.85). 
A composite BACS score index was computed from z-score standardized and 
gender corrected individual test component scores. There was a significant 
difference in global BACS performance (F:10.15, p<0.01, d:2.98), representing 
reduced composite BACS scores for both CHR (t=-3.03, p<0.01) and FEP (t=-3.51, 
p<0.007) participants compared to controls. 
The three groups differed significantly in terms of the proportion of 
unmedicated subjects. No controls were prescribed medication for psychological 
complaints, while members of both the FEP and CHR groups received 
pharmacological treatment for psychotic or comorbid symptoms. Specifically, 3 
FEP subjects were unmedicated, 2 were given anti-depressants, 1 antipsychotics, 
and 11 multiple long-term medications. The majority of CHR participants were 
unmedicated (n=44), 22 were prescribed antidepressants, 1 antipsychotics, 1 
mood stabilizers, and the remaining were prescribed other types of long-term 
medication (including anti-anxiety drugs such as beta-blockers) or multiple 
medications.  
2.3 Conclusion 
Despite a heterogenous sample including both self-referred subjects from the 
general public and patients referred from clinical services, the analysis of 
demographic and psychological variables follow an expected pattern, with 
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functional impairments being evident in CHR and FEP and overall lower scores on 
PAS, BACS and GAF assessments. Furthermore, the FEP and CHR groups were to a 
greater extent prescribed medication. Importantly however, the groups did not 
differ with regards to the potentially confounding variables age, handedness and 
gender.
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Chapter 3 The Auditory Steady State 
Response in Chronic Schizophrenia: A Meta-
Analysis  
3.1 Introduction 
The auditory steady state response (ASSR) allows the study of high frequency 
neural oscillations in auditory areas (O’Donnell et al., 2013) and gives rise to a 
robust entrainment response in healthy individuals (Tan, Gross, & Uhlhaas, 
2015a). The measure has been widely used for the study of auditory function 
(Herdman & Stapells, 2001; Tlumak, Rubinstein, & Durrant, 2007), and has been 
applied for the evaluation of oscillatory signatures in psychiatric disorders 
(Isomura et al., 2016; O’Donnell et al., 2013; Rass, Forsyth, & Krishnan, 2012; 
Rass et al., 2010; Wilson, Rojas, Reite, Teale, & Rogers, 2007), including in ScZ 
(Javitt & Sweet, 2015).  
The 40 Hz ASSR is thought to be a right hemisphere dominant response (Ross, 
Herdman, & Pantev, 2005), arising from the brain stem and primary auditory 
cortex (Herdman & Stapells, 2001), with further input from secondary auditory 
regions (Gutschalk et al., 1999; Herdman et al., 2002). The sources are distinct 
from those linked to auditory evoked potentials (Draganova, Ross, Wollbrink, & 
Pantev, 2008; Pantev, Roberts, Elbert, Ross, & Wienbruch, 1996). In fact, the 40 
Hz ASSR is thought to represent a cortical resonance frequency response linked 
both to activation in auditory cortex as well as cerebellar sources (Pastor et al., 
2002).  
The 40 Hz ASSR response reflects interactions between GABAergic and 
glutamatergic signalling (Vierling-Claassen et al., 2008). In-vivo work has 
supported this view through the observation that NMDA receptor antagonists 
alter the 40 Hz ASSR (Leishman et al., 2015; Sivarao, 2015; Sivarao et al., 2013; 
Sullivan, Timi, Hong, & O’Donnell, 2015; Vohs et al., 2012). However, the 
direction of change has been inconclusive, and it was recently suggested that 
the degree of NMDA receptor failure could determine in which direction 
oscillations are affected (Sivarao, 2015).  
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ASSR analyses in ScZ have focused primarily on two measures; evoked 40 Hz ASSR 
spectral power, and inter-trial phase coherence (ITPC) (O’Donnell et al., 2013). 
The MEG signal can be expressed as a complex number, represented as a vector 
in a coordinate system with a real and an imaginary axis (Bastos et al., 2015). 
The length of the vector reflects signal amplitude, while the angle indicates 
signal phase (Bardouille & Ross, 2008). The power of an oscillatory signal 
represents the signal amplitude squared (Izhikevich, Gao, Peterson, & Voytek, 
2018), with evoked power being the change in power from baseline following 
stimulation (David, Kilner, & Friston, 2006). In contrast, computing signal phase 
from the complex vector angle at a particular time point and comparing across 
trials provides a measure of phase consistency, which is called either the ITPC 
(when amplitude is included in the calculation) or the phase-locking factor (PLF) 
(when the amplitude is not considered in the calculation), and which provides 
valuable information about the capacity of cortical neurones to coordinate their 
firing and respond to stimulation in a synchronised manner (Bastos et al., 2015). 
Signal phase coherence in particular is thought to be essential for neural 
communication within and across brain regions (Fries, 2015), and abnormalities 
could therefore be important for understanding clinical symptoms of ScZ. 
Impaired 40 Hz ASSR power and ITPC has been observed in chronic ScZ patients 
(O’Donnell et al., 2013; Thuné et al., 2016). An ASSR impairment was first 
reported by Kwon et al., who found reduced 40 Hz ASSR averaged power and 
altered phase delay in ScZ compared to healthy controls (Kwon et al., 1999). 
Subsequently, the initial findings were replicated (Brenner et al., 2003; Edgar et 
al., 2014; Hamm et al., 2015; Hamm, Gilmore, & Clementz, 2012; Hamm, 
Gilmore, Picchetti, Sponheim, & Clementz, 2011; Hirano et al., 2015; Hong et 
al., 2004; Kirihara et al., 2012; Komek, Bard Ermentrout, Walker, & Cho, 2012; 
Krishnan et al., 2009; Rass et al., 2012; Roach et al., 2013; Spencer, 
Niznikiewicz, Nestor, Shenton, & McCarley, 2009; Spencer, Salisbury, Shenton, & 
McCarley, 2008; Tada et al., 2016; Teale et al., 2008; Tsuchimoto et al., 2011; 
Vierling-Claassen et al., 2008; Wilson et al., 2008), and expanded to include 
additional stimulation frequencies (Vierling-Claassen et al., 2008; Hirano et al., 
2015; Spencer et al., 2008). However, abnormalities in the 40 Hz range remain 
the most frequently reported ASSR finding in ScZ. Furthermore, reports from two 
FEP samples (Koshiyama et al., 2018b; Spencer et al., 2008; Tada et al., 2016) 
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and one CHR sample (Koshiyama et al., 2018a; Tada et al., 2016) suggest that 
impairments may begin already early stages of psychosis. 
Thus, the 40 Hz ASSR measure has been highlighted as a potential biomarker for 
ScZ, yet until recently the findings from ScZ patients had not been 
systematically evaluated, and the potential impact of methodology and sample 
characteristics had not been explored. Thus, in preparation for the empirical 
work presented in this thesis, the author performed a meta-analysis on the 40 Hz 
ASSR ScZ literature available at the time (Thuné et al., 2016). The main findings 
from this published report are presented in this chapter. 
3.2 Methods 
3.2.1 Sample 
Relevant studies published from November 1999 to March 2016 were identified 
through searches on PubMed using the following search terms: (1) auditory 
steady state response, (2) ScZ, (3) 40 Hz, (4) EEG, (5) MEG, and (6) steady state 
response. The search yielded 42 reports which were included in the present 
meta-analysis if they met pre-determined inclusion criteria: human studies, 
presenting new data, using EEG or MEG to measure ASSRs, sufficient statistical 
information (sample sizes and mean values and/or raw data and/or p values 
and/or effect sizes), including at least one sample of patients with ScZ and one 
sample of healthy controls, and reporting measures of evoked spectral power 
and/or ITPC or PLF. In the subsequent analyses, ITPC and PLF measures were 
treated as equal, as the difference between the two measures is minimal; the 
overall phase consistency across trials is considered to be reliably detected 
irrespective of whether amplitude is included or excluded from the calculation 
(Bastos et al., 2015).  
Based on the criteria, 25 studies were excluded (reviews [n=5], animal studies 
[n=6], studies without ScZ patients or which examined another sensory modality 
[n=8], studies that did not report measures of spectral power and/or ITPC [n=3], 
and studies that used a sample already included in the analysis [n=3]). The final 
sample included 20 studies; 17 from PubMed searches, 2 obtained through 
searches in reference-sections in the original 42 papers, 1 highlighted by a 
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reviewer. Additional statistical information was provided by the authors for 
three of the included studies, as insufficient detail was included in the original 
publications (Hamm et al., 2011; Krishnan et al., 2009; Rass et al., 2012).  
3.2.2 Effect Size Calculations 
Effect sizes were computed in the software Comprehensive Meta-Analysis 
(version 3.3.070) (Borenstein, 2005) Hedge’s g effect sizes (mean1- 
mean2/SDpooled) were calculated for each measure (spectral power and ITPC 
measures) in each study using sample sizes for each group and either a p value 
or Cohen d value. Hedge’s g effect sizes were chosen for the comparison since 
the pooled standard deviation used to calculate Hedge’s g values is weighted by 
the number of participants in each group (Erickson et al., 2015). Secondary 
analyses were performed to investigate the effect of outliers more than 2 
standard deviations away from the mean effect size. 
Computation of the I2 index (Higgins & Thompson, 2002) for the resulting effects 
revealed heterogeneity between studies (Overall I2=46.78). This was reduced 
when random as opposed to fixed effect sizes were considered (Overall I2=6.72). 
Thus, the rest of this chapter reports estimated random-effect sizes.  
Two studies included analyses of several conditions or time-windows respectively 
(Hamm et al., 2015; Tada et al., 2016). In these cases, overall effects across 
conditions were included in the analyses. 
3.2.3 Evaluation of Reporting Bias 
Potential reporting bias was evaluated first through visual inspection of funnel 
plots, then through statistical evaluation of funnel asymmetry using Egger’s 
regression test (Egger, Smith, Schneider, & Minder, 1997). Finally, effect sizes 
were corrected using the “trim and fill” method (Duval & Tweedie, 2000), with 
the aim to ascertain the possible effect of unpublished studies. In 9 studies in 
which both phase and power measures were reported, we only included power-
effects in this analysis (resulting in a total n=15 [power] and n=5 [phase]), as 
there was no significant difference between power and phase effect sizes.  
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3.2.4 Exploration of Influencing Factors 
Further analyses of the effect of sample and study design were performed using 
R (R Core Team, 2013) in R-studio. Selected covariates were explored using a 
mixed linear model approach in the R package nlme (Pinheiro, Bates, DebRoy, & 
RCoreTeam, 2011). The model was restricted to four independent fixed effect 
variables and one random effect variable. Because the majority of studies using 
MEG reported source level data and EEG-studies sensor/electrode level data, 
only one of these factors – analysis level (sensor/source) – was included in the 
model. The other selected variables were patient age, stimulus type (click trains 
vs amplitude-modulated tones) and stimulus duration. The r2 values of the model 
were calculated using the package MuMIn (Barton, 2015), which allows the 
calculation of r2 values adapted for mixed linear models (Nakagawa & 
Schielzeth, 2013).  
Due to the low number of studies including FEP/CHR individuals, a comparison 
between FEP and chronic ScZ was not possible. Instead, the sample was divided 
into 2 age groups based on the median age (39.8 years). Likewise, since only 5 
different stimulus durations have been reported (475, 500, 1000, 1024 and 1500 
ms), durations were treated as categorical variables in the mixed linear model 
and were defined as either brief (≤500 ms) or long (≥1000 ms) in post-hoc 
analyses. One study reported 2 stimulus duration conditions (Hamm et al., 2015) 
and these were both included in the post-hoc t test evaluation of stimulus 
duration effects. 
Statistical results are presented rounded to two decimal points. 
3.1 Results 
3.1.1 Effect Size 
The final sample included 606 ScZ patients and 590 healthy controls (Table 2 and 
Table 3). In total, 15 studies included 40 Hz ASSR evoked power measures, 14 
included 40 Hz ASSR phase measures (reported as ITPC or PLF), and 9 studies 
included both measures. 
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Table 2 Patients and Healthy Controls in Meta-Analysis Sample 
a) mean years/*days since admission 
Hedge’s g effect sizes ranged from 0.69 to -1.50. In total, 3 effect sizes were 
greater than 0, suggesting an increase in patients with ScZ compared to controls 
(g=0.20 for spectral power in Hong, 2004; g=0.53 for spectral power and g=0.69 
for phase locking in Hamm, Gilmore, & Clementz, 2012). One of these effects 
was statistically significant (phase locking in Hamm et al., 2012). The remaining 
26 negative effect sizes reflect a reduction in ASSR measures in ScZ. The average 
Hedge’s g random effect size was -0.58 for power measures and -0.46 for phase 
Author HC 
(N) 
Gender 
HC 
(M/F) 
ScZ 
(N) 
Gender 
ScZ 
(M/F) 
HC 
Mean 
Age 
(y) 
ScZ 
Mean 
Age 
(y) 
Patient 
Group 
Illness 
Durationa 
Medication 
Status 
Imaging 
Technique 
Image 
Analysis 
Level 
Kwon et al., 1999  15 15/0 15 15/0 44.6 43.3 Chronic 21.1 Mixed EEG Sensor 
Brenner et al., 
2003 
22 13/9 21 18/3 39.7 45.6 Chronic 
 
Mixed EEG Sensor 
Hong et al., 2004  17 8/9 24 14/10 41.1 39.7 Chronic 
 
All 
medicated 
EEG Sensor 
Spencer et al., 
2008  
33 19/14 16 19/14 27.5 25.5 FEP *13.6  All 
medicated 
EEG Sensor 
Vierling-Claassen 
et al., 2008  
12 12/0 12 18/0 
  
Chronic 26.2 All 
medicated 
MEG Source 
Teale et al., 2008 15 12/3 15 13/2 34.8 37.9 Chronic 12.6 All 
medicated 
MEG Source 
Wilson et al., 2008 10 4/6 10 7/3 15.82 14.64 Early 
onset 
3.4 Mixed MEG Source 
Krishnan et al., 
2009  
21 11/10 21 13/8 40 42.6 Chronic 
 
All 
medicated 
EEG Sensor 
Spencer et al., 
2009  
16 16/0 18 18/0 44.4 39.8 Chronic 
 
All 
medicated 
EEG Sensor 
Hamm et al., 2011 18 13/5 18 16/2 39.7 40.7 Chronic 18.2 Mixed MEG Source 
Tsuchimoto et al., 
2011  
22 9/13 17 6/11 37 35.6 Chronic 13.5 All 
medicated 
MEG Sensor 
Hamm et al., 2012  16 9/7 17 11/6 39.5 41.5 Chronic 
 
Mixed EEG Sensor 
Komek  et al., 
2012 
12 7/5 12 7/5 31.4 30.3 Chronic  All 
medicated 
EEG Sensor 
Rass et al., 2012  56 26/30 42 23/19 38.75 36.86 Chronic 
 
Mixed EEG Sensor 
Kirihara et al., 
2013 
188 94/94 234 182/52 43.9 44.5 Chronic 22.7 Mixed EEG Sensor 
Roach et al., 2013  25 14/11 18 21/7 36.1 39.3 Chronic 
 
All 
medicated 
EEG Sensor 
Edgar et al., 2014  29 22/7 39 33/6 37.9 40.87 Chronic 
 
Mixed MEG Source 
Tada et al., 2016  21 11/10 15 8/5 22.4 22.1 FEP 
 
All 
medicated 
EEG Sensor 
Hirano et al., 
2015  
24 20/4 24 20/4 44.1 46 Chronic 21.1 All 
medicated 
EEG Source 
Hamm et al., 2015  18 11/7 18 9/9 40.8 45.6 Chronic 
 
Mixed EEG Sensor 
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measures (Figure 4), indicating a moderately strong effect. However, initial 
analysis revealed that 3 effect sizes were more than 2 SD from the total mean 
effect size (i.e., the total [SD] mean effect size was −0.55 [0.46]), and, 
therefore, they were treated as outliers (both power and phase in Hamm et al 
(Hamm et al., 2012) and power in Vierling-Claassen et al. (2008). Without these 
outliers, the Hedge’s g random effect sizes were -0.45 [phase n=13] and -0.59 
[power n=13], suggesting a robust effect also in the absence of outliers. 
Table 3 Meta-Analysis Sample Characteristics 
Measure 
All 
included 
studiesa 
Phase 
locking 
Spectral 
power p 
N (studies) 20 14 15 
 
Mean N: ScZ 30.3 36.4 18.8 0.28 
Mean N: Controls  29.5 35.6 21 0.26 
Mean Age: ScZ 37.5 38.3 36.4 0.54 
Mean Age: Controls 36.8 37.9 36.2 0.57 
Stimulus duration 696.2 708.9 663.3 0.73 
a) The characteristics were compared between the 14 articles reporting phase measures and the 15 articles 
reporting spectral power measures (9 studies were part of both groups). 
The initial statistical comparison revealed no difference between phase and 
power measures (95% CI: −0.49 to 0.22; t(28)=−0.80; p=0.43), justifying the 
inclusion of one single effect size from each study in further explorations 
(15 studies with power measures and 5 studies with phase measures). Mixed 
linear model analyses revealed a significant effect of patient age (p=0.03) and a 
trend effect of stimulus duration (p=0.05) on the 40 Hz ASSR measures. There 
was, however, no effect of stimulus type (p=0.40) or analysis level (p=0.79). The 
conditional R2 of this model was 0.94, indicating that the fixed and random 
variables combined explained more than 90% of the variance. The R2 of the fixed 
variables alone (marginal R2) was 0.54. When the same model was used to 
evaluate the data set without outliers, only the effect of age remained (patient 
age: p=0.04; stimulus duration: p=0.34; stimulus type: p=0.27; analysis level: 
p=0.84).  
3.1.2 Post-Hoc Analyses 
Post-hoc t tests were used to investigate these results further. None of the 
above effects remained statistically significant, but there was a trend toward 
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stronger ASSR reductions in studies with younger participants (t=1.41; p=0.18; 
95% CI:−0.14 to 0.69, g[≤39.8 years]=-0.67, g[>39.8 years]=-0.40), and in studies 
with shorter stimulus durations (t=1.50;p=0.17; 95% CI:−0.18 to 0.90, g[short]=-
0.72, g[long]=-0.37). One outlier each were identified for the post-hoc 
evaluations of the effects of analysis level (Hamm et al., 2012) and stimulus 
duration (Hong et al., 2004), and 2 for the age comparison (Hamm et al., 2012; 
Hong et al., 2004), but removing these studies from the respective analyses did 
not alter the outcome.
 
Figure 4 Effects of 40 Hz ASSR in Patients with ScZ vs Healthy Controls (HC). Meta-Analysis 
Hedge’s g Random Effect Sizes, Showing Power and Phase Effects Separately. For Later 
Post-Hoc Analyses Only One Effect Size Value from Each Study was Included, Selecting the 
Value for Power in all Cases where both Measures were Reported.  
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3.1.3 Reporting Bias 
Plotting one 40 Hz ASSR effect size from each study in a funnel plot revealed 
some asymmetry (Figure 5), suggesting that the sample could be affected by 
reporting bias (Egger regression test: t=2.20; p=0.04; 95% CI: −2.73 to −0.07). 
Using the “trim and fill” method of Duval and Tweedie(2000) we estimated 5 
hypothetically missing studies, which suggests a slight bias in favour of studies 
reporting ASSR impairments in patients with ScZ. The addition of these studies 
adjusted the overall Hedge’s g random model effect size to -0.42. 
 
Figure 5 A) Hedge’s g Effect Sizes for 40 Hz Auditory Steady State Response (ASSR) 
Measures from all Studies (n=20) Plotted Against Effect Size Standard Errors.  The Plot 
Shows Some asymmetry. B)Trim and Fill–Corrected Funnel Plot with Additional Studies on 
the Right Side of the Mean, Showing an Adjusted Overall Hedge’s g Random Effect Size of 
−0.42. 
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3.2 Discussion 
This meta-analysis provides evidence for a moderate reduction in both spectral 
power and ITPC measures during 40 Hz stimulation in patients with ScZ, 
highlighting impairments in both the generation of high-frequency oscillations, 
and in the precise temporal coordination of rhythmic activity in response to 
entrainment of auditory neural circuits. Importantly, this effect remained 
significant after correction for potential publication bias.  
Optogenetic and pharmacological findings indicate that disturbances in cortical 
E/I pathways may underlie 40 Hz ASSRs impairments (Sivarao, 2015; Sohal, 
Zhang, Yizhar, & Deisseroth, 2009). Thus, the observed pattern of 40 Hz ASSR 
deficits could inform the understanding of circuit impairments in ScZ, and 
emphasise the possible contribution of disrupted parvalbumin GABAergic 
interneuron signalling (Lewis, Curley, Glausier, & Volk, 2012) and/or 
dysfunctional NMDA receptors (Kantrowitz & Javitt, 2010) in ScZ.  
The meta-analysis indicated a trend toward more pronounced impairments in the 
40 Hz ASSRs in younger patients with ScZ compared with older patients. This 
contrasts with previous reports of progressive reductions in EEG evoked 
potentials in psychosis (Salisbury, Shenton, Griggs, Bonner-Jackson, & McCarley, 
2003) and magnetic resonance imaging parameters (Kasai et al., 2003) during 
the course of ScZ. However, the majority of current 40 Hz ASSR studies have 
been conducted in patients with chronic ScZ, and further research is required to 
establish the pattern and strength of ASSR deficits in patients with a first 
episode of psychosis and in at-risk populations.  
Due to the modest number of studies, further replication of the 40 Hz ASSR 
deficit in patients with ScZ is required; the effect size of the ASSR deficit is 
currently lower than other electrophysiological indices of auditory dysfunctions 
in ScZ, such as the mismatch negativity (Erickson et al., 2015) (Hedge’s g=0.95 
for all patients with ScZ and Hedge’s g=0.81 for patients with chronic ScZ) and 
P50 (de Wilde, Bour, Dingemans, Koelman, & Linszen, 2007)(Cohen’s d=1.28).  
Based on the current data, the meta-analysis can only provide a preliminary 
indication regarding the potential impact of recording techniques (EEG vs MEG) 
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and analysis parameters (source vs sensor). However, the meta-analysis does 
highlight that source reconstructed data are available predominantly from MEG 
studies, suggesting that these reports may have superior sensitivity to detect 
subtle regional effects. In addition, further relationships with cognitive deficits 
as well as clinical parameters in patients with ScZ would significantly enhance 
the utility of the 40 Hz ASSR as an important index of auditory circuit functions 
in patients with ScZ. Finally, additional investigations focusing on early stages of 
psychosis are essential to establish the potential clinical usefulness of 40 Hz 
ASSR measures.  
3.3 Conclusion 
This systematic meta-analysis of the 40 Hz ASSR in ScZ indicates a moderately 
robust impairment in both evoked power and phase-locking measures in 
patients. However, further work in younger psychosis patients and CHR samples 
is required to build on the understanding of neurobiological circuit dysfunctions 
in psychosis, and to establish if 40 Hz ASSR measures could constitute a useful 
biomarker. Subsequent chapters will present data which provide a starting point 
for addressing these questions
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Chapter 4 The 40 Hz Auditory Steady State 
Response in the Clinical High-Risk State and 
First Episode Psychosis 
4.1 Introduction  
The meta-analysis presented in Chapter 3 established that 40 Hz ASSR ITPC and 
spectral power are robustly impaired in chronic ScZ (Thuné et al., 2016). 
However, data from CHR participants and FEP patients remain limited. 
Preliminary findings indicate that alterations may occur prior to diagnosis 
(Koshiyama et al., 2018a; Tada et al., 2016), but the available studies are 
limited by the small number of CHR participants and the potentially confounding 
influence of antipsychotic medication.  
To address these issues, this chapter presents analyses of MEG-measured ASSR 
data from the YouR study, with the aim to investigate further whether ASSR 
impairments are present in CHR individuals. In addition, analyses comparing the 
control and CHR data with data from a small FEP sample are presented. Due to 
the limited CHR 40 Hz ASSR reports available, a data-driven approach was used 
for selection of regions for analysis. However as stated in Section 1.1, the 
analysis was based on the hypothesis that CHR individuals would show reduced 
40 Hz ASSR evoked power and ITPC compared to healthy controls. MEG-measured 
data were utilised as spatial reconstruction of cortical regions, which was a key 
component of the planned analysis, is easier with MEG than with EEG (Barkley & 
Baumgartner, 2003).   
The clinical potential of the 40 Hz ASSR depends on whether abnormalities are 
robustly and reliably present in affected patients, but also on whether deficits 
can be detected in vulnerable undiagnosed individuals. Reports of ASSR 
measures in first-degree relatives of schizophrenia patients indicate that the 
40 Hz ASSR is sensitive to genetic risk (Hong et al., 2004; Rass et al., 2012). In 
addition, 40 Hz ASSR impairments have been reported in Autism Spectrum 
Disorders and Bipolar Disorder (Maharajh, Abrams, Rojas, Teale, & Reite, 2007; 
Rass et al., 2010; Rojas et al., 2011; Wilson et al., 2007), suggesting that ASSR 
deficits may not be specific to schizophrenia, but reflect genetic vulnerability 
for psychosis and disorders with similar sensory processing deficits.  
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In psychosis research, initial reports indicated that impairments in both 40 Hz 
ASSR power and phase coherence are present in FEP patients (Koshiyama et al., 
2018a; Spencer et al., 2008; Tada et al., 2016). Moreover, impaired 30 Hz ASSR 
power and phase-locking, measured using EEG, has been observed in FEP 
(Spencer et al., 2008), indicating potential deficits in high beta frequency 
oscillations in addition to gamma band deficits.  
Similarly, one research group observed abnormal 40 Hz ASSR in the earliest 
component of the response (0-100ms and 200-300ms) in FEP, and impairments in 
both FEPs and CHR participants, during the later stimulation periods (300-500ms) 
(Tada et al., 2016). These findings were replicated with a larger sample size 
(Koshiyama et al., 2018a). Hence, available data suggest that sustained gamma 
oscillatory responses may be aberrant in CHR as well as in FEP. However, the 
meta-analysis presented in the previous chapter (Thuné et al., 2016) revealed 
some publication bias in the ScZ literature and it is possible that a similar bias is 
present for CHR and FEP studies. Accordingly, more data from larger samples are 
needed to clarify the nature of 40 Hz ASSR alterations at different stages of 
psychosis. 
4.2 Methods 
4.2.1 Data Collection 
Analyses included data from the 93 CHR participants, 17 FEP patients and 46 
healthy controls described in Chapter 2. 
MEG data were recorded on a 4D Neuroimaging Magnes 3600 Whole Head 248 
channel MEG scanner at a sampling rate of 1kHz. Auditory stimuli were 1000 Hz 
carrier tones amplitude-modulated at 40 Hz. One hundred tones were presented 
for 2000 ms, with an inter-trial interval of 2000 ms (± 500 ms jitter) through MEG 
compatible inner-ear tubes. In addition, a simple attention task consisting of the 
detection of non-amplitude modulated target 1000 Hz tones (N=10) was added in 
order to ensure that participants attended the auditory stimuli (Figure 6). 
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4.2.2 MEG Data Pre-Processing 
Data were pre-processed and analysed in Fieldtrip (Oostenveld, Fries, Maris, & 
Schoffelen, 2011) in MATLAB (version 2013b). Raw data were epoched from 
1000 ms prior to stimulus onset to 2400 ms post stimulus onset, linear trends 
were removed, data were ‘de-noised’ relative to reference MEG channel signals 
and down sampled to 500 Hz. Moreover, muscle, eye movement and cardiac 
artefacts were removed from data through visual inspection, principal 
component analysis and independent component analysis. Following pre-
processing, the average number of trials available was 93.8 (± sd 3.9) and trial 
numbers did not differ significantly between groups (p>0.05). 
 
Figure 6 ASSR Stimulation Task Setup 
 
Pre-processed cleaned MEG data were transformed from axial to planar 
orientation (Bastiaansen & Knösche, 2000), to aid subsequent plot 
interpretation. Next, grand average spectral power and ITPC data were 
calculated for each group during the stimulation period (0-2000ms). Cleaned 
baseline and task data were compared across groups to establish whether the 
stimulation paradigm successfully entrained brain regions to fire synchronously 
in the 40 Hz frequency range. In other words, the presence of an overall 
stimulation effect was explored. This analysis indicated that both evoked power 
and ITPC in the 38-42 Hz range evolved around 150 ms and were sustained until 
1950 ms post-stimulus onset in the present sample. Thus, statistical evaluations 
of group effects were performed at 38-42 Hz and from 150-1950 ms, using non-
parametric Monte-Carlo permutation based independent samples F-tests, which 
1 kHz Carrier Tone
1 kHz Carrier Tone
40 Hz amplitude modulation
x100 
x10 
40 Hz ASSR Stimulus
Attention task target
2000 ms 2000 (±500) ms
Trial                                             Inter-trial interval
Time
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were corrected for multiple comparisons using a cluster-based permutation 
approach. 
4.2.3 Evoked Spectral Power and ITPC Analyses 
Similar to the meta-analysis presented in Chapter 3, the main analyses focused 
on evoked spectral power, indicating the squared amplitude of the signal 
(Izhikevich et al., 2018), and the ITPC, reflecting phase consistency of 
oscillations across trials (Bardouille & Ross, 2008).   
Time-frequency representations of data were obtained by convolving the planar 
preprocessed data with a complex wavelet, using a Hanning taper sliding window 
Fourier transform approach. The computation was done using a step-size of 
25 ms across epochs, 4 s padding and smoothing ± 1Hz, including frequencies 1-
100 Hz and keeping individual trials. Statistical group comparisons of evoked 
spectral power were performed on time-frequency data computed relative to 
baseline power (-600 to -100 ms prior to stimulus onset, relative change 
method).  
Furthermore, post-hoc statistical tests of spectral power in the 15-25 Hz range, 
at 500-1500 ms, were performed. In addition, potential differences in baseline 
(-600 to -100 ms) 40 Hz power were explored between groups as previous work 
has indicated altered ASSR baseline power in ScZ (Spencer, 2012). 
The ITPC index was computed in two steps. First, a fourier spectrum was 
computed using the time-frequency analysis approach described above. Next, 
the ITPC was estimated from the complex norm of the time–frequency 
decomposition by dividing by vector amplitude, summing vector angles, finding 
the absolute value and normalizing this and finally removing the singleton 
dimensions. The resulting ITPC values range in value from 0 to 1 and reflect the 
degree of phase consistency across trials. For statistical analyses, ITPC was 
computed across time (150-1950 ms), averaged over frequency (38-42 Hz) and 
expressed relative to baseline (-600 to -100 ms prior to stimulus onset, absolute 
change method). 
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All statistical group comparisons of sensor level data focused on grand average 
data calculated for each study group, and group effects at 38-42 Hz were 
explored both on whole brain data and on 12 selected sensors of interest (six 
sensors covering temporal and parietal regions of each hemisphere) identified 
based on analyses of overall effects of stimulation (see Section 4.3.2).  A non-
parametric montecarlo permutation-based approach was employed to perform 
independent samples F-tests and tests were corrected for multiple comparisons 
using a cluster-based permutation approach. 
4.2.4 Source Reconstruction 
A T1 weighted MRI scan was recorded on a Siemens 3T Trio Trim scanner using 
3D MPRAGE sequences (192 slices, voxel size 1 mm3, FOV=256x256x176 mm, 
TR=2250 ms, TE=2.6 ms, FA=9°), and converted to SPM8 format using MRIcron 
(Rorden & Brett, 2000). During the scan, a vitamin E pill was placed by the left 
ear to allow for detection of the left hemisphere in the MRI data. MEG head 
models were computed and aligned with the T1, first using the nasion, right and 
left ears as anatomical landmarks and subsequently fine-tuning the match using 
digitized MEG head shape points.  
MEG data were reconstructed in the source space using Linearly Constrained 
Minimum Variance (LCMV) (Van Veen, Van Drongelen, Yuchtman, & Suzuki, 1997) 
beamformer spatial filters and the standardized Automated Anatomical Labelling 
(AAL) brain atlas (Tzourio-Mazoyer et al., 2002). Coordinates for the centroids of 
116 AAL regions were specified in each subject brain from an MNI template and 
used to model signals at each brain region. Source modelling at the 116 AAL 
centres was done using a grid size of 5 mm, individual subject head models and 
normalised lead fields. Next, the AAL source estimations from individual subject 
grid-points were normalized to an MNI template brain with dimensions 
91x109x91 mm, to allow averaging data from different subject grids despite 
individual differences in brain anatomy data. Subsequent statistical group 
comparisons were based on data averaged for each experimental group.   
Similar to sensor level data, successful activation of brain regions following ASSR 
stimulation (a stimulation effect) was confirmed prior to the performance of any 
further analyses. This was done by comparing two stimulation time-windows 
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(500-1000 ms and 1000-1500 ms) with the baseline (-600 to -100 ms) across 
groups, using a non-parametric Monte-Carlo permutation based dependent 
samples t test. Following this initial statistical inspection of the data, auditory, 
subcortical and cerebellar nodes significantly activated during ASSR stimulation 
were selected as regions of interest (ROI). For the ITPC measure, only nodes 
with a t value >5 were considered, given the large number of activated nodes. 
Group effects were evaluated statistically in the 38-42 Hz range, both averaged 
over frequency and time (150-1950 ms) and averaged over frequency but not 
time. 
4.2.5 Behavioural and Clinical Data 
Behavioural data (reaction times (RTs) and response accuracy), were analysed in 
SPSS. Differences in reaction times were evaluated using a Welch test, as 
differences in group variance were detected. Response accuracy was determined 
by computing d’ scores for each participant and subsequently analysing group 
differences using a Kruskal-Wallis H-test. Post-hoc tests were performed using 
Mann Whitney U-tests. 
Correlations between clinical and demographic measures (see Chapter 2) and 
ASSR data were performed using Spearman correlations. In the CHR group, the 
relationship between ITPC and spectral power, composite BACS scores, total 
CAARMS scores and GAF scores was explored. In addition, CAARMS perceptual 
abnormality scores were included, as auditory gamma-band oscillations may also 
be relevant for the generation of hallucinations (Spencer et al., 2009). 
The potential impact of demographic variables age and gender on the 40 Hz 
ASSR-measures was explored in separate analyses. Results indicated that neither 
variable likely affected the outcome of the main ASSR analyses, as no significant 
relationship was found with ASSR measures in the ROIs. Thus, these variables 
were not corrected for in the main analyses.  
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4.3 Results 
4.3.1 Behavioural Data 
Mean RTs were not different between groups (Welch F(2)=1.06, p=0.36), but 
differed in group variance (Levene statistic=4.22, p=0.02). Furthermore, there 
was a significant group difference in response accuracy, expressed as d’ 
(H(2)=6.88, p=0.03). This difference represented a significantly poorer response 
accuracy in CHR (U=1651.50, p=0.01, N=135), and FEP (U=441.00, p<0.001, N=57) 
compared to controls. 
4.3.2  Effect of Stimulation Across Groups 
Data recorded during baseline and 40 Hz stimulation were compared across 
groups to establish whether the paradigm elicited a statistically significant 
evoked response (stimulation effect).  A statistically significant evoked increase 
spectral power was observed in sensor MEG data (t(155)=9.01, p<0.001, cluster 
correction), as well as for 40 Hz ITPC (t(155) =14.78, p<0.01, cluster correction), 
primarily over temporal regions. In addition, a wide-spread whole brain beta 
power activation at 15-25 Hz was also observed (t(155)=0.86 to 6.37; p=6.66e-04 
to 0.17). Across groups, this beta response emerged around 350 ms over frontal, 
temporo-parietal and occipital areas (Figure 7B), with particularly pronounced 
activation over the left-hemisphere. 
The sensor level effects were reflected in virtual channel source data, where 
significant false discovery rate (fdr) corrected effects were observed for 
40 Hz ASSR power and ITPC (Table 4). A significant stimulation effect for 
spectral power in the beta 15-24 Hz range was also found on virtual channel 
level, across all nodes (all p≤0.002, fdr corrected)  
4.3.3 40 Hz Spectral Power: Sensor Analysis 
Group comparisons of sensor level data revealed no significant difference in 
40 Hz ASSR power (38-42 Hz) (F(2)=3.49e-05 to 9.54; p=0.41 to 1.00) (Figure 7A). 
Moreover, no significant difference was found in a separate analysis focusing 
only on CHR and control participants (t(138)=-3.91 to 3.48; p=0.41 to 1.00). 
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Figure 7 Evoked Spectral Power Measured during 40 Hz ASSR Stimulation, in Control 
Participants, CHR Participants and FEP patients. Showing A) Time-Frequency Plots and 40 
Hz Topographies, B) Beta (15-25 Hz) Post-Hoc Topographies 
4.3.4 Beta Spectral Power: Sensor Analysis 
A strong beta band activation in the 15-25 Hz range was observed across groups 
at sensor level (Figure 7B), warranting post-hoc investigation. However, there 
was no difference in beta power between groups in sensor data (F(2)=3.13e-04 
to 5.80, p=0.14 to 1.00), measured from 500-1500 ms.  
4.3.5 Inter-Trial Phase Coherence: Sensor Analysis 
Sensor level analyses comparing the 40 Hz ASSR ITPC between groups revealed 
no significant effect (F(2)=5.76x105 to 9.97,  p=0.55 to 1.00). Planned post-hoc 
tests between CHR and controls (t(138)=3.88 to -3.42, p=1.00 to 0.28) and 
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between FEP and controls (t(62)=3.66 to -4.01, p=1.00 to 0.15) also did not 
reveal significant differences between groups.   
Figure 8 Sensor Level ITPC Data Recorded During 40 Hz ASSR Stimulation. Absolute 
Baselined Data.  
In addition to sustained 40 Hz activity, a low-frequency evoked response in the 
0-20 Hz range was observed from stimulus onset to 250 ms post-stimulus 
(Figure 8). Analyses of this evoked response revealed no significant differences 
between groups at sensor level (F(2)=0.003 to 8.41, min p=0.34).  
4.3.6 40 Hz ASSR Power: Source Analysis 
Nine ROI nodes were selected for spectral power analyses, identified by 
selecting auditory, subcortical and cerebellar nodes significantly activated 
during ASSR stimulation (Table 4). 
Group analyses revealed no effect in primary auditory areas, but a statistical 
trend was found in the RSMG (F(2)=2.77, p=0.06) (Table 5). Post-hoc tests 
showed a significant reduction for both the CHR and FEP-groups. A transient 
reduction was also seen the right cerebellar areas 4-5 (Figure 9). The effects did 
not survive fdr correction for multiple comparisons. 
No statistical group difference in 40 Hz ASSR baseline power was detected 
(F(2)=0.11 to 2.05; p=0.13 to 0.91).  
LEFT - Phase-locking value GA46HC
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
LEFT - Phase-locking value GA93AR
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
Time (s)
F
re
q
u
e
n
c
y
 (
H
z
)
LEFT - Phase-locking value GA17FEP
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
RIGHT - Phase-locking value GA46HC
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
Time (s)
F
re
q
u
e
n
c
y
 (
H
z
)
RIGHT - Phase-locking value GA93AR
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
RIGHT - Phase-locking value GA17FEP
 
 
0 0.5 1 1.5 2
10
20
30
40
50
0
0.1
0.2
ITPC
ITPC
ITPC
Control
time=150-1950 ms
 
 
0 0.1 0.2
ITPC
CHR
time= 150-1950 ms 
 
0 0.1 0.2
ITPC
FEP
time=150-1950 ms 
 
0 0.1 0.2
ITPC
Chapter 4 
68 
 
Table 4 Brain Regions of Interest Selected for 40 Hz ASSR Analyses 
Brain Region Local Maxima MNI 
Coordinates  
(right, anterior, superior) a 
ITPC ROI Spectral power ROI 
Left Supramarginal Gyrus (LSMG) -55.79 -33.64 30.45 ✓  
Right Supramarginal Gyrus (RSMG) 57.61 -31.5 34.48 ✓ ✓ 
Left  esch ’s Gyr s  L ES  -41.99, -18.88, 9.98 ✓  
Ri ht  esch ’s Gyr s (RHES) 45.86, -17.15, 10.41 ✓ ✓ 
Left Superior Temporal Gyrus (LSTG) -53.16, -20.68, 7.13 ✓  
Right Superior Temporal Gyrus (RSTG) 58.15, -21.78, 6.8 ✓ ✓ 
Left Medial Temporal Gyrus (LMTG) -55.52, -33.8, -2.2 ✓  
Right Medial Temporal Gyrus (RMTG) 57.47, -37.23, -1.47 ✓ ✓ 
Left Inferior Temporal Gyrus (LITG) -49.77, -28.05, -23.17 ✓  
Right Inferior Temporal Gyrus (RITG) 53.69, -31.07, -22.32 ✓ ✓ 
Left Hippocampus (LHIP) -25.03, -20.74, -10.13 ✓  
Right Hippocampus (RHIP) 29.23, -19.78, -10.33 ✓ ✓ 
Left Thalamus (LTHA) -10.85, -17.56, 7.98 ✓ ✓ 
Right Thalamus (RTHA) 13, -17.55, 8.09 ✓ ✓ 
Right Cerebellar areas 4-5 (RCRBL45) 17.20, -42.86, -18.15 ✓ ✓ 
Right Cerebellar area 10 (RCRBL10) 25.99, -33.84, -41.35 ✓  
a) Coordinates from Tzourio-Mazoyer et al. 2002 
 
 
Table 5 40 Hz Spectral Power Analyses 
Brain 
region 
Group Analysis CHR vs HC FEP vs HC 
F p t  p d t    p d 
RSMG 2.77 0.06 -2.23 0.02* -0.45 -1.41 0.06 -0.39 
RHES 0.12 0.89 0.41 0.35 0.08 -0.04 0.49 -0.01 
RSTG 0.12 0.89 0.05 0.47 0.02 -0.37 0.42 -0.10 
RMTG 1.08 0.35 -1.15 0.12 -0.20 0.34 0.35 0.10 
RITG 0.08 0.91 -0.05 0.46 -0.00 -0.39 0.37 -0.10 
RHIP 0.04 0.96 0.61 0.28 0.05 -0.39 0.37 0.00 
LTHA 0.45 0.66 0.23 0.42 0.04 -0.05 0.50 0.22 
RTHA 0.32 0.74 0.12 0.45 -0.10 0.73 0.25 -0.19 
RCRBL45 0.47 0.61 -0.61 0.26 0.13 -0.67 0.25 -0.10 
a) Data averaged across trial time-window 
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Figure 9 40 Hz ASSR Spectral Power Group Effects Across Trial in RSMG and RCRBL45. 
Including Group Difference Plots. Highlighted Regions Indicate Time Periods where Group 
Effect p<0.05 (uncorrected). No Effects Survived fdr Correction.  
 
4.3.7 Beta Power: Source Analysis 
Analyses of source reconstructed data in the beta (15-25 Hz) frequency band 
indicated whole brain increases in beta power during the 40 Hz ASSR stimulation 
compared to baseline . Group differences in 15-25 Hz power were detected in 7 
AAL nodes (Table 6; Figure 10). The largest effect was observed in the RSMA 
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(F(2)=3.85, p=0.02) and the LROL (F(2)=5.51, p<0.01). In particular, 15-25 Hz 
power in the LROL was impaired in both CHR and FEP participants compared to 
controls, with a more pronounced reduction in the FEP-group compared to CHR 
participants. 
 
Figure 10 Nodes with Significant Beta Range (15-25 Hz) Spectral Power Group Differences 
between 500-1500 ms (all p<0.05, fdr corrected). 
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Table 6 Beta Spectral Power: Virtual Channels with Significant Group Effects 
Brain Area Group Effect Post-Hoc 
CHR vs HC FEP vs HC FEP vs CHR 
F p t p d t p d t p d 
Right Superior 
Frontal Gyrus (RSFG) 
3.24 0.04* -2.59 0.01* 0.47 -0.82 0.22 0.23 0.78 0.21 -0.21 
Left Inferior Frontal 
Gyrus (LIFG) 
3.18 0.04* -2.11 0.02* 0.38 -2.32 0.01* 0.66 -0.73 0.24 0.19 
Right Supplementary 
Motor Area (RSMA) 
3.85 0.01* -2.31 0.01* 0.42 -2.08 0.01* 0.59 -1.02 0.16 0.27 
Left Dorsal Cingulate 
Gyrus (LDCG) 
3.23 0.04* -2.16 0.02* 0.39 -1.94 0.02* 0.55 -0.77 0.23 0.20 
Right Dorsal 
Cingulate Gyrus 
(RDCG) 
3.58 0.02* -2.26 0.01* 0.41 -2.01 0.02* 0.57 -0.87 0.20 0.23 
Left Rolandic Area 
(LROL) 
5.51 0.01* -2.00 0.02* 0.36 -3.17 0.00* 0.90 -2.17 0.02* 0.57 
Left Thalamus 
(LTHA) 
3.91 0.02* -2.27 0.02* 0.41 -2.21 0.01* 0.63 -1.11 0.14 0.29 
 
 
4.3.8 Inter-Trial Phase Coherence: Source Analysis 
Sixteen auditory, subcortical and cerebellar regions showed a significant change 
in ITPC (with T> 5) during ASSR stimulation and were selected as ROI nodes 
(Table 4). 
Source reconstructed time averaged ITPC data differed significantly between 
groups in the RSMG (Table 7; Figure 11). Moreover, in data not averaged across 
time, less sustained effects were seen in the LTHA, the LITG and the RCRBL10 
(Figure 11). All effects were driven by reduced ITPC in the CHR group. However, 
the effects did not remain significant after false discovery rate correction. 
Analyses of the early evoked ITPC response observed in the 0-20 Hz range at 0-
250 ms post-stimulus revealed a group difference in LHES (F(2)=3.10, p=0.02), 
representing increased ITPC in CHR compared to controls (t(138)=2.64, p=0.002, 
d=0.48). A trend group difference was present in LMTG (F(2)=3.07, p=0.05), 
corresponding to decreased ITPC in FEP compared to controls (t(62)=-2.20, 
p=0.01, d=-0.62). 
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Table 7 40 Hz ITPC Source Analyses 
Brain 
region 
Group Analysis CHR vs HC FEP vs HC 
F p t p d t p d 
LSMG 0.35 0.72 -0.83 0.21 -0.17 -0.04 0.50 -0.02 
RSMG 3.62 0.03* -2.69 0.00* -0.49 -1.43 0.07 -0.41 
LHES 0.10 0.92 -0.24 0.41 -0.04 0.23 0.40 0.07 
RHES 0.47 0.63 -0.88 0.20 -0.16 0.03 0.48 0.01 
LSTG 0.13 0.91 -0.17 0.41 -0.02 0.33 0.36 0.11 
RSTG 0.20 0.82 -0.45 0.34 -0.09 -0.55 0.30 -0.16 
LMTG 0.04 0.96 0.29 0.38 0.05 0.10 0.45 0.03 
RMTG 0.50 0.62 -0.98 0.16 -0.17 -0.19 0.45 -0.05 
LITG 0.87 0.43 1.16 0.13 0.21 0.96 0.16 0.28 
RITG 0.79 0.46 -0.88 0.19 -0.16 -1.09 0.14 -0.30 
LHIP 0.45 0.67 -1.05 0.15 -0.17 -0.16 0.44 -0.04 
RHIP 0.95 0.38 -0.72 0.24 -0.14 -1.26 0.09 -0.37 
LTHA 0.86 0.42 -1.33 0.10 -0.24 -0.06 0.50 -0.02 
RTHA 0.37 0.69 -0.88 0.20 -0.16 -0.42 0.35 -0.12 
RCRBL45 0.37 0.70 -0.46 0.32 -0.07 -0.75 0.23 -0.21 
RCRBL10 1.01 0.36 -0.40 0.35 -0.07 -1.28 0.10 -0.37 
  
4.3.9 Correlations 
No significant correlation was found between 40 Hz ASSR power in ROI’s and 
composite BACS scores across groups, or between 40 Hz ASSR power, composite 
BACS, total CAARMS scores or GAF scores within the CHR group alone. Likewise, 
there was no significant correlation between ASSR power and perceptual 
abnormality scores in CHR participants (Table 8). 
A significant correlation was found across groups between 40 Hz ASSR ITPC and 
composite BACS scores in the LSTG (Rho=-0.176, p=0.040) (Table 9). In the CHR 
group, a significant correlation was found between ITPC and total BACS scores in 
the LSTG (Rho=-0.264, p=0.015), total CAARMS scores in the LMTG (Rho=0.247, 
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p=0.023) and LITG (Rho=0.230, p=0.034), and between ITPC and perceptual 
abnormality scores in the LITG (Rho=0.266, p=0.013) (Table 9, Figure 12). 
Following false discovery-rate correction for multiple comparisons the 
correlations did not remain significant, with the lowest corrected values being 
p=0.125, for the correlations between 40 Hz ASSR ITPC and total CAARMS scores 
in the RSMG, RSTG, RHES, and LITG. 
 
Figure 11 ITPC during 40 Hz ASSR: Group Effects across Trial in RSMG, RCRBL10, LITG 
and LTHA, Including Group Difference Plots. Highlighted Regions Indicate Time Periods 
where Group Effect p<0.05 (uncorrected). No Effects Survived fdr Correction.  
Correlation analyses investigating relationships between beta range (15-25 Hz) 
spectral power and clinical measures demonstrated a positive relationship 
between GAF scores and power across all seven identified beta ROIs (Table 10, 
Figure 13). In the RSMA, RSFG and bilateral DCG, the correlations with GAF 
scores survived correction for multiple comparisons (fdr). A correlation was also 
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observed between total CAARMS scores and RDCG beta power in CHRs (Table 10, 
Figure 13). 
Table 8 40 Hz Spectral Power: Spearman Correlation Coefficients 
Brain 
Area 
All groups CHR only 
Composite 
BACSa 
Composite 
BACS 
Total 
CAARMS 
Perceptual 
Abnormalitiesc 
GAF 
RSMG  0.16b 0.05 0.11 0.11 -0.03 
RMTG  0.04 0.1 -0.05 -0.06 -0.05 
RSTG  0.04 0.09 0.00 -0.05 0.02 
RHES  -0.05 -0.07 -0.11 -0.16 0.01 
RITG  -0.04 -0.09 -0.13 -0.04 0.03 
a) z-transformed and gender corrected BACS score 
b) Spearman correlation coefficient 
c) Perceptual abnormality score measured on the CAARMS scale 
Table 9 40 Hz ITPC: Spearman Correlation Coefficients 
Brain 
Area 
All groups CHR only 
Composite 
BACSa 
Composite 
BACSa 
Total CAARMS Perceptual 
Abnormalitiesc 
GAF 
RSMG  
0.15b 0.16 -0.05 -0.13 -0.15 
LSMG 
-0.01 0.05 -0.02 0.05 0.04 
RSTG -0.01 0.03 -0.16 -0.10 0.06 
LSTG  -0.18* -0.26 0.16 0.21 -0.17 
RMTG 0.07 0.09 -0.03 -0.10 -0.04 
LMTG  -0.09 -0.07 0.25* 0.14 -0.07 
RHES 0.00 0.01 -0.15 -0.16 0.09 
LHES  -0.11 -0.19 0.08 0.15 -0.07 
RITG  0.02 0.04 0.03 -0.01 -0.16 
LITG  -0.13 -0.15 0.23* 0.27* -0.07 
a)z-transformed and gender corrected BACS score 
b) Spearman correlation coefficient 
C)Perceptual abnormality score measured on the CAARMS scale 
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Figure 12 Spearman Correlations between ITPC and Psychological Measures in CHR 
Participants. No fdr Correction.  
 
Table 10 Beta (15-25 Hz) Spectral Power: Spearman Correlation Coefficients 
Brain 
Area 
All groups CHR only 
Composite 
BACSa 
Composite 
BACS 
Total CAARMS Perceptual 
Abnormalitiesc 
GAF 
RSMA 0.16b 0.16 -0.19 -0.05 0.35** 
LROL 0.15 0.14 -0.15 0.03 0.21* 
LTHA 0.12 0.16 -0.15 -0.04 0.25* 
RSFG 0.09 0.06 -0.18 -0.09 0.30** 
LIFG 0.10 0.06 -0.08 -0.08 0.22* 
LDCG 0.10 0.14 -0.14 -0.06 0.32** 
RDCG 0.12 0.19 -0.21* -0.07 0.39** 
a)z-transformed and gender corrected BACS score 
b) Spearman correlation coefficient 
c) Perceptual abnormality score measured on the CAARMS scale 
*=p<0.05 (2-tailed); **=p<0.01 (2-tailed), effects survived fdr correction in RSMA, RSFG and bilateral 
DCG. 
rho = -.247*
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Figure 13 Spearman Correlations between Beta (15-25 Hz) Spectral Power, GAF and 
CAARMS Scores in CHR Participants. P-values for RSMA, RSFG and bilateral DCG survive 
fdr correction.  
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4.4 Discussion 
The results indicate that changes in 40 Hz ASSR spectral power and ITPC were 
present in CHR and FEP, but these were only detected in source reconstructed 
MEG-data. The absence of group differences in sensor data could be attributed 
to field spread, causing the signal at each sensor to contain information from 
multiple neuronal sources (Schoffelen & Gross, 2009), thus diluting small local 
effects in individual ROIs. Hence, the results suggest that alterations in 40 Hz 
ASSR spectral power and ITPC are subtle in both the CHR and FEP states. 
Behavioural analyses revealed no significant difference in RTs. However, 
response accuracy was reduced in CHR and FEP participants compared to 
controls. Thus, while overall response speed was equal across groups, 
performance was poorer in CHR and FEP, possibly reflecting attention 
impairments.  
Both spectral power and ITPC data point to impairments in the capacity of 
auditory networks to generate synchronised 40 Hz neural oscillations in FEP and 
CHR individuals, but this abnormality stemmed from aberrant functioning in 
secondary (RSMG), as opposed to primary, auditory areas. Hence, the data 
indicate that basic auditory processing impairments reflected by 40 Hz ASSR 
oscillation measures first develop in higher level secondary regions before 
affecting primary auditory regions in later stages of psychosis.  
The strongest impairments in both CHR and FEP participants were found in the 
RSMG. The SMG is part of the inferior parietal lobule, one of the last cortical 
regions to mature during development (Torrey, 2007). This area is involved in 
the integration of sensory data (Torrey, 2007), is closely linked to the auditory 
P300 event-related potential (Horovitz, Skudlarski, & Gore, 2002; Menon, Ford, 
Lim, Glover, & Pfefferbaum, 1997; Skosnik, Krishnan, & Donnell, 2007), and is 
also central in several complex auditory functions (Bangert et al., 2006; 
Niznikiewicz et al., 2000; Oberhuber et al., 2016; Rauschecker & Scott, 2009; 
Vines, Schnider, & Schlaug, 2006). Furthermore, an early study reported inferior 
parietal lobule involvement in the 40 Hz ASSR (Reyes et al., 2005). 
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In ScZ, the SMG has been highlighted as one of the regions involved in auditory 
hallucinations (Gaser, Nenadic, Volz, Büchel, & Sauer, 2004). In view of this 
potential role of the SMG in ScZ, future ASSR work should further explore 
impairments in this region, as the current findings suggest that such alterations 
may precede the onset of the first psychotic episode. 
Existing evidence suggests that CHR subjects may fail to sustain the 40 Hz ASSR 
(Koshiyama et al., 2018a; Tada et al., 2016). However, the current results 
indicate impairments in RSMG throughout the stimulation period, indicating that 
also the initiation of the ASSR could be abnormal. It should be noted that none 
of the 40 Hz ITPC and spectral power reductions in FEP and CHR-groups survived 
corrections for multiple comparisons. Nevertheless, the fact that both ITCP and 
spectral power reductions were observed in the same ROI suggests that 
potentially these impairments reflect an important aspect of circuit dysfunctions 
during emerging psychosis. 
An unexpected widespread increase in beta range power was detected during 40 
Hz ASSR stimulation across groups. This activation was not seen in ITPC data, 
suggesting that beta oscillations were non phase locked. Moreover, the 
activation did not resemble a resonance response to 40 Hz stimulation as it 
spanned approximately 10 Hz. Thus, the next paragraphs discuss established 
roles of beta oscillations and speculate about the signal observed in the current 
data.  
Beta oscillations play an important part in motor preparation and inhibition, 
manifested as a decrease in beta power immediately prior to a motor action, 
and a beta power increase, or rebound, during motor termination or inhibition 
(Kuhn et al., 2004; Y. Zhang, Chen, Bressler, & Ding, 2008). Thus, the observed 
beta response might reflect inhibition of motor activity (Heinrichs-Graham, Kurz, 
Gehringer, & Wilson, 2017; Wagner, Wessel, Ghahremani, & Aron, 2017), 
triggered as participants evaluated the ASSR stimulus and determined that it was 
not a “target” sound. This hypothesis is supported by the pattern of response, 
which was most pronounced in the left hemisphere, contralateral to the finger 
used for button presses in the attention task. Notably, spectral power at 15-25 
Hz was impaired in CHR and FEP participants compared to controls in several 
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regions, including areas implicated in motor function, such as the LROL and the 
RSMA. This is consistent with reported motor impairments in ScZ patients 
(Morrens, Docx, & Walther, 2014) and CHR individuals (Bernard & Mittal, 2014a; 
Gschwandtner et al., 2006). Notably, pharmacological data suggest a close link 
between beta oscillations and  GABAergic function in the motor system (Premoli 
et al., 2017). In vivo data have revealed a positive correlation between post-
movement beta rebound power and GABA levels in motor cortex (Gaetz, Edgar, 
Wang, & Roberts, 2011). Thus, the present findings may reflect early GABAergic 
changes in CHR individuals.  
Previous reports of beta oscillatory abnormalities in ScZ have also been linked to 
deficits in sensory and multi-sensory processing (Balz et al., 2016), as well as 
attention (Ghorashi & Spencer, 2015; Todorovic, Schoffelen, Ede, Maris, & De, 
2016) and salience signalling (Liddle et al., 2016) abnormalities. Among the 
regions affected in the current analyses are frontal and subcortical regions 
known to be involved in such functions (Pratt et al., 2017; Rueckert & Grafman, 
1996). Moreover, correlation analyses revealed a strong relationship between 
beta power and global functioning, whereby beta spectral power was positively 
related to GAF scores in the CHR group, suggesting that those assessed as lower 
functioning also showed weaker beta power activation. Hence, beta range group 
differences detected in CHR and FEP participants may represent early 
impairments in multiple functional domains.  
Correlation analyses in the 40 Hz range revealed a negative association between 
composite BACS scores and LSTG ITPC across groups, indicating a weak 
significant relationship between neural activity and cognition. These results 
suggest a relationship between the capacity to elicit 40 Hz auditory oscillations 
and cognitive performance. Furthermore, in the CHR group ITPC measures were 
correlated to both BACS and CAARMS scores in several nodes, but these 
relationships did not survive correction for multiple comparisons. Few prior 
investigations have explored clinical correlates of the ASSR in psychosis, nor in 
the at-risk state, and future investigations should map potential relationships 
further.  
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Finally, potential baseline power group differences were explored, as increased 
left hemisphere baseline power has previously been reported in 40 Hz ASSR 
recordings in chronic ScZ patients, along with trend increases in left hemisphere 
broadband power (Spencer, 2012). However, the present analyses did not 
replicate this finding in FEP and failed to detect any differences in baseline 
power in CHR. Thus, the current data do not indicate that baseline power 
differences could account for the task related effects reported here.  
The current results have limitations; 40 Hz ASSR abnormalities found in CHR and 
FEP were subtle, with small to moderate effect sizes, and did not survive 
stringent statistical correction. However, consistent impairments in RSMG in 
both spectral power and ITPC support the notion that the ASSR was impaired in 
this area. Furthermore, the study focused on CHR participants, resulting in a 
small FEP sample relative to the other two groups. However, power analyses 
indicated that the size of the FEP sample was sufficient to detect ASSR 
impairments with a power of 0.8. Furthermore, the CHR and FEP groups 
consisted of a mixture of unmedicated and medicated participants, including a 
variety of psychiatric medications ranging from anxiolytic to antipsychotic drugs. 
Future work should address the influence of various medications on the ASSR.  
Finally, the use of a beamformer algorithm for source reconstruction is a crucial 
methodological limitation which might have hindered the detection of statistical 
effects. The beamformer methods rely on the assumption that no sources in the 
brain are strongly correlated (Hillebrand, Singh, Holliday, Furlong, & Barnes, 
2005), yet in the case of 40 Hz ASSR stimulation where both hemispheres are 
entrained to the same auditory stimulus, the left and right auditory cortex are 
naturally correlated. This caused clear issues when whole-brain source data 
were explored using the LCMV algorithm compared to an alternative “exact low-
resolution brain electromagnetic tomography” approach (eLoreta) (Pascual-
Marqui et al., 2011; Pascual-Marqui, Michel, & Lehmann, 1994). However, when 
analyses focused on specific centroids of AAL ROIs, the results obtained using 
LCMV were equivalent to those from eLoreta. Thus, it was assumed that AAL ROI 
LCMV data were successfully reconstructed despite correlated auditory sources, 
and these data were therefore selected for analyses instead of eLoreta data due 
to the superior resolution of beamformer data (Hillebrand et al., 2005). 
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Nevertheless, it is possible that correlated signals may have caused some 
cancellation of sources, meaning that the effects seen in the present analyses 
may be weaker than if a more appropriate method had been employed.  
4.5 Conclusion 
Analyses provide evidence that the patterns of 40 Hz ASSR activation are 
aberrant in CHR and FEP participants, but effects were small to moderate. 
Furthermore, a strong relationship was seen between beta power elicited during 
40 Hz ASSR stimulation and CHR participants’ GAF scores. As such, the measure 
could help inform the understanding of oscillatory changes associated with 
auditory function in the CHR state, and highlight alterations leading to the 
transition to psychosis and functional deterioration. Follow-up data from the 
current sample will be important to further investigate these changes.  
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Chapter 5 Neural Connectivity During 
Auditory Steady State Response Stimulation in 
the CHR State 
5.1 Introduction  
A prominent theory of ScZ postulates that the pathophysiology involves 
widespread neural dysconnectivity (Stephan, Friston, & Frith, 2009). Moreover, 
altered connectivity may underlie both sensory impairments and hallucinations 
in psychosis (Ford et al., 2012). Neuroimaging methods have been used to 
evaluate this hypothesis by exploring both structural and functional connectivity 
in ScZ (Fitzsimmons et al., 2013; Maran et al., 2016) and more recently in 
clinical CHR populations (Andreou, Leicht, et al., 2015; Ramyead et al., 2015). 
MEG/EEG allow the study of dynamic interactions between multiple brain 
regions (Maran et al., 2016), and are thus ideally suited for the study of 
functional connectivity. However, the number of MEG/EEG-studies in 
psychosis/ScZ are limited (Maran et al., 2016). In this chapter, Granger Causality 
(GC) functional connectivity data estimated from auditory steady state response 
(ASSR) task data from CHR individuals, FEP patients and healthy controls are 
presented. The aim of the analyses was to address the following questions: 1) Is 
functional connectivity impaired during the ASSR paradigm in FEP? and 2) Are 
potential impairments also present in participants meeting CHR criteria?  
Previous data suggest that ScZ patients have altered functional connectivity 
compared to control participants (Maran et al., 2016). Findings in resting state 
data indicate that alterations are present in all frequency bands from delta to 
gamma (Andreou, Leicht, et al., 2015; Di Lorenzo et al., 2015; Kam et al., 2013; 
Lehmann et al., 2014; Tauscher, Fischer, Neumeister, & Rappelsberger, 1998). 
Similarly, data from task based paradigms have revealed local changes in 
specific frequency bands (Griesmayr et al., 2014; Henshall et al., 2013; Krishna 
et al., 2015; Popov et al., 2014; Winterer et al., 2003). Moreover, there is some 
evidence that functional connectivity is altered also in CHR (Andreou, Leicht, et 
al., 2015).  
In the visual domain, EEG/MEG data indicate that healthy controls have higher 
frontal-posterior phase synchronization in the beta and low gamma frequency 
Chapter 5 
83 
 
range during a remembered pursuit task studying smooth pursuit eye movements 
(Krishna et al., 2015). A similar pattern of aberrant frontal-posterior connections 
was observed in a cognitive visuospatial delayed match to sample task 
(Griesmayr et al., 2014). Furthermore, ScZ patients displayed altered power and 
connectivity in the alpha and beta range in a facial affect recognition 
experiment (Popov et al., 2014).  
Notably, connectivity analyses of auditory data have revealed reductions in 
fronto-temporal coherence during an odd-ball paradigm in ScZ patients and their 
siblings (Winterer et al., 2003). Moreover, one study observed reduced 
interhemispheric coherence in four EEG electrode pairs in patients with auditory 
hallucinations compared both to healthy controls and patients with no recent 
auditory hallucinations (Henshall et al., 2013).  
So far there is insufficient data on connectivity networks implicated in the ASSR 
task (Chapter 3). Two studies have reported measures of functional connectivity 
during ASSR stimulation in ScZ patients (Mulert, Kirsch, Pascual-marqui, 
McCarley, & Spencer, 2011; Ying et al., 2015). One reported impaired inter-
hemispheric functional connectivity between primary, but not secondary 
auditory areas during the 40 Hz ASSR in ScZ relative to controls (Mulert et al., 
2011). Others found disrupted connectivity in a fronto–temporal network in ScZ 
during ASSR stimulation (Ying et al., 2015). Thus, connectivity data from local 
auditory networks during 40 Hz ASSR stimulation are lacking, both for ScZ, FEP 
and CHR. 
One measure of functional connectivity is Granger Causality (GC), a statistical 
measure of directed functional (“causal”) interactions, first developed in 
economics (Granger, 1969). The method is widely used in neuroscience, as it 
allows the identification of functional connections from time-series data (Seth, 
Barrett, & Barnett, 2015). In brief, the algorithm determines to what degree 
time-series data in a region A at time point t can be used to estimate the time-
series data in a region B at time point t+1. “Causal” connectivity is assumed if 
the signal at region B can be predicted better when the information from region 
A is included in the algorithm than when it is excluded (Granger, 1969), 
interpreted as signals in region A “causing” the time-course in region B.  
Chapter 5 
84 
 
Provided that data meet a set of assumptions (e.g. stochastic, stationary data), 
the GC method is efficient and has several benefits over other methods; In the 
frequency domain the GC index can be estimated both using a parametric and 
non-parametric method (Bastos & Schoffelen, 2016). The parametric approach is 
based on an autoregressive model, the selection of which is affected by 
individual subject data variability, task and data quality (Bastos & Schoffelen, 
2016). However, the non-parametric alternative circumvents this issue by 
estimating GC using data points from the entire frequency spectrum (Bastos & 
Schoffelen, 2016). Furthermore, the GC index can be estimated both in the time 
and frequency space, and the effect of potential confounding factors, such as 
differences in signal strength, can be minimized (Seth et al., 2015). However, 
the analyses remain prone to bias when trial numbers are low or when groups 
are unequal in size (Bastos & Schoffelen, 2016). 
In addition to evaluating strength of connections, recent findings suggest that GC 
data can provide an indication of whether a connection is primarily involved in 
feedforward or feedback signalling in terms of laminar connections (Michalareas 
et al., 2016). Interactions between feedforward and feedback signals are 
implicated in cognitive processing (Bubic, 2010; Clark, 2013; MacKay, 1954) and 
impairments in either type of pathway could account for impairments in 
cognition.  
Anatomically, feedforward connections are thought to originate primarily in 
superficial layers of the cortex and project to the granular layer (Felleman & 
Van Essen, 1991). In contrast, feedback connections typically originate in 
infragranular layers (Markov et al., 2014) and target cortical layers 1 and 6 
(Michalareas et al., 2016). These cellular divisions have been found to correlate 
with neural oscillation frequencies. Specifically, feedforward-associated layers 
show strong gamma-band synchronisation, while infragranular feedback layers 
appear associated with stronger alpha/beta oscillations (van Kerkoerle et al., 
2014). 
GC connectivity studies have provided further evidence for this framework 
(Bastos et al., 2015; Michalareas et al., 2016). A directed influences asymmetry 
index (DAI) was computed using GC neuroimaging data, and was found to 
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correlate with a supragranular labelled neuron index capturing the anatomical 
signature of the feedforward or feedback character of a projection (Bastos et 
al., 2015; Michalareas et al., 2016). Thus, it follows that computation of DAI 
from GC data may help elucidate how anatomical feedforward and feedback 
connections are involved in early deficits observed in psychosis 
In the following sections of this chapter, connectivity data from the YouR study 
CHR and FEP samples are presented. The analyses aim to evaluate ASSR task 
related connectivity in this group and investigate whether connectivity 
alterations could account for the subtle changes in spectral power and ITPC 
reported in Chapter 3. In addition, exploratory analyses of DAI indices are 
performed.  
5.2 Methods 
5.2.1 Data Collection and Statistical Analyses 
The analyses included ASSR data from 93 at risk participants, 17 FEP patients 
and 46 healthy controls outlined in Chapter 2. Detailed descriptions of 
psychological assessments and collection of MEG data are provided in Chapters 2 
and 4. All analyses described below were performed in the MATLAB toolbox 
Fieldtrip (Oostenveld et al., 2011). Statistical group differences were evaluated 
using a non-parametric Monte-Carlo permutation-based approach on time- and 
group-averaged data, across the analysed frequencies. Results were corrected 
for multiple comparisons using a fdr method. All statistical output reported are 
rounded to two decimals. 
5.2.2 MEG Data Analyses 
MEG-data were pre-processed and reconstructed as described in Chapter 4,  
Section 4.2. T1 weighted MRI scans recorded on a Siemens 3T Trio Trim scanner 
with 3D MPRAGE sequences (192 slices, voxel size 1 mm3, FOV=256x256x176 mm, 
TR=2250 ms, TE=2.6 ms, FA=9°), and converted to SPM8 format using MRIcron 
(Rorden & Brett, 2000) were used to create individual subject MEG headmodels 
and generate leadfields. MEG data were reconstructed in the source space using 
Linearly Constrained Minimum Variance (LCMV) (Van Veen et al., 1997) 
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beamformer spatial filters and the standardized Automated Anatomical Labelling 
(AAL) brain atlas (Tzourio-Mazoyer et al., 2002). Coordinates for the local 
maximum centroids of 116 AAL regions were specified in each subject brain from 
an MNI template and used to model signals at each brain region. Source 
modelling at the 116 AAL centroids was done on a grid size of 5mm, using the 
LCMV beamformer approach, individual subject head models and normalised 
leadfields. Next, the AAL source estimations from individual subject grid-points 
were normalized to an MNI template brain with dimensions 91x109x91 mm, to 
allow averaging data from different subject grids despite individual differences 
in brain anatomy data. The regions of interest (ROIs) selected for connectivity 
analyses were right Heschl’s gyrus (RHES), right superior marginal gyrus (RSTG) 
and right supramarginal gyrus (RSMG) (Figure 14). These regions were chosen 
based on their functional roles and observations from power and ITPC analyses 
(see Chapter 4).  
 
 
Figure 14 Nodes Included in GC Connectivity analysis 
 
The data from selected AAL ROIs were rescaled to account for individual 
differences in data strength and variability, potentially biasing statistical 
analyses. The maximum and minimum amplitude per trial and channel for each 
participant were used to transform the data to values between 0 and 1 
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(formula=X(t) – minamp/(maxamp-minamp), where X(t)=raw amplitude at time t) 
(Grent-’t-Jong et al., 2018). Furthermore, prior to Fourier Transformation the 
data were down sampled from 500 Hz to 200 Hz (using ft_resampledata) to make 
connectivity computations more efficient. 
Trials were cut into segments of 500 ms, starting at 350 ms to avoid evoked 
signals (analysis window: 350 ms – 1350 ms). This doubled the number of trials 
included in the analysis, improving the signal-to-noise ratio and thus making GC 
computations more reliable (Bastos & Schoffelen, 2016). A similar approach was 
adopted for the baseline analysis (-1000 ms - 0 ms).  
Fast Fourier Transformation (FFT) of AAL ROI data was performed by convolving 
the data with a complex wavelet (‘mtmconvol’), using a Hanning taper sliding 
window approach, 1 s padding, and smoothing of ±2 Hz, for frequencies 0-99 Hz. 
Measures of single subject GC connectivity between the 3 ROIs were computed 
using a non-parametric approach through matrix factorization and variance 
decomposition of the resulting Fourier spectrum. GC analyses were performed 
separately on data collected during stimulation and baseline data. GC data 
measured during ASSR stimulation was subsequently baseline corrected by 
subtracting GC baseline data.  
Additional frequency specific GC analyses were performed on FFT data averaged 
around the 40 Hz frequency band (38-42 Hz), as pronounced GC-values in this 
frequency range were expected given the 40 Hz entrainment of auditory 
networks during the ASSR-stimulation.  
As the FEP group was smaller (n=17) than the other two groups, this group was 
compared to a subset of randomly drawn control participants (Bastos & 
Schoffelen, 2016).   
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5.2.3 Directed Influences Asymmetry Index 
Finally, the CHR and control 40 Hz specific GC data were studied further to 
clarify the degree to which each of the three GC connection pairs were 
feedforward or feedback. This was done using the DAI method which has been 
used recently in both in-vivo and human brain connectivity research (Bastos et 
al., 2015; Michalareas et al., 2016):  
𝐷𝐴𝐼(𝐴 −  𝑡𝑜 −  𝐵)  =
(𝐺𝐶(𝐴− 𝑡𝑜−𝐵)− 𝐺𝐶(𝐵− 𝑡𝑜−𝐴)
(𝐺𝐶(𝐴− 𝑡𝑜−𝐵)+𝐺𝐶(𝐵−𝑡𝑜−𝐴))
  
The numerator captures the predominant net direction of the connection (i.e. 
whether the connection is primarily feedforward or feedback), while the 
denominator serves as a normalization factor to account for differences in 
connectivity strengths between areas (Michalareas et al., 2016).  
5.2.4 Correlation Analyses 
Associations between GC connectivity data and attenuated psychotic symptoms 
and cognitive impairments in CHR were investigated using Spearman correlation 
analyses. GC connectivity at 40 Hz (38-42 Hz) in each connection was correlated 
with total CAARMS scores, perceptual abnormality CAARMS scores, and BACS 
scores (z-scored and adjusted for gender).  
5.3 Results 
5.3.1 Broadband Baseline Analyses 
Analyses of baseline connectivity across the 0 to 90 Hz range showed transient 
differences between CHR-participants and controls (p<0.05) in the connections 
RHES to RSMG around 80 Hz (CHR>Controls), RSMG to RHES around 40 Hz 
(Controls>CHR), RSMG to RSTG and RHES to RSTG (at 20, 30 and 40 Hz, 
Controls>CHR). Similar differences (p<0.05) were seen between the FEP-group 
and controls around 30-40 Hz for the connections RHES to RSTG and RSMG to 
RHES (Controls>FEP). Furthermore, stronger increases were seen around 20 and 
40 Hz for RSTG to RSMG in FEP baseline data (p<0.01) (Figure 15B). 
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5.3.2 Broadband Stimulus Evoked Analyses 
Analyses of stimulus-related GC data (baseline corrected) revealed significant 
(p<0.01) group differences for FEP compared to controls at 20 Hz for the 
connection RHES to RSTG (Control > FEP), and at 30 Hz for RSMG to RSTG 
(Control > FEP). There was also a weaker reduction in FEP GC compared to 
controls in RSMG to RSTG at 20 Hz (p<0.05). 
There was a significant group difference (p<0.01) between CHR and controls at 
30-40 Hz for RSTG to RSMG (Control > CHR) and at around 40-50 Hz for RSMG to 
RHES (Control > CHR) (Figure 15A). In addition, CHR GC was also reduced for 
RSMG to RSTG around 15, 30 and 70 Hz (p<0.05).  
5.3.3 40 Hz Frequency Specific Analyses 
When analyses were restricted to the 38-42 Hz range, no significant differences 
were found between FEP and controls. However, a network of reduced 
connectivity was found in CHR-participants (Figure 17), involving connections 
between the following nodes: RSTG to RSMG (t(138)=-3.04, p=0.003,d=0.53), 
RSMG to RHES (t(138)=-2.23 , p=0.01, d=0.39) and RHES to RSMG (t(138)=-1.94, 
p=0.03, d=0.33 ) (Table 11A).  
5.3.4 Directed Influences Asymmetry Index 
Across groups, DAI values at 40 Hz indicated feedback connectivity for the RSMG 
to RHES connection, while the RSTG to RSMG and RSTG to RHES connections 
were predominantly feedforward (Table 11B).The DAI values were lower in 
CHRs, suggesting that the degree of feedforward or feedback directionality was 
less pronounced in the CHR group, but there was no statistically significant 
group difference.  
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Figure 15 GC in Baseline Data for A) CHR vs Controls and B) FEP vs Random Subset of 
Controls. All p-values uncorrected.  
 
5.3.5 Correlation Analyses 
Correlation analyses between GC averaged at 40 Hz (38 – 42 Hz) and total 
CAARMS, CAARMS PA and total BACS scores did not reveal any significant 
relationships between symptom severity and connectivity measures in the CHR-
group. Associations varied in strength from RHES to RSTG connectivity vs total 
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CAARMS scores (Rho=0.16, p=0.14) to RSMG to RSTG connectivity vs total 
CAARMS (Rho=0.01, p=0.94).  
 
Figure 16 GC Data during ASSR Stimulation for A) CHR vs Controls and B) FEP vs Random 
Subset of Controls. All p-values uncorrected. 
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Figure 17 40 Hz GC Reduced Connectivity in CHR vs Controls. P-values uncorrected. 
 
Table 11 A) Group Comparison of 40 Hz GC in CHR vs control participants. B) Directed 
Influence Asymmetry Index (DAI) at 40 Hz. All p-values uncorrected. 
A Connection t 
Statistic 
95% Confidence 
Interval 
p d 
 RHES to RSMG -1.95 -0.02 to 0.69 0.03* 0.33 
RSTG to RSMG -3.04 0.17 to 0.89 0.00* 0.53 
RSMG to RHES -2.23 0.04 to 0.75 0.01* 0.39 
RSTG to RHES -1.58 -0.08 to 0.63 0.07 0.27 
RSMG to RSTG -0.40 -0.27 to 0.44 0.36 0.08 
RHES to RSTG -1.50 -0.09 to 0.62 0.08 0.26 
 
B Connection Control DAI CHR DAI Mann Whitney U  p d 
 RHES to RSMG -2.20 -0.32 1045.00 0.87 0.32 
RSTG to RSMG 10.56 3.13 939.00 0.37 -0.06 
RSTG-to-RHES 4.48 0.67 1050.00 0.89 -0.04 
 
5.4 Discussion 
The results suggest altered connectivity patterns in auditory pathways in FEP 
and CHR individuals compared to controls. The nature of these alterations differ 
between groups, with FEP participants showing baseline deficits in lower 
Granger Causality  
  
At-risk vs. Controls 
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frequency bands during the 40 Hz stimulation period, while CHR impairments 
were primarily seen in the 40-50 Hz range during stimulation.  
Broadband analyses of the baseline data showed increased baseline connectivity 
in the FEP group compared to controls around 20 Hz and in the 40-50 Hz band in 
the RSTG to RSMG connection (p<0.01). No such elevations were detected in the 
CHR group. Hyperconnectivity has been highlighted as a potential mechanism 
underlying auditory hallucinations (Ford et al., 2012), through elevated 
connectivity between temporal and subcortical regions, as demonstrated by fMRI 
evidence (Hoffman, Hernandez, Pittman, & Hampson, 2011). Thus, baseline 
hyperconnectivity in FEP individuals may reflect emerging auditory 
hallucinations. This should be explored further through correlation analyses with 
auditory hallucination scores in a larger FEP group.  
In contrast, baseline analyses also revealed connections with reduced GC 
(p<0.05) in CHR and FEP participants in both the beta and gamma frequency 
range. Paradoxically, hypoconnectivity could also be implicated in hallucinations 
(Ford et al., 2012), via resulting impairments in self-monitoring and self-
recognition processes such as efference copy (Melloni et al., 2007). Moreover, 
hypoconnectivity is thought to contribute to basic attention deficits (Rosenberg 
et al., 2016), reflected in negative and cognitive symptoms of psychosis. Thus, 
the detected emerging connectivity alterations may interact to contribute to 
both perceptual and cognitive abnormalities.  
Analyses of task data measured during 40 Hz ASSR stimulation showed reduced 
connectivity at 20 Hz from RHES to RSTG, and at 30 Hz from RSMG to RSTG for 
FEP patients, while GC-connectivity at 40 Hz was intact. Notably, one of the 
connections affected by this reduction was intact in the baseline (RSMG-RSTG). 
Hence, stimulation deficits are unlikely to be driven exclusively by underlying 
baseline differences. Thus, the data indicate that the FEP state is associated 
with auditory connectivity alterations both in baseline and during stimulation, 
primarily in the beta and low gamma frequency range.  
Significant group differences in GC were also seen between CHR participants and 
controls, reflecting reduced connectivity between RSTG and RSMG at 30-40 Hz, 
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and between RSMG and RHES in the 40-50 Hz frequency range. Thus, the GC 
impairments in CHR were observed around the frequency range of the ASSR 
stimulus, indicating that emerging CHR symptoms may be associated with a 
reduction in the ability to entrain to the 40 Hz ASSR stimulation. Indeed, CHRs 
showed bidirectional connectivity impairments between lower- and higher-level 
auditory processing regions during 40 Hz ASSR stimulation, suggestive of 
abnormal network entrainment. 
Frequency specific analyses of GC data averaged around 40 Hz (38-42 Hz) were 
performed for the CHR and control groups. In line with broadband analyses, 
results showed significantly lower connectivity from RSTG to RSMG and bi-
directionally between RSMG and RHES in CHRs compared to controls. 
Moreover, the 40 Hz specific GC data were used to compute DAI values for each 
participant in both CHR and control groups, with the aim to determine the 
degree to which each node pair represented a laminar feedforward or feedback 
connection in the 40 Hz range. This approach was based on previous work 
indicating a close link between DAI measures and a supragranular labelled 
neuron index (Bastos et al., 2015). Across controls and CHR participants, DAI 
indices indicated that 40 Hz GC connections between the RSTG and RSMG, and 
between RSTG and RHES were primarily feedforward, while the connection 
between RHES and RSMG represented primarily feedback laminar projections. 
The DAI values were lower in the CHR group across all three node pairs, 
potentially suggesting a less clear division between feedforward and feedback 
connections in this group. However, this group difference was not statistically 
significant. 
Results presented in Chapter 4 suggest that spectral power and ITPC during 
40 Hz ASSR stimulation were impaired in CHR individuals compared to controls, 
particularly in the RSMG. The present connectivity analyses provide a theoretical 
framework to explain these findings as the GC analyses reveal that the 
establishment of network connectivity at 40 Hz is impaired between primary 
auditory regions and RSMG, especially in the bottom-up direction, suggesting 
that the 40 Hz ASSR generated in RHES and RSTG could not successfully transfer 
to RSMG through these pathways. Subsequent DAI analyses revealed that the 
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affected connections represented both feedforward and feedback laminar 
projections, potentially pointing to bidirectional anatomical connectivity 
abnormalities between primary auditory regions and RSMG during ASSR 
stimulation. This has implications for the development of psychotic symptoms, 
as the SMG and surrounding areas are involved in a range of sensory and 
language processing functions, and have been highlighted as key regions in the 
emergence of hallucinations (Torrey, 2007).  
Correlation analyses did not indicate a relationship between clinical data and 
connectivity measures in CHR. Contrary to the notion that connectivity deficits 
mirror hallucination symptoms (Ford et al., 2012), no relationship was seen 
between perceptual abnormality scores and connectivity measures.  
In this study, the selected nodes were spatially close, which could pose problems 
due to field-spread (Schoffelen & Gross, 2009). One way to address this issue 
would be to use alternative connectivity measures such as the weighted phase 
lag index, imaginary coherence or orthogonalized envelope correlation, which all 
involve correction for source signal leakage (Colclough et al., 2016). However, in 
the present analysis the direction of connectivity and the possible differential 
alterations in top-down and bottom-up connectivity between groups was of 
interest. GC provides information about directed connectivity, while none of the 
previously mentioned alternatives do (Colclough et al., 2016). Therefore, 
attempts to deal with signal leakage issue were instead done by reconstructing 
the data in source space, which reduces signal leakage (Schoffelen & Gross, 
2009). Assuming that any remaining field spread affected all experimental 
groups equally, the primary research question, whether there were connectivity 
differences between groups, could be addressed. Nevertheless, future studies 
should explore this SMG-HES and SMG-STG bilateral connections using both GC 
and other connectivity measures, in order to establish further to what degree 
signal leakage may have contributed to the present results.  
5.5  Conclusion 
This is the first report of GC connectivity during 40 Hz ASSR stimulation in a CHR 
sample and indicates impaired connectivity bidirectionally between higher and 
lower-level auditory regions during the stimulation period in the 40 Hz range. 
Chapter 5 
96 
 
Furthermore, similar patterns of connectivity deficits were seen in FEP, with 
additional observations of baseline hyper connectivity. Combined, the data 
reveal mechanisms potentially contributing to early psychotic symptoms and 
provide a novel insight into auditory connectivity during 40 Hz ASSR stimulation 
in CHR and FEP.  
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Chapter 6 Magnetic Resonance Spectroscopy 
Measures of GABA and Glx 
6.1 Introduction 
ScZ has been associated with impairments in glutamate and GABA signalling, 
indicating an abnormal cortical E/I balance (Anticevic & Lisman, 2017). Such 
deficits could account for gamma oscillatory abnormalities observed in patients 
(Uhlhaas & Singer, 2014), and could hence be a source of sensory processing 
deficits and cognitive impairments (Senkowski & Gallinat, 2015). Yet, the time 
of alteration onset is unclear, as studies exploring CHR participants remain 
relatively few in numbers and results have been inconclusive (Mikanmaa et al., 
2017). Thus, the aim of the analyses presented in this chapter was to use 1H-MRS 
to explore E/I balance changes in a larger CHR sample. Specifically, 1H-MRS  was 
used to collect measures of GABA and Glx, the latter being a molecular complex 
in the 1H-MRS metabolite spectrum containing the overlapping peaks of 
glutamate and glutamine (Merritt et al., 2016). Moreover, relationships between 
1H-MRS data and MEG-measures of neural oscillations were investigated. 
Uniquely, the 1H-MRS data were collected from bilateral auditory cortex, which 
is a key region of interest in terms of ScZ symptoms (Javitt & Sweet, 2015). 
As the major excitatory and inhibitory neurotransmitters in the central nervous 
system, glutamate and GABA are implicated in a vast number of neural 
functions, ranging from neural development and metabolic processes to higher 
cognitive functions (Newsholme, Procopio, Ramos Lima, Pithon-Curi, & Curi, 
2003; Wu & Sun, 2015). Reliable and accurate measures are thus important to 
map illness mechanisms and to evaluate pharmacological responses (Keshavan, 
Lawler, Nasrallah, & Tandon, 2017). Accumulating 1H-MRS evidence supports the 
notion that glutamate and GABA are altered in ScZ.  
The most consistently reported findings are elevated glutamate/Glx levels across 
multiple brain regions, including both temporal regions, the basal ganglia 
(Merritt et al., 2016; Poels et al., 2014) and frontal cortex (Poels et al., 2014). 
Notably, these observations are now also increasingly reflected in the CHR 
literature (Bossong et al., 2018; Fuente-Sandoval et al., 2011; Fuente-Sandoval 
et al., 2016; N. Tandon et al., 2013). In contrast, no significant effects were 
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found in relatives of ScZ patients (Block et al., 2000; Capizzano et al., 2011; 
Keshavan et al., 2009).  
GABA 1H-MRS measures in psychosis have been inconclusive (Egerton et al., 
2017; Wijtenburg et al., 2015), and the data available are limited. Reductions 
were noted in dorsal anterior cingulate cortex (Marenco et al., 2016) and 
bilateral calcarine sulci (Yoon et al., 2010) in ScZ, and in left basal ganglia, 
parietal occipital lobe (Goto et al., 2010) and the bilateral calcarine sulci 
(Kelemen et al., 2013) in FEP patients. In contrast, GABA elevations were 
observed in medial and dorsolateral prefrontal cortex, anterior cingulate cortex, 
occipital cortex and basal ganglia (Kegeles et al., 2012; Öngür et al., 2010; 
Rowland et al., 2013; Tayoshi et al., 2010) in ScZ. Changes in GABA have also 
been reported in CHR samples, suggesting that deficits may occur prior to 
diagnosis. Increased GABA was observed in bilateral dorsal caudate and medial 
prefrontal cortex (Fuente-Sandoval., 2016), while reduced GABA and GABA/Glx 
concentrations were seen in the left frontal lobe (Menschikov et al., 2016).  
1H-MRS measures of GABA and glutamate/Glx show high test-re-test reliability 
(Greenhouse, Noah, Maddock, & Ivry, 2016; Jensen, Auerbach, Pisoni, & 
Pizzagalli, 2017). However, GABA concentrations are not consistent across the 
cortex but vary between brain regions (Greenhouse et al., 2016). In addition, 
depending on the brain area, voxels contain different proportions of grey matter, 
white matter and cerebrospinal fluid (CSF), which may contain different levels 
of metabolites of interest and thus influence the overall result (Harris, Puts, & 
Edden, 2015). Traditionally, large voxels were placed over the centre of the 
brain. However, increased scanner strengths combined with modern optimized 
techniques and shimming sequences make it possible to place voxels over more 
specific regions, thus avoiding CSF and allowing for higher signal strength from a 
smaller voxel volume (Harris et al., 2015). 
In the present study, 1H-MRS data were collected from bilateral auditory cortex 
to allow correlations between 1H-MRS data with MEG-measurements of 40 Hz 
ASSRs. To the author's knowledge, these are the first reported 1H-MRS measures 
of GABA and Glx from auditory regions in psychosis. However, successful 
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recordings of 1H-MRS data from auditory cortex have been reported in other 
populations (Brown, Singel, Hepburn, & Rojas, 2013; Richards et al., 1997).  
The data were recorded on a 3T MRI scanner, which does not provide sufficient 
resolution to study the glutamate peak alone (Wong, Schranz, & Bartha, 2018). 
Therefore, the Glx complex (the overlapping peaks of glutamate and the 
glutamate pre-cursor glutamine) were measured to obtain an estimation of 
neural glutamate levels. This approach is supported by existing data suggesting 
that glutamate is the primary contributor to the Glx peak (Shungu et al., 2013). 
Furthermore, measures of glutamine and changes in the glutamine-glutamate 
equilibrium are potentially also useful as they may reflect glutamate turnover 
rates (Merritt et al., 2016).   
1H-MRS metabolite concentrations are measured relative to a reference 
molecule, typically the peak of water or of the metabolite creatine, since these 
are thought to be stable across disease states (Wijtenburg et al., 2015). 
However, empirical evidence suggests that creatine levels may be altered in 
psychotic patients compared to controls (Öngür, Prescot, & Jensen, 2009), and 
some papers reported a decrease (Bossong et al., 2018; Yoo et al., 2009) or 
speculated decrease (Wood et al., 2003) in creatine in high-risk populations. If 
true, using creatine as a reference could lead to misleading conclusions 
regarding Glx and GABA concentrations. Yet, others controlled for creatine group 
differences and found no significant effect (Fuente-Sandoval et al., 2016; 
Marenco et al., 2016), leaving the exact role of creatine in psychotic and CHR 
individuals unclear. In an attempt to clarify this question, a separate analysis 
was carried out on some data in this chapter, comparing measures done with 
water and creatine as reference respectively. 
6.2 Methods 
6.2.1 Sample  
Participants were recruited as part of the YouR study (Chapter 2). 1H-MRS data 
from voxels in right and left auditory cortex were analysed separately. Right 
hemisphere analyses included data from 64 CHR, 11 FEP and 31 healthy control 
Chapter 6 
100 
 
participants. For the left voxel the final sample size was 39 CHR, 7 FEP and 22 
healthy controls. 
6.2.2 1H-MRS Data Collection  
1H-MRS data were collected on a 3T Siemens Trio MRI scanner, using the 
MEGAPRESS+ sequence which is optimised for measures of GABA and has an 
inbuilt macro-molecule suppression. Voxels of 2 cm3 were placed in the bilateral 
auditory cortex and in the right visual cortex. Measures in the left auditory 
cortex started after approximately 12 months of data collection. Results from 
the visual cortex voxel are reported elsewhere (Grent-‘t-Jong, 2019, in press). 
Voxels were placed manually over Heschl’s gyrus and parts of the superior 
temporal cortex, using three planar views to identify anatomical landmarks and 
ensure optimal standardization across participants. Subsequently, the voxel was 
rotated to best fit the angle of the gyrus.  
 
Figure 18 Representative Voxel Placement in Right Auditory Cortex Placed Using T1 Planar 
Slice Views.  
FASTMAP shimming (Gruetter & Tkáč, 2000) of each voxel was applied to improve 
local-field homogeneity in ROIs. Next, three scans were acquired, including a 
full spectrum acquisition, a GABA-edited MEGAPRESS scan (128 trials) providing 
data on GABA and Glx concentrations, and an unsuppressed water scan (64 
trials). The MEGAPRESS parameters were: TR/TE=1500/68 ms, 1.9 ppm ON- and 
1.5 ppm OFF-resonance editing pulse frequencies (i.e., symmetric editing to 
suppress macromolecule contribution), 44 Hz editing Gaussian pulse bandwidth, 
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delta frequency of -1.7 ppm relative to water, 50 Hz water suppression, 90° flip 
angle, acquisition bandwidth of 1200 Hz, duration 426 ms, number of points 512. 
6.2.3 1H-MRS Data Processing and Analysis 
All 1H-MRS-data processing was performed in the open-source software Gannet 
(Gannet 2.1, Edden, Puts, Harris, Barker, & Evans, 2013). Water was used as the 
primary reference molecule for calculating GABA and Glx levels, but separate 
Glx analyses were also carried out with the metabolite creatine as reference. 
Levels of GABA were adjusted for voxel grey matter, white matter and 
cerebrospinal fluid content. 
Data quality was judged by inspecting GABA and Glx peaks and baselines visually, 
and by computing H/Cr fit-errors and the water peak width. Generally, data 
were included in the analyses if the H/Cr fit-error was lower than 15 and the 
water peak width was 12 or lower.  
Data were analysed statistically using SPSS statistics software (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM 
Corp). The distribution and variance of the data in each group was determined 
for each of three variables (GABA, Glx and the ratio GABA/Glx measured relative 
to water). All statistical output is presented rounded to 2 decimal figures. 
Initial analyses focused on CHR participants compared to controls, as the 
primary aim was to establish if differences exist between these groups. Due to 
non-parametric data the comparison was evaluated using Mann Whitney U non-
parametric tests. Exploratory secondary group analyses including FEP patients 
were performed using Kruskal-Wallis non-parametric tests.  
6.2.4 Correlation Analyses 
Spearman correlation analyses were performed between 1H-MRS data and total 
CAARMS scores, composite BACS scores and 40 Hz ASSR oscillatory power and 
ITPC measures across groups. Oscillatory data were extracted from the Heschl’s 
gyrus, superior temporal gyrus, medial temporal gyrus, supramarginal gyrus and 
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thalamus. The correlations were false discovery rate (fdr) corrected for multiple 
comparisons using the R stats package (version 3.1.2).  
The relationship between H1-MRS data and gender, age and global functioning 
(GAF) scores were explored in separate analyses to determine the potential 
impact of these variables on H1-MRS measures. Age and GAF scores were 
explored using ANOVA analyses, while gender was analysed using Pearson’s Chi2 
tests.  
Table 12 Demographic Characteristics of Samples 
Hemisphere Demographic 
variable 
Control At Risk FEP Group 
Statistic 
p 
Right Age (±sd) 22.33 (3.68) 21.85 (4.34) 23.73 (4.36) 0.98 (F) 0.38 
Gender (f:m) 1.73:1 3.57:1 0.57:1 6.89 (Chi2) 0.03 
CAARMS total (±sd) N/A 27.71 (16.64) 84.13 (27.81) -8.22 (t) <0.00 
GAF  (±sd) 86.90 (7.28) 57.78 (12.57) 45.33 (14.38) 82.63 (F) <0.00 
Left Age (±sd) 22.10 (3.06) 21.94 (4.52) 25.57 (5.13) 2.28 (F) 0.11 
Gender (f:m) 1.88:1 2.17:1 0.4:1 2.73 (Chi2) 0.26 
CAARMS total (±sd) N/A 28.17 (17.61) 90.67 (21.28) -7.81 (t) <0.00 
GAF (±sd) 89.75 (5.62) 56.69 (9.85) 41.14 (10.92) 119.02 (F) <0.00 
 
6.3 Results 
6.3.1 Sample 
Demographic characteristics are reported in Table 12. Neither the left nor right 
voxel samples differed significantly in age between groups. Gender proportions 
in each differed in the right (Pearson Chi2=6.89, Cramer V=0.26, p=0.03), but not 
in the left hemisphere (Pearson Chi2 =2.73, Cramer V=0.21, p=0.255). No 
association was found between any of the variables and the MRS measures in 
either the right or left hemisphere voxel.  
6.3.2 1H-MRS Group Comparisons 
There were no significant differences in 1H-MRS measures between CHR and 
controls in either hemisphere voxel (Table 13). Furthermore, secondary group 
analyses including the FEP group showed no statistical group difference in any of 
the measures (Table 13). 
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Figure 19 1H-MRS Measures of GABA, Glx and GABA/Glx Ratio in the Right and Left 
Auditory Cortex.  
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Table 13 Group Comparisons of 1H-MRS Data 
Main Analyses: 
 Controls vs CHR 
Control CHR  Ua p d 
Mean SD Mean SD 
Right GABA/Water) 2.65 0.81 2.77 1.12 989.0 0.92 -0.08 
Glx/Water  6.68 1.44 7.08 1.91 1111.0 0.58 0.08 
Ratio  0.41 0.15 0.41 0.16 918.0 0.64 -0.13 
Left GABA/Water  2.06 0.74 2.31  0.96 406.5 0.32 0.33 
Glx/Water  7.74 1.90 6.95 3.00 270.5 0.10 -0.21 
Ratio  0.28 0.12 2.17 10.61 440.5 0.11 0.25 
Additional Analyses: 
 Including FEP 
Controls CHR FEP Hb  p d 
Mean SD Mean SD Mean SD 
Right GABA/Water) 2.65 0.81 2.77 1.12 2.30 0.91 3.64 0.16 0.26 
Glx/Water  6.68 1.44 7.08 1.91 7.00 1.60 0.38 0.83 0.25 
Ratio  0.41 0.15 0.41 0.16 0.34 0.15 2.73 0.26 0.17 
Left GABA/Water  2.06 0.74 2.31  0.96 2.17  0.53 1.48 0.48 0.19 
Glx/Water  7.74 1.90 6.95 3.00 7.74 2.39 2.76 0.25 0.23 
Ratio  0.28 0.12 2.17 10.61 0.30 0.13 2.76 0.25 0.23 
a) U statistic from Independent Samples Mann-Whitney U test 
b) H-statistic from Kruskal-Wallis test 
 
 
 
Figure 20 A) Right Hemisphere Glx Data Referenced by Creatine, and  B) Right Hemisphere 
Glx Data Referenced by Water. 
Post-hoc comparisons of FEP compared to controls confirmed that there was no 
group difference between these groups, however there was a trend reduction in 
right hemisphere auditory GABA in FEP relative to controls (Left: GABA U=89.00, 
p=0.29, d=0.33, Glx U=74.00, p=0.98, d=0.17, Ratio U=77.00, p=0.70, d=0.29; 
Right: GABA U=111.00, p=0.09, d=-0.43, Glx U=199.00, p=0.64, d=0.34, Ratio 
U=117.00, p=0.13, d=-0.43).  
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The distribution and spread of data were inspected graphically (Figure 19) and 
evaluated statistically. There was no difference in variance between groups in 
either voxel for measures of GABA (Left: Levene statistic=1.19, p=0.28; Right: 
Levene statistic=0.83, p=0.36), Glx (Left: Levene statistic=1.07, p=0.31; Right: 
Levene statistic =3.02, p=0.09), or ratio (Left: Levene statistic=2.28, p=0.14; 
Right: Levene statistic =0.02, p=0.90).  
6.3.3 Role of Reference Molecule 
The comparison of water- and creatine-referenced right voxel Glx revealed that 
the data distribution and difference between groups remained similar 
(Glx/creatine: F(2)=1.15, p=0.32; Glx/Water: F(2)=0.73, p=0.49) (Figure 20). 
Thus, there was no indication that creatine-levels in the CHR or FEP groups had 
an impact on differences in GABA/Glx levels. 
6.3.4 Correlation Analyses 
A negative correlation was found between composite BACS scores and right 
auditory voxel Glx levels (Table 14), indicating that individuals performing worse 
in the BACS assessment had higher levels of Glx (Figure 21). Moreover, left 
auditory 1H-MRS Glx/water was positively correlated with ASSR power in LHES 
and LSTG (Table 15, Figure 21). However, the correlations did not survive fdr 
correction for multiple comparisons. 
Table 14 Psychological Variables: Spearman Correlations across Groups 
Hemisphere MRS Measure BACS (Rho) CAARMS (Rho) 
Right GABA/Water -0.08 -0.09 
Glx/Water  -0.23* 0.03 
Ratio  0.14 -0.06 
Left GABA/Water  0.12 0.15 
Glx/Water  0.14 -0.07 
Ratio  -0.01 0.07 
P<0.05 = * (uncorr) 
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Table 15 Spearman correlation coefficients for correlations between 1H-MRS data and 
ipsilateral 40 Hz ASSR power and phase measures 
ASSR 
Measure 
Hemisphere MRS measure HES (Rho) STG 
(Rho) 
MTG 
(Rho) 
SMG 
(Rho) 
THA 
(Rho) 
40 Hz 
Power 
Right GABA/Water 0.13 0.04 -0.03 -0.07 0.12 
Glx/Water -0.00 -0.16 -0.16 -0.09 -0.04 
Ratio (GABA/Glx) 0.06 0.16 0.10 -0.00 0.07 
Left GABA/Water 0.17 0.20 -0.03 0.19 -0.03 
Glx/Water 0.30* 0.29* -0.00 0.23 0.11 
Ratio (GABA/Glx) -0.11 -0.11 0.02 -0.09 -0.09 
ITPC Right GABA/Water -0.04 -0.01 -0.14 -0.13 -0.01 
Glx/Water -0.05 -0.10 -0.11 -0.12 -0.04 
Ratio (GABA/Glx) -0.03 0.06 -0.02 -0.01 0.01 
Left GABA/Water 0.03 0.15 0.14 0.06 0.06 
Glx/Water 0.01 0.25 0.12 0.06 0.07 
Ratio (GABA/Glx) 0.08 -0.10 -0.01 -0.02 0.06 
P<0.05 = * (uncorr) 
 
6.1 Discussion 
Based on the results presented in this chapter it is not possible to accept the 
hypothesis that E/I imbalances are present in the primary auditory cortex in CHR 
individuals. Earlier findings have varied, and in line with the present analyses 
several previous studies have failed to detect a difference in glutamate/Glx 
(Block et al., 2000; Keshavan et al., 2009; Wood et al., 2010, Cappizzano et al., 
2011) or GABA (Modinos, Şimşek, Horder, et al., 2018; Wang et al., 2016) 
compared to controls. However, the current analysis is limited by several 
methodological problems, possibly contributing to the lack of significant results.   
The preliminary results from FEP patients did not indicate prominent glutamate 
or GABA deficits compared to controls. However, a trend reduction in GABA 
levels was detected in the right auditory voxel, suggesting that subtle emerging 
deficits may be present. Potentially, this difference might be stronger in a larger 
sample. Here data could not be used or were missing from 6 (right voxel) or 8 
(left voxel) participants, resulting in 11 and 9 included participants respectively 
and thus underpowered analyses (power for left voxel max effect=0.13; power 
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for right voxel max effect =0.22). Thus, further work is required to clarify the 
extent to which auditory 1H-MRS impairments are present in FEP.  
 
Figure 21 Relationship between A) Left Heschl’s Gyrus 40 Hz ASSR Power and Left 
Hemisphere Glx Data, B) Left Superior Temporal Gyrus 40 Hz ASSR Power and Left 
Hemisphere Glx Data and C) Total BACS Scores and Right Hemisphere Glx Data, across the 
Three Study Groups. All p-values uncorrected. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
C 
rho = 0.23
p = 0.02*
-8
-4
0
4
6 9 12
Glx
B
A
C
S
Group
At-risk
Control
FEP
Total BACS score vs. Right Glx Correlation Across Groups
rho = 0.29
p = 0.02*
-0.1
0.0
0.1
0.2
0 5 10 15
LGlx
L
S
T
G
_
p
o
w Group
AtRisk
Control
FEP
Left STG power vs. Left Glx Correlation Across Groups
rho = 0.30
p = 0.02*
-0.1
0.0
0.1
0.2
0.3
0 5 10 15
LGlx
L
H
E
S
_
p
o
w Group
AtRisk
Control
FEP
Left HES power vs. Left Glx Correlation Across Groups
Chapter 6 
108 
 
Right hemisphere Glx measures were negatively correlated with composite BACS 
scores, indicating that 1H-MRS abnormalities may be present in participants with 
poorer cognitive capacity. The potential link between Glx and cognition could 
have further implications as cognition is closely linked to basic sensory and 
neural functions and is the strongest predictor of global functioning (Fusar-Poli , 
Papanastasiou, et al., 2015). However, the correlation was weak and did not 
survive correction for multiple comparisons.   
One of the analysis objectives was to investigate the relationship between GABA 
and Glx measured through 1H-MRS, and oscillatory 40 Hz ASSR measures. 
Previous studies have reported correlations between 1H-MRS measures of GABA 
(Muthukumaraswamy, Edden, Jones, Swettenham, & Singh, 2009) and glutamate 
(Falkenberg, Westerhausen, Specht, & Hugdahl, 2012) with fMRI and MEG 
measures in controls.  The present results revealed that left hemisphere 
Glx/water data were weakly correlated with 40 Hz ASSR oscillatory power in 
ipsilateral primary auditory regions (Heschl’s gyrus and superior temporal gyrus) 
across groups, however this association did not survive correction for multiple 
comparisons. Hence, the current results are in line with others which failed to 
detect significant correlations between MEG and 1H-MRS measured GABA and 
glutamate in controls (Cousijn et al., 2014). 
Water was selected as reference molecule in this analysis, primarily to enable 
correction for tissue composition in the computation of GABA, but also to 
circumvent potential group differences in creatine (Öngür et al., 2009). Early 
H1-MRS reports in ScZ highlighted alterations in creatine kinase, an enzyme 
which catalyses the conversion of creatine (Burbaeva, Savushkina, & Boksha, 
2003), and indicated impaired creatine in patients (Öngür et al., 2009).   
However, the exploratory comparisons of water- and creatine-corrected Glx 
measures in the current study did not suggest significant differences in outcome 
depending on which reference molecule was used.  
The auditory cortex poses challenges for 1H-MRS measurements due to its small 
size and the proximity to the scalp and cerebrospinal fluid, which can adversely 
affect the signal quality. Yet, the shimming and data quality parameters 
obtained from the 1H-MRS scans were within the normal range for the data 
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presented in this chapter, suggesting adequate quality. However, rejection of 
poor data and limited data availability resulted in relatively small groups and 
low statistical power, particularly for FEP participants. Accordingly, larger 
datasets are required to obtain more robust insights into the presence of E/I-
abnormalities in early-stage psychosis. 
Moreover, the present analyses focused on GABA and Glx rather than GABA and 
glutamate. Glx is assumed to provide an indirect indication of glutamate levels 
but is also affected by glutamine (Merritt et al., 2016). Consequently, any 
detected changes in Glx could be caused by alterations in glutamate, but also by 
altered glutamine levels, complicating the interpretation of results. 
Furthermore, it is important to note that glutamate has many roles in the human 
brain (McKenna, 2007), including non-excitatory metabolic functions  and exact 
levels vary between individuals (Krause & Kadosh, 2014). Thus, the usefulness of 
cross-sectional group comparisons for identifying true clinically relevant 
differences between patients and controls is unclear. Potentially, longitudinal 
follow-up measures could provide more meaningful measures for the detection 
of neurotransmitter alterations associated with psychosis onset risk.  
6.2 Conclusion 
The present analyses suggest that merely meeting threshold criteria for CHR or 
FEP diagnoses may not in itself be indicative of changes in auditory cortical E/I 
balance. However, neurocognitive functional impairments may be linked to a 
change in the equilibrium between Glx and GABA, through elevations of Glx, as 
indicated by weak correlations in left primary auditory cortex.
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Chapter 7 Longitudinal Data 
7.1 Introduction 
Traditionally, CHR intervention studies have focused on comparing CHR 
participants who transition to FEP versus those who do not (Fusar-Poli  et al., 
2013). However, 40-85% of participants meeting CHR criteria have been found to 
not convert within the time scope of studies (Addington et al., 2011), with 
declining transition rates in recent years (Fusar-Poli  et al., 2013). Furthermore, 
the CHR state is fluid, with a proportion of participants typically remitting fully 
over time, while others continue to meet CHR criteria.  
Previous work has highlighted that duration of symptoms as well as baseline 
global functioning are indicative of the functional prognosis (Fusar-Poli et al., 
2009; Larsen, Moe, Vibe-Hansen, & Johannessen, 2000). Furthermore, MRI 
studies have revealed correlations between baseline grey matter (GM) volume 
and conversion risk among CHR participants (Cannon et al., 2015; Pantelis et al., 
2003). Crucially, the relationship was not driven by antipsychotic medication 
(Cannon et al., 2015). Moreover, follow-up data revealed progressive GM loss in 
converted CHR individuals, while non-converters only showed GM impairments in 
the cerebellum at follow-up (Pantelis et al., 2003). Finally, the mismatch-
negativity ERP measured has been found to differentiate between CHR remitters 
and non-remitters (Kim, Lee, Yoon, Lee, & Kwon, 2018), and between converting 
and non-converting CHRs (Bodatsch et al., 2011). Thus, there is evidence that 
both clinical and neuroimaging variables may be useful for the detection of 
individuals who may require early intervention to prevent a poor clinical 
outcome.   
Attempts to develop individualised risk-predictors have employed computational 
modelling strategies and machine learning (Orrù, Pettersson-Yeo, Marquand, 
Sartori, & Mechelli, 2012). For instance, multiple demographic and clinical 
measures were combined to create a risk index calculator (Cannon et al., 2016), 
which showed reasonable prediction accuracy (Harrell’s concordance index 0.71 
and 0.79 respectively) in two separate samples (Cannon et al., 2016; Carrión et 
al., 2017).  
Chapter 7 
111 
 
Other investigators have employed machine learning strategies with structural 
(Koutsouleris et al., 2012, 2010; Sun et al., 2009) and functional (Shen, Wang, 
Liu, & Hu, 2010) MRI data in both CHR and established ScZ. These efforts yielded 
promising results (Orrù et al., 2012), but there is a lack of data from other 
imaging modalities such as EEG and MEG, which may be better suited for 
capturing subtle neural changes at early stages of psychosis.  
Accordingly, the aim of this chapter was to explore potential relationships 
between baseline ASSR measures (see Chapter 4) and clinical variables, with the 
objective to establish whether MEG oscillation measures are predictive of long-
term clinical outcomes. Four separate analyses were performed on contrasting 
CHR subgroup pairs, defined based on participant CHR state at follow-up, 
transitions to FEP, baseline and longitudinal measures of GAF.  
7.2 Methods 
7.2.1 Sample 
Data from 93 CHR participants and 46 healthy controls (described in Chapter 2) 
formed the basis for the analyses in this chapter. Data available from the 12-
month follow-up visit were used to explore the relationship between 40 Hz ASSR 
and beta power oscillatory data and longitudinal psychological/clinical 
outcomes.  
7.2.2 ROI Selection 
The present work was based on a data-driven approach whereby analyses were 
focused on source reconstructed 40 Hz power and ITPC-data from RSMG. 
Furthermore, analyses explored beta power (15-25 Hz) from seven nodes found 
to differ between CHR and controls in Chapter 4: Right Superior Frontal Gyrus 
(RSFG), Left Inferior Frontal Gyrus (LIFG), Right Supplementary Motor Area 
(RSMA), Left Dorsal Cingulate Gyrus (LDCG), Right Dorsal Cingulate Gyrus 
(RDCG), Left Rolandic Area (LROL), Left Thalamus (LTHA). Additional 
supplementary analyses of 40 Hz measures included all nodes from Chapter 4 
(Appendix 3). 
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7.2.3 Statistical Comparisons 
Analyses focused on CHR subgroups based on CHR status at the 12-month follow-
up (sustained CHR n=14; resolved CHR n=36), transitions (Transitions n=4; Non-
converters n=89) and GAF scores at baseline (high GAF scores ≥65: n=26; low GAF 
scores <65:n=61) and at the 12-month follow-up (high GAF scores ≥65: n=24; low 
GAF scores <65:n=26). High GAF scores represented no or mild functional 
impairment and low scores reflected moderate to severe impairments (Haining 
et al., 2019). 
7.3 Results 
At the 12-month follow-up, 14 of the included CHR participants met the CAARMS 
criteria for attenuated psychosis, while 36 did not meet criteria. Furthermore, 
at the time of analysis four CHR individuals had reached the FEP threshold. They 
were found to meet FEP criteria at their 6-month, 9-month and 12-month (two 
participants) follow-up visits respectively. 
 
Figure 22 Global Assessment of Functioning in CHR Sample at Baseline and 12M 
Assessments. 
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GAF data from the 12-month follow-up visit was available for 50 CHR 
participants. Data loss relative to baseline was due in part to participant 
disengagement, but 13 participants had not yet reached the 12-month follow-up 
at the time of analysis. Twelve CHR participants had high GAF scores (≥65) at 
both baseline and 12-months, 19 CHR had low GAF scores at both time-points 
and the remaining 19 participants changed GAF level between baseline and the 
12-month follow-up (Figure 22). At 12-months, the mean GAF score in the CHR 
group was 63.34 (sd±14.90). 
 
Table 16 RSMG 40 Hz Power: Comparisons between CHR Subgroups and Healthy Controls 
Groups 
based on 
Group 
Analysis 
Poor outcomea vs HC Good outomeb  vs HC Poor vs Good outcome 
F p t p d t  p d t p d 
CHR status at 
12 M 
0.55 0.55 -0.42 0.34 -0.11 -1.06 0.15 -0.25 0.32 0.35 0.14 
GAF at 
Baseline 
2.92 0.05* -2.39 0.01* 0.46 -0.88 0.20 0.20 1.11 0.13 -0.27 
GAF at 12 M 2.26 0.12 -0.31 0.38 0.09 -2.18 0.02* 0.55 1.65 0.05* -0.47 
Transitions 2.48 0.09 -0.54 0.33 0.28 -2.22 0.02* 0.40 0.19 0.37 -0.10 
a) Sustained CHR; GAF<65, Converted CHR 
b) Resolved CHR; GAF≥65, Non-converted CHR 
P<0.05 = * (uncorr) 
  
Table 17 RSMG 40 Hz ITPC:  Comparisons between CHR Subgroups and Healthy Controls 
Groups 
based on 
Group 
Analysis 
Poor outcomea vs HC Good outomeb  vs HC Poor vs Good outcome 
F p t p d t  p d t p d 
CHR status at 
12 M 
1.26 0.29 -0.90 0.19 -0.27 -1.52 0.06 -0.34 0.17 0.43 -0.05 
GAF at 
Baseline 
1.26 0.04* -2.45 0.01* 0.48 -1.61 0.06* 0.40 -0.37 0.35 0.09 
GAF at 12 M 1.79 0.17 -1.16 0.13 -0.28 -1.8 0.04* -0.45 0.57 0.29 -0.16 
Transitions 3.77 0.03* -0.35 0.43 0.18 -2.75 0.00* 0.50 0.61 0.25 -0.31 
a) Sustained CHR; GAF<65, Converted CHR 
b) Resolved CHR; GAF≥65, Non-converted CHR 
P<0.05 = * (uncorr) 
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7.3.1 RSMG 40 Hz ASSR 
7.3.1.1 Risk status 
Statistical comparisons showed no 40 Hz spectral power or ITPC group difference 
in RSMG (Figure 23, Figure 24).  
However, supplementary analyses indicated an increase in 40 Hz ASSR spectral 
power in sustained CHR participants in the right cerebellar areas 4-5 (RCRBL45) 
compared to both controls and resolved CHR participants (F=3.06, p=0.05; post-
hoc sustained CHR vs Controls t=2.25 , p=0.02 , d=0.70 ; post-hoc sustained CHR 
vs resolved CHR t=2.21, p=0.01, d=0.63) (Appendix 3). Considering small group 
sizes and modest statistical effects, this finding is preliminary and should be 
explored more, but it nevertheless highlights the cerebellum as a potentially 
important area in the CHR state.  
7.3.1.2 Global functioning levels  
Significant RSMG group effects were detected for both spectral power and ITPC 
measures, representing significant reductions in the CHR group with low GAF 
scores, and a trend for the CHR group with high GAF scores at baseline, relative 
to controls (Figure 23, Figure 24,Table 16; Table 17).  
When follow-up GAF scores were used to form CHR subgroups, no overall group 
effect was seen, yet post-hoc comparisons revealed that 40 Hz spectral power 
and ITPC measures were significantly reduced in the CHR group with high follow-
up GAF scores, relative to controls (Table 17). Furthermore, 40 Hz spectral 
power was reduced in CHR participants with high follow-up GAF scores compared 
to those with low follow-up GAF scores (Table 16). However, none of the 
observed effects survived fdr correction. 
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Figure 23 RSMG 40 Hz ASSR Power in Controls and CHR Subgroups Based on A) Risk 
Status at 12 Months Follow-Up, B) GAF Scores at Baseline, C) GAF Scores at 12 Month 
Follow-Up, D) Transitions  
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Figure 24 RSMG 40 Hz ASSR ITPC in Controls and CHR Subgroups Based on A) Risk Status 
at 12 Months Follow-Up, B) GAF Scores at Baseline, C) GAF Scores at 12 Month Follow-Up, 
D) Transitions   
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7.3.1.3 Transitions 
Visual observation of data indicated that the four CHR participants who 
converted to psychosis had stronger spectral power activation during 40 Hz ASSR 
stimulation in several nodes than the 89 CHRs who did not transition. There was 
no overall group effect in neither spectral power nor ITPC data (Figure 23, 
Figure 24). However, post-hoc tests showed that both RSMG spectral power 
(Table 16) and ITPC (Table 17) differed significantly in non-transitioned but not 
in transitioned CHR participants.  
7.3.2 Beta Frequency Nodes 
7.3.2.1 Risk status 
Trend group effects for the comparison between sustained and resolved CHR and 
healthy controls were detected for beta (15-25 Hz) spectral power in the right 
superior frontal gyrus (RSFG) and the left Rolandic area (LROL). These effects 
represented significant decreases in beta power in the sustained CHR group 
compared to controls in both regions and decreased LROL power in sustained 
CHR compared to resolved CHR (Table 18, Figure 25).  
Table 18 Comparisons of Beta Power in CHR Risk Subgroups and Healthy Controls 
ROI Group 
Analysis 
Sustained CHR vs HC Resolved CHR  vs HC Sustained vs Resolved 
CHR 
F p t p d t  p d t p d 
Right Superior 
Frontal Gyrus 
2.86 0.06* -1.98 0.01* 0.61 -1.69 0.05* 0.38 -0.91 0.17 0.28 
Left Inferior 
Frontal Gyrus 
1.34 0.29 -1.69 0.05* 0.52 -1.15 0.13 0.24 -0.50 0.31 0.17 
Right 
Supplementary 
Motor Area 
2.02 0.14 -1.90 0.03* 0.58 -0.95 0.17 0.19 -1.38 0.08 0.45 
Left Dorsal 
Cingulate Gyrus 
1.28 0.30 -1.49 0.07 0.46 -1.01 0.14 0.19 -0.73 0.24 0.27 
Right Dorsal 
Cingulate Gyrus 
1.89 0.18 -1.91 0.03* 0.58 -0.77 0.22 0.15 -1.43 0.06 0.48 
Left Rolandic Area 2.72 0.07* -2.38 0.01* 0.73 -0.87 0.18 0.17 -1.66 0.04* 0.55 
Left Thalamus 1.56 0.22 -1.65 0.05* 0.50 -1.03 0.14 0.17 -0.95 0.17 0.36 
P<0.05 = * (uncorr) 
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Figure 25 Beta Power (15-25 Hz) in Seven ROIs where CHR Differ Significantly from Healthy 
Controls; Subgroups Based on Risk Status at 12 Month Follow-Up. 
7.3.2.2 Global functioning levels 
Group effects were observed in all seven ROI’s for comparisons of controls and 
baseline GAF CHR subgroups. Post-hoc analyses revealed a strong reduction in 
power across all nodes for CHR participants with low baseline GAF (<65) 
compared to controls (fdr corrected), while individuals with high baseline 
GAF (≥65) did not differ from controls. Moreover, the low baseline GAF CHR 
group showed significantly reduced beta power relative to the group with high 
baseline GAF in the RSFG, RSMA, RDCG, and LROL. In addition, trend 
impairments were seen in the LIFG, LDCG and LTHA (Figure 26, Table 19).  
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Figure 26 Beta Power (15-25 Hz) in Seven ROIs where CHR Differ Significantly from Healthy 
Controls; Subgroups Based on CHR GAF Score at Baseline. 
For CHR subgroups divided based on the 12-month follow-up GAF score, 
significant group effects were detected in LIFG, bilateral DCG and LTHA, and 
trend effects were observed in remaining nodes. These reflected significant 
impairments in the CHR group with low follow-up GAF scores across nodes (fdr 
corrected in LIFG, LDCG and RDCG) compared to controls, and impairments 
relative to CHR participants with high follow-up GAF scores in all nodes except in 
the right superior temporal gyrus (Figure 27,Table 19).  
7.3.2.3 Transitions 
Statistical evaluations revealed a significant group effect in right superior frontal 
gyrus, reflecting reduced beta power in non-converters compared to controls. 
Furthermore, trend group effects were present in the remaining six ROIs, 
reflecting significant reductions for both converters and non-converters relative 
to controls in the LIFG and the LROL, and significant reductions in non-
converters vs controls in the RSMA, bilateral DCG and the LTHA. No group 
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differences were observed between converted and non-converted CHRs 
(Figure 28, Table 20). 
Table 19 Comparisons of Beta Power in CHR GAF Subgroups and Healthy Controls 
ROI Group Analysis Low GAF vs HC High GAF  vs HC Low vs High GAF 
F p t p d t p d t p d 
Baselinea 
RSFG 5.35 0.00* -3.13 0.00* 0.61 -0.70 0.23 0.17 -2.12 0.02* 0.50 
LIFG 3.16 0.04* -2.59 0.01* 0.51 -0.41 0.34 0.10 -1.50 0.07 0.35 
RSMA 4.69 0.01* -3.02 0.00* 0.59 -0.67 0.21 0.17 -1.92 0.03* 0.45 
LDCG 3.58 0.03* -2.64 0.01* 0.52 -0.58 0.26 0.14 -1.62 0.07 0.38 
RDCG 4.17 0.01* -2.84 0.00* 0.55 -0.62 0.24 0.15 -1.79 0.05* 0.42 
LROL 4.52 0.01* -2.72 0.00* 0.53 0.09 0.47 -0.02 -2.40 0.01* 0.56 
LTHA 3.64 0.03* -2.62 0.01* 0.51 -0.59 0.27 0.15 -1.65 0.06 0.39 
12 Months Follow-upb 
RSFG 2.69 0.07 -2.16 0.01* 0.53 -1.34 0.10 0.34 -0.76 0.21 0.21 
LIFG 4.30 0.02* -3.08 0.00* 0.76 -0.21 0.41 0.05 -2.13 0.02* 0.60 
RSMA 2.73 0.06 -2.38 0.01* 0.58 -0.59 0.30 0.15 -1.66 0.05* 0.47 
LDCG 3.39 0.04* -2.62 0.00* 0.64 -0.06 0.49 0.02 -2.24 0.02* 0.63 
RDCG 3.33 0.04* -2.58 0.00* 0.63 -0.22 0.44 0.06 -2.17 0.02* 0.61 
LROL 2.86 0.06 -2.45 0.01* 0.60 -0.41 0.34 0.10 -1.72 0.05* 0.49 
LTHA 3.47 0.04* -2.57 0.01* 0.63 -0.11 0.48 0.03 -2.31 0.02* 0.65 
a) P<0.05 = *  (All significant results survived fdr correction) 
b) P<0.05 = * (fdr corrected in LIFG, LDCG and RDCG) 
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Table 20 Comparisons of Beta Power in CHR Transition Subgroups and Healthy Controls 
ROI Group Analysis Converted vs HC Non-converters vs HC Converters vs Non-
converters 
F p t p d t p d t p d 
RSFG 3.32 0.04* -0.81 0.20 0.43 -2.53 0.00* 0.46 -0.07 0.49 0.04 
LIFG 2.58 0.08 -1.67 0.04* 0.87 -1.98 0.02* 0.36 -0.82 0.21 0.42 
RSMA 2.65 0.07 -0.76 0.22 0.40 -2.26 0.01* 0.41 -0.11 0.48 0.06 
LDCG 2.37 0.10 -0.94 0.17 0.49 -2.08 0.03* 0.38 -0.33 0.38 0.17 
RDCG 2.60 0.08 -0.97 0.15 0.51 -2.18 0.02* 0.40 -0.38 0.37 0.19 
LROL 2.64 0.08 -1.69 0.03* 0.88 -1.83 0.04* 0.33 -1.17 0.13 0.60 
LTHA 2.78 0.07 -1.26 0.08 0.66 -2.15 0.02* 0.39 -0.72 0.26 0.37 
a) P<0.05 = * (uncorr) 
 
Figure 27 Beta Power (15-25 Hz) in Seven ROIs Where CHR Differ Significantly from Healthy 
Controls; Subgroups Based on CHR GAF Scores at 12 Month Follow-Up. 
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7.4 Discussion 
The results provide tentative evidence that RSMG 40 Hz ASSR measures may 
reflect functional vulnerability in CHR individuals. However, these preliminary 
analyses did not indicate a specific relationship between long-term presentation 
of attenuated psychotic symptoms and RSMG deficits. In contrast, beta 
(15-25 Hz) power measures in ROIs selected based on results in Chapter 4, were 
found to be selectively impaired in individuals with sustained CHR symptoms and 
low GAF scores (at both baseline and 12 months), suggesting that ROI power 
measures in this frequency range may be potentially useful for prognosis 
prediction.  
Impairments in both RSMG 40 Hz ASSR power and ITPC were found to be more 
pronounced in the CHR group with low baseline GAF scores, suggesting that 
RSMG deficits may reflect functional vulnerability. However, analyses based on 
follow-up GAF scores showed no overall group effects, and only the high GAF 
group differed from controls. Thus, 40 Hz ASSR impairment reflected the degree 
of functional impairment at the time of scanning to some degree but does not 
appear clearly related to future functioning levels. This is in line with recently 
published findings showing that baseline ASSR measures predicted functioning at 
the 1-2 year follow-up assessments in FEP participants, but not in CHR subjects 
(Koshiyama et al., 2018a) 
Notably, supplementary analyses (Appendix 3) indicated that the sustained CHR 
group had significantly higher 40 Hz spectral power in the right cerebellar areas 
4-5. This is a preliminary result as comparison groups were small, but 
abnormalities in cerebellum are in line with previous findings in CHR and 
psychosis (Pantelis et al., 2003; Shen et al., 2010). Thus, the present finding 
highlights that further investigation of cerebellar oscillatory changes in CHR is 
warranted, as impairments appear potentially specific to individuals with long-
term presence of attenuated psychotic symptoms.  
Chapter 4 revealed seven nodes where CHR and FEP participants showed 
significant reductions in 15-25 Hz beta power, and a positive relationship 
between beta power and GAF scores was found across these nodes in the CHR 
group. In line with this observation, a clear difference was detected here 
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between control participants and CHR participants with low GAF scores at both 
baseline and the 12-month follow-up assessment, while no difference was 
detected between controls and CHR participants with high GAF scores. Crucially, 
the results also revealed more pronounced impairments in individuals with 
sustained CHR symptoms at the 12-month follow-up. Thus, these findings 
highlight the possibility to employ beta power measures for predictions of long-
term functioning. 
The functional relevance of the observed beta response was discussed in 
Chapter 4, highlighting motor function as a likely candidate. In CHR individuals 
and first-degree relatives, neurological soft sign deficits have been the most 
frequently reported motor impairments (Mittal et al., 2014). Importantly, 
previous studies reported that neurological soft signs predicted negative but not 
positive symptoms in a small CHR sample (Mittal et al., 2014). Furthermore, a 
link between neurological soft sign symptoms and neuropsychological  
impairments has been reported in FEP (Mohr et al., 2003). Both cognitive and 
negative impairments have been found to be associated with global functioning 
(Milev et al., 2005). Thus, if beta abnormalities observed in the current sample 
are indeed related to motor function, potential deficits in motoric neurological 
soft signs could account for the clear relationship seen with global functioning 
scores.  
The present analyses were restricted by the limited amount of follow-up data 
available at the time of analysis. In addition, only four individuals had 
transitioned to FEP, resulting in low statistical power for analyses including this 
group, and noisy plots. However, while the results should be viewed with this 
limitation in mind and interpreted cautiously, the findings provide insight into 
relationships between the ASSR measure and long-term clinical profiles. Thus, 
the present results can provide guidance for future analyses, and possibly for the 
development of clinical test batteries.  
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Figure 28 Beta Power (15-25 Hz) in Seven ROIs where CHR Differ Significantly from 
Controls; Subgroups Based on CHR Conversion to FEP. 
Moreover, it is controversial whether MEG can detect signals from deep brain 
regions such as the cerebellum (Dalal, Osipova, Bertrand, & Jerbi, 2013). 
Supplementary analyses (reported in detail in Appendix 3) indicated that 
subjects with sustained CHR symptoms had significantly higher 40 Hz spectral 
power in the right cerebellar areas 4-5. However, the cerebellum is located 
deep in the back of the skull, close to the neck (Dalal et al., 2013), and it is 
therefore possible that measures may be affected by differences in muscle 
tension. However, it is worth noting that magnetometers used for measures in 
the present study, while sensitive to artefact activity, also are superior to 
gradiometers for detection of deep brain signals (Vrba & Robinson, 2000). 
Furthermore, previous reports indicate that cerebellar measures using MEG are 
possible provided sufficient signal-to-noise ratio (Attal & Schwartz, 2013; Kirsch 
et al., 2003; Wibral et al., 2011). Here, data were cleaned carefully prior to 
analysis in order to avoid influence from muscle artefacts, which combined with 
extensive evidence for cerebellar involvement in ScZ from other modalities 
(Picard, Amado, Mouchet-Mages, Olié, & Krebs, 2008), support the notion that 
the results observed reflect true differences in brain activity. Nevertheless, it 
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cannot be ruled out that muscle artefacts contributed to the statistical group 
difference. 
7.5 Conclusion 
Analyses in this chapter and supplementary findings (Appendix 3) reveal a 
possible link between both 40 Hz ASSR alterations and beta power deficits and 
long-term clinical prognosis, measured through assessment of both attenuated 
psychotic symptoms and GAF levels. 
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Chapter 8 General Discussion  
This thesis focused on auditory high frequency oscillations in CHR and FEP 
individuals, using a MEG ASSR paradigm. Furthermore, MEG-data were explored 
in the context of clinical variables as well as MRS-measured Glx and GABA levels. 
Finally, the potential relationship between ASSR measures and CHR outcome was 
addressed.  
8.1 40 Hz ASSR  
Results from the 40 Hz ASSR data analysis revealed a modest but consistent 
impairment in RSMG in both 40 Hz spectral power and ITPC. At source level, this 
effect was significant and sustained (uncorrected) in CHR and reached a trend 
level in the FEP sample. Furthermore, Chapter 5 explored connectivity between 
right primary auditory areas (HES and STG) and the RSMG during 40 Hz ASSR. 
Analyses revealed both bottom-up (RSTG to RSMG and RHES to RSMG) and top-
down (RSMG to RHES) reductions in connectivity at 40 Hz in CHR participants.  
The SMG in the inferior parietal lobule is involved in a range of functions,  
including complex auditory functions, such as auditory language processing 
(Niznikiewicz et al., 2000; Oberhuber et al., 2016; Rauschecker & Scott, 2009), 
auditory pitch memory (Vines et al., 2006) and auditory-motor multisensory 
processing (Bangert et al., 2006). In addition, the SMG has been implicated in 
basic auditory target detection and is thought to be closely linked to the 
auditory P300 ERP (Horovitz et al., 2002; Menon et al., 1997; Skosnik et al., 
2007). Notably, impairments in these functional domains have been observed in 
ScZ (Bambini et al., 2016; Bernard & Mittal, 2014a; Javitt & Sweet, 2015; 
Morrens et al., 2014).  
Both structural and functional abnormalities have been documented in ScZ in the 
inferior parietal lobule, including the SMG (reviewed by Torrey, 2007). Crucially, 
the SMG is involved in self-awareness and self-reflection (Shad et al., 2012; Van 
Der Meer et al., 2013), the cognitive processes required to differentiate 
between the self and non-self and the recognition of self-generated feelings and 
actions (Van Der Meer et al., 2013). Accordingly, inhibition of the right inferior 
parietal lobule, using repetitive transcranial magnetic stimulation, disrupts 
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performances in a self-others discrimination task in healthy volunteers (Uddin, 
Molnar-Szakacs, Zaidel, & Iacoboni, 2006). Consistent with this observation, 
degree of insight in ScZ patients has been found to correlate with inferior 
parietal lobule activation (Van Der Meer et al., 2013). Moreover, machine 
learning investigations identified the SMG as part of a network with pronounced 
impairments and strong discrimination power in a comparison between controls 
and chronic ScZ patients (Guo, Kendrick, Yu, Wang, & Feng, 2014). 
Notably, the SMG is also implicated in aberrant ScZ sensory integration (Torrey, 
2007) and auditory hallucinations (Gaser et al., 2004). Structural findings have 
indicated a link between auditory hallucinations and left SMG GM volume loss in 
chronic ScZ (Gaser et al., 2004), while fMRI data highlighted bilateral SMG in 
auditory verbal hallucinations (Sommer et al., 2008). Furthermore, inter-
hemispheric synchronization between auditory regions appears crucial for 
conscious auditory perception (Steinmann et al., 2014), and interhemispheric 40 
Hz ASSR connectivity deficits were found to correlate with auditory 
hallucinations in ScZ (Mulert et al., 2011). In the current findings no direct link 
was found between RSMG MEG-data and overall perceptual abnormalities, yet 
the findings support SMG involvement in aberrant sensory processing. 
Specifically, the present data indicate that the basic auditory response to 
stimulation in primary auditory cortex is intact in CHR, but that the propagation 
of the oscillatory entrainment response to the SMG is impaired, potentially 
reflecting deficits that could account for sensory integration and auditory 
perceptual abnormalities.  
Two studies reported inferior parietal lobule involvement in the 40 Hz ASSR 
(Koenig, van Swam, Dierks, & Hubl, 2012; Reyes et al., 2005). It was suggested 
that the response involves the activation of a temporally dispersed network 
including the temporal lobe, medial frontal, frontal parietal, inferior parietal, 
contralateral cerebellum and temporal cortices (Reyes et al., 2005). Crucially, 
Koenig et al (2012) observed impaired 40 Hz phase-coherence in the inferior 
parietal lobule in ScZ patients with auditory hallucinations. However, to the 
author’s knowledge there are no other investigations of inferior parietal lobule 
involvement in the ASSR in ScZ as studies have primarily focused on sensor level 
data or source reconstructed data from primary auditory regions (Thuné et al., 
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2016). In contrast, the present data-driven ROI selection approach supports the 
notion that a wider network of regions is activated through ASSR stimulation and 
reveals that ASSR deficits in emerging psychosis do not appear to involve primary 
auditory regions. 
The oscillatory response captured by ASSR stimulation is thought to reflect the 
underlying neural circuitry (Spellman & Gordon, 2015) through activation of 
interacting glutamatergic and GABAergic signals. Specifically, evidence suggests 
that glutamate released from pyramidal neurons acts on NMDA receptors on 
GABAergic interneurons to trigger inhibition through subsequent GABA release, 
resulting in a rhythmical excitation-inhibition pattern (Carlén et al., 2012).  
The crucial role of both GABA and glutamate in the generation of gamma 
oscillations has been demonstrated in previous investigations. Optogenetic work 
has revealed that blockage of GABAergic PV+ inhibitory interneurons prevents 
gamma activity, while stimulation of these cells significantly enhances gamma 
oscillations (Sohal et al., 2009). Furthermore, in-vivo work has demonstrated the 
involvement of glutamate through pharmacological manipulations with ketamine 
(Sigurdsson, 2016) and MK800 (Sivarao, 2015). Administration of NMDA glutamate 
receptor antagonists has revealed altered gamma oscillations, including both 
increases (Rebollo, Perez-zabalza, Ruiz-mejias, Perez-mendez, & Sanchez-vives, 
2018; Sivarao et al., 2013) and decreases (Sullivan et al., 2015; Vohs et al., 
2012). Evidence suggests that the direction of gamma oscillatory abnormalities 
can depend on the degree of NMDA receptor blockage (Sivarao, 2015; Sivarao et 
al., 2016).  
In-vivo work has indicated the possibility that NMDA receptor dysfunction begins 
on GABAergic interneurons during neural development, causing impaired 
interneuron maturation and ultimately aberrant regulation of both glutamate 
and GABA cortical signalling (Nakazawa, Jeevakumar, & Nakao, 2017). A 
relatively novel addition to this neural model of ScZ is the role of oxidative 
stress (Ng, Berk, Dean, & Bush, 2008). Recent work has demonstrated that 
disrupted oxidant/anti-oxidant balance, resulting in elevated oxidative stress, is 
a candidate mechanism explaining such early developmental NMDA receptor 
deficits (Hardingham & Do, 2016). 
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Notably, the SMG matures late in neural development (Leroy et al., 2011; 
Torrey, 2007), extending until mid-late adolescence (Paus, 2005). Moreover, 
there is evidence for sex differences in the development of this area, with a 
hypothesized earlier maturation in males than females (Raznahan et al., 2010). 
Combined with findings discussed above, one interpretation of the observed 
RSMG oscillatory deficit in CHR individuals is thus that aberrant neural 
development of NMDA receptors on GABAergic interneurons, occurring during 
adolescence around the time of SMG maturation, could account for early 
auditory impairments and attenuated psychotic symptoms in emerging psychosis. 
The earlier maturation of this brain region in males provides a potential 
explanation for the typically earlier age of psychosis onset in men (Angermeyer 
& Kühn, 1988). Furthermore, 1H-MRS findings in the current investigation 
provide preliminary evidence for a trend reduction of GABA in right primary 
auditory areas in FEP patients. This suggests a potential spread of impairments 
from higher inferior parietal areas to auditory cortex with increasing psychotic 
symptoms.  
Potential long-term implications of observed RSMG deficits in the CHR group 
were explored in longitudinal analyses, revealing a relationship between RSMG 
impairments and baseline GAF scores. However, the preliminary longitudinal 
analyses did not indicate a direct link between RSMG measures and acute 
psychosis risk.  
In addition, longitudinal analyses including supplementary nodes provide 
preliminary support for an increase in cerebellar 40 Hz ASSR power in the right 
cerebellar areas 4-5 (from AAL atlas), corresponding to the lateral lobules (4 and 
5) of the cerebellum. Interestingly, these alterations appear specific to 
prolonged attenuated psychotic symptoms. These findings may be in line with a 
model suggesting that ScZ arises through abnormal connections in the cortico-
cerebellar-thalamic-cortical circuit, associated with both higher-order mental 
and motor functions (Andreasen & Pierson, 2008). Furthermore, meta-analysis 
data (fMRI and PET) of measures in five functional domains (language, working 
memory, emotion, executive processing/attention and motor) found alterations 
in the cerebellar functional topography in ScZ, with areas of both increased and 
decreased activation (Bernard & Mittal, 2014b). Thus, cerebellar alterations 
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contributing to ASSR abnormalities in emerging psychosis should be explored 
further.  
At a circuit level, elevated cerebellar gamma oscillations may also be accounted 
for by NMDA receptor blockage/hypofunction (Rebollo et al., 2018; Sivarao et 
al., 2016, 2013). As discussed above, increases in 40 Hz ASSR power and ITPC 
may reflect partial NMDA receptor hypofunction (Sivarao et al., 2016). Thus, the 
current data imply that in the CHR group, NMDA receptor impairments were 
more pronounced in the RSMG, where a reduction in ASSR measures was found, 
than in the RCRBL4-5 area where 40 Hz oscillation measures were augmented. 
Finally, an important question is whether ASSR impairments in ScZ are riding on 
underlying oscillatory baseline changes (Spencer, 2012). Reports of increased 
baseline power in the 40 Hz range (Spencer, 2012), in line with a notion that 
NMDA receptor deficits cause increases in non-stimulus evoked gamma power 
independent of degree of receptor impairments (Sivarao et al., 2016), have 
given rise to a debate about whether ASSR impairments truly reflect abnormal 
evoked gamma entrainment. To address this issue, baseline data in the current 
analysis were compared between groups. No statistically significant differences 
were found, demonstrating that at least in CHR and FEP individuals, ASSR 
deficits are unlikely to be influenced by underlying baseline differences. 
Moreover, the present findings also do not indicate global NMDA receptor 
deficits in CHR and FEP but suggest that any NMDA receptor alterations are 
regionally specific to a limited brain area, notably the RSMG.  
8.2 ASSR Data Analysis 
Statistically significant group differences in ASSR measures were found in source 
reconstructed data, but not at the sensor level. The ASSR has been found to be 
robust using both MEG (Tan et al., 2015b) and EEG measures (Legget, Hild, 
Steinmetz, Simon, & Rojas, 2017) in healthy controls, and the meta-analysis 
performed in preparation of this PhD project (Chapter 3) revealed no difference 
between chronic ScZ measures from source or sensor level analyses (Thuné et 
al., 2016). However, the regional specificity of sensor level data is compromised 
by field spread through input from multiple neural sources to each sensor 
(Schoffelen & Gross, 2009). Combined with the generally small-moderate effect 
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sizes seen in the present analyses and in previous CHR studies (Koshiyama et al., 
2018b), it is not surprising that regionally specific group differences may be 
diluted at sensor level and thus not detected.  
Both MEG and EEG allow the reconstruction of data on source level (Darvas, 
Pantazis, Kucukaltun-Yildirim, & Leahy, 2004), but methodological challenges 
have resulted in the majority of ASSR studies reporting source analyses using 
MEG (Chapter 3; Thuné et al., 2016), with only two studies exploring source 
reconstructed EEG measures of ASSR in ScZ (Koenig et al., 2012; Spencer et al., 
2009). The methods share similarities, but while MEG has the advantage of being 
resistant to confounding effects from tissue conductivity (Darvas et al., 2004), 
EEG enables superior capture of radial sources (Ahlfors, Han, Belliveau, & 
Hämäläinen, 2010). Thus, for a full picture of CHR deficits, evaluations of both 
MEG and EEG source reconstructed data may be valuable.  
8.3 Beta Oscillations  
In addition to 40 Hz findings, analyses of oscillatory data in Chapter 4 revealed a 
group effect of power in the beta frequency range (15-25 Hz) in seven nodes, 
including two frontal (Right Superior Frontal Gyrus, Left Inferior Frontal Gyrus), 
two motor (Right Supplementary Motor Area, Left Rolandic Area) and three 
subcortical regions (Left Dorsal Cingulate Gyrus, Right Dorsal Cingulate Gyrus, 
Left Thalamus). This effect represented impaired beta power in CHR and FEP 
compared to controls across regions, and impaired beta power in FEP compared 
to CHR in LROL.  
Increased contralateral beta power is an established feature of motor inhibition 
after movements (“beta rebound”) (Y. Zhang et al., 2008) and during the 
withholding of motor actions (Solis-Escalante, Müller-Putz, Pfurtscheller, & 
Neuper, 2012). In the present ASSR paradigm, participants were instructed to 
press a button with their right index finger when hearing a deviant non-ASSR 
stimulus. Therefore, each trial involved the active evaluation of stimuli to 
determine whether a response was appropriate or not. Hence, it is possible that 
the beta signal observed in the current sample represents a beta motor 
evaluation and subsequent suppression of a prepared motor action. 
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Thus, the current findings provide further tentative evidence for abnormal 
motor processing in both CHR and FEP. Motor impairments have been reported in 
ScZ, CHR populations and first-degree relatives of patients (Schäppi, Stegmayer, 
Viher, & Walther, 2018), highlighting motor dysfunction as a potential 
endophenotype for ScZ (Chan & Gottesman, 2008). Notably, neurological soft 
signs, which have been reported as the most prominent motor impairment in 
CHR (Mittal et al., 2014), are potentially related to deficits in the inferior 
parietal lobule and specifically in the SMG (Torrey, 2007). However, while beta 
analyses highlight possible motor suppression deficits in CHR and FEP, 
clarification through further explorations of relationships between beta 
oscillations and motor performance tasks are required to test this speculative 
hypothesis.  
Beta power oscillations are implicated in a range of functions (Engel & Fries, 
2010) and the observed changes may also mirror abnormalities in other 
functional domains. One proposed hypothesis is that beta deficits in ScZ reflect 
impaired salience signalling (Liddle et al., 2016), whereby high neural 
significance is attributed to insignificant external and internal experiences, 
proposed to contribute to both positive (Kapur, 2003) and cognitive symptoms 
(Palaniyappan & Liddle, 2012). Beta power deficits seen in CHR and FEP 
participants could thus potentially represent an emerging aberrant attribution of 
salience to repetitive neural activation elicited by ASSR stimulation. 
Moreover, there is intriguing evidence that beta frequency abnormalities may be 
implicated in auditory hallucinations (van Lutterveld et al., 2012). Specifically, 
left temporal cortex beta power was found to correlate with auditory verbal 
hallucination severity (van Lutterveld et al., 2012). This possible role is note-
worthy firstly as the beta power topographies in the present study suggested 
pronounced left hemisphere impairments in CHR and FEP, and secondly 
considering the clearly established role of the SMG in hallucinations. However, 
further investigation is needed to establish how the detected beta power 
impairments in CHR and FEP may contribute to these symptoms.  
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8.4 1H-MRS Measures 
The 1H-MRS study investigated the relationship between oscillatory findings and 
possible neurotransmission deficits in GABA and Glx, with the aim to further 
elucidate potential E/I balance alterations in emerging psychosis. In addition, 
possible effects of the selection of 1H-MRS reference molecule on Glx measures 
were explored in a separate analysis.  
While no significant impairments were seen in CHR compared to controls, a 
trend impairment in right auditory cortical GABA was seen in the small FEP group 
(U=111.00, p=0.09, d=-0.43). This analysis was underpowered, but highlights a 
potential deficit driven by GABA reductions in auditory cortex in early psychosis 
and demonstrates that further work in this brain region is warranted. 
Additional analyses explored correlations between 1H-MRS measures and both 
clinical parameters and 40 Hz ASSR measures. In contrast to previous reports 
from healthy volunteers (Falkenberg et al., 2012; Muthukumaraswamy et al., 
2009), only weak correlations were seen here between left voxel Glx and 40 Hz 
ASSR power in left HES and STG, but neither relationship survived correction for 
multiple comparisons. Importantly, the auditory cortex is a small folded region 
with high individual anatomical variability (Da Costa et al., 2011), and thus the 
1H-MRS voxel covered not only primary auditory regions, but some adjacent 
regions as well. This was adjusted for by correcting for GM/WM and CSF content, 
but overlap with surrounding brain regions could nevertheless account for the 
limited correlations observed. In addition, the present 1H-MRS analyses had 
relatively low statistical power due to small sample size (Control N=31right, 22left; 
CHR N=64right, 39left; FEP N=11right, 7left). However, the findings are in line with 
other reports which also failed to replicate 1H-MRS correlations with 
neuroimaging measures (Cousijn et al., 2014). Thus, the present analyses 
constitute evidence for a relationship between 1H-MRS measures and gamma 
oscillations assessed through a 40 Hz ASSR paradigm in the auditory cortex.   
Correlation analyses with psychological measures revealed a weak negative 
relationship between right auditory cortical Glx and composite BACS scores, 
representing superior cognitive performance in individuals with lower auditory 
Glx concentrations.  
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Correlations between clinical parameters and 1H-MRS measures have not 
previously been explored in auditory voxels. One previous study reported a 
positive correlation between dorsolateral prefrontal cortex Glx and performance 
on an auditory verbal learning test in chronic ScZ patients (Ohrmann et al., 
2007). However, correlations between Glx and cognitive measures have been 
inconsistent, with some reporting positive and some negative relationships in 
frontal regions and cingulate cortex (Merritt, Mcguire, & Egerton, 2013). 
Moreover, prefrontal 1H-MRS GABA was positively correlated with negative 
symptoms in CHR (Modinos, Şimşek, Horder, et al., 2018), while anterior 
cingulate GABA was positively correlated with performance on a cognitive coding 
test and an attention task (Rowland et al., 2013). Thus, the timing and 
implications of Glx and GABA alterations in emerging psychosis may depend on 
the brain regions measured.   
Moreover, in the current study, right auditory 1H-MRS measures were computed 
twice, using first water and subsequently creatine as reference molecule. This 
was done in order to establish whether the chosen reference molecule could 
influence results, as has been suggested previously (Öngür et al., 2009). 
However, in this sample the results did not differ significantly depending on 
reference, indicating that if deviations in creatine levels are present in emerging 
psychosis, they were not substantial enough to affect group comparisons here.  
8.5 Sample Characteristics 
Chapter 2 presented demographic and clinical features of the sample. Analyses 
of clinical variables confirmed that the sample was adequately matched in terms 
of age, gender and handedness. This is critical as differences in these variables 
could potentially confound results (Edgar et al., 2014; Melynyte et al., 2018; 
Thuné et al., 2016). Furthermore, CHR and FEP participants were impaired 
compared to controls in GAF score ratings, composite BACS scores, total CAARMS 
scores and childhood functioning, demonstrating deficits in line with existing 
knowledge of the CHR and FEP states (Fusar-Poli , Rocchetti, et al., 2015; Riley 
et al., 2000). 
A consideration when interpreting the data is that both the FEP and CHR samples 
studied here were relatively high functioning; a majority of participants were 
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non-help-seeking individuals recruited from the community, and the average 
global functioning scores were higher than an estimated average in a recent 
meta-analysis (Fusar-Poli , Rocchetti, et al., 2015). Notably, higher overall risk 
of conversion to psychosis has been observed in samples recruited from clinical 
services than in samples recruited from the public (Fusar-Poli et al., 2016). 
However, individuals with lower functioning levels were also represented in the 
present sample, including individuals referred from NHS services. Accordingly, 
these data suggest that the online recruitment method is not only a valid 
approach, but also a useful method to identify a functionally and clinically 
diverse sample of CHR individuals. 
8.6 Correlations between ASSR and Clinical Parameters 
Potential relationships between 40 Hz ASSR oscillatory data and clinical variables 
were explored. Links between clinical symptoms and 40 Hz ASSR measures in 
patients with ScZ are potentially important for understanding the 
behavioural/clinical relevance of oscillatory changes. In the current sample, ROI 
specific positive correlations were seen for CHR participants between 40 Hz ASSR 
ITPC and global CAARMS severity scores in the LITG and LMTG, and between 
40 Hz ASSR ITPC and perceptual abnormality ratings in the LITG. These results 
constitute a replication of previous findings, suggesting a link between left 
hemisphere 40 Hz ASSR synchrony and positive symptoms, particularly auditory 
hallucinations (Spencer et al., 2009). However, a recent contrasting publication 
reported a negative correlation between 40 Hz ASSR synchrony and 
hallucinations, but in contrast to previous findings and the present analyses, that 
observation was based on sensor level EEG data analyses which did not 
differentiate between hemispheres (Zhou et al., 2018).  
Given the role of gamma-band oscillations in facilitating cognition and 
perception (Fries, 2015; Uhlhaas & Singer, 2010) correlations may be expected 
between the 40 Hz ASSR impairments and cognitive deficits in patients with ScZ. 
A modest relationship was noted between working memory performance and 
40 Hz ASSR ITPC in ScZ patients (Light et al., 2006). However, Kirihara et al 
(2012) examined this relationship in a larger ScZ group, and found that only total 
theta (4-8 Hz) amplitude reductions were correlated with deficits in verbal 
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memory in patients with ScZ, whereas no relationship was found with 40 Hz 
ASSRs. In the current thesis, only a weak negative correlation between 
composite BACS scores and 40 Hz ASSR ITPC in LSTG was detected across the 
three groups and no correlation was seen in the CHR group alone. These 
conflicting results suggest that ASSR measures are not directly related to overall 
cognitive performance, \but could potentially reflect performance in specific 
cognitive domains.  
No measure of negative symptoms was explored here. However, global 
functioning has been found to be predicted by this symptom category (Wittorf, 
Wiedemann, Buchkremer, & Klingberg, 2007), and analyses of GAF scores did not 
indicate a direct correlation between 40 Hz ASSR measures and baseline global 
functioning levels. This is in line with previous work, which has only 
demonstrated a relationship between high gamma (80-Hz) ASSR amplitude and 
negative symptoms. However, recent evidence suggests a significant correlation 
between 40 Hz ASSR and community functioning (Zhou et al., 2018), highlighting 
a need to further investigate potential associations to specific functional 
domains.  
In addition to replication of previous findings, the current investigation also 
revealed novel correlations. Unexpectedly, a strong robust association in CHR 
was found between beta power (15-25 Hz) and GAF scores across the seven 
nodes where beta deficits were detected in the CHR group. While no such 
observation has previously been published, knowledge about the functional 
implications of beta oscillations allow for speculations about the nature of this 
relationship. As mentioned previously, beta oscillations are implicated in a range 
of motor functions, including neurological soft signs which are impaired in CHR 
(Mittal et al., 2014). Neurological soft signs include deficits in sensory 
integration, and in motor inhibition and coordination (Chan & Gottesman, 2008). 
Moreover, beta oscillations have been implicated in salience signalling (Liddle et 
al., 2016) as well as basic attention (Wróbel, 2000). Thus, lower GAF ratings in 
individuals with deficit capacity to elicit beta oscillations could reflect severity 
of impairments in several domains important for global functioning.  
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8.7 Predicting Psychosis 
As discussed in Chapter 7, promising attempts to assess individual risk levels 
have involved the development of risk indices based on combinations of 
measures known to be impaired in ScZ (Cannon et al., 2016). This method has 
the potential advantage of capturing risk based on data from a single individual, 
which would be required in a clinical setting (Gifford et al., 2016). One such 
risk-calculator was found to have a moderate to strong ability to separate 
psychosis converters from non-converters (Harrell’s concordance index 0.71 and 
0.79 respectively) in two separate samples (Cannon et al., 2016; Carrión et al., 
2017). Such compound risk scores may provide a way to capture more of the 
underlying biological changes and constitute a more reliable marker than one 
stand-alone measure. 
A similar potentially useful approach is to combine neuroimaging measures with 
computational modelling strategies and machine learning (Orrù et al., 2012). So 
far, the method has been applied primarily on structural (Koutsouleris et al., 
2012, 2010) and functional (Shen et al., 2010) MRI data. These efforts have 
yielded promising results (Orrù et al., 2012), but there is a lack of machine 
learning based prediction data from other imaging modalities such as EEG and 
MEG which may be better suited for capturing subtle neural changes at early 
stages of psychosis.  
However,  focusing solely on psychosis transition is unhelpful since transition 
rates are declining (Lim et al., 2018), but many participants remain in a low 
functioning CHR state for a substantial period of time and may benefit from 
interventions (Addington et al., 2011). Instead, developing methods to predict 
long-term functional impairments may be more meaningful. Thus, future work 
should focus on the development of prediction batteries designed to detect 
individuals with a poor long-term functional prognosis. 
An important issue for risk and prognosis predictions is whether measures are 
specific to psychosis or merely sensitive to a general state of vulnerability. 
Notably, ScZ shares many pathological similarities with bipolar disorder (Cardno 
& Owen, 2014; Meda et al., 2012; Schretlen et al., 2007) and autism spectrum 
disorder (ASD) (Radeloff et al., 2014; Sheitman, Kraus, Bodfish, & Carmel, 2004) 
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and previous work has demonstrated 40 Hz ASSR impairments in both bipolar 
disorder (Rass et al., 2010) and ASD (Wilson et al., 2007). However, the work 
presented in this thesis highlights that ASSR measures analysed using regionally 
and frequency specific approaches potentially allow the detection of 
differential, functionally distinct alterations. For example, general impairments 
in functioning appear linked to RSMG 40 Hz ASSR deficits, which may be similar 
to abnormalities seen in bipolar disorder and ASD patients. In contrast, increased 
40 Hz power in the right cerebellar areas 4-5 (demonstrated in supplementary 
analyses) could potentially reflect deficits specific to attenuated psychotic 
symptoms. Such differential functional roles should be evaluated further and 
considered in future developments of prediction tools.  
8.8 Considerations and Future Work 
The project set out primarily to study CHR individuals, with a lower number of 
FEP patients recruited in order to compare CHR and FEP findings and to replicate 
existing FEP findings. However, the smaller FEP sample size poses a limitation 
for data interpretation: The trend level statistical results seen for FEP 
participants in several analyses (compared to significant results for CHR in many 
of the same analyses) could reflect either underpowered analyses or a true 
trend. Further recruitment of FEP participants to the YouR study will help clarify 
this issue.  
Moreover, due to the size of the YouR study and the longitudinal nature of 
recruitment and data collection, only some participants had attended the 12-
month follow-up visit when this thesis was prepared. Data available from the 24- 
and 36-months follow-up assessments were insufficient for meaningful analysis. 
However, ongoing collection of data will provide additional data for important 
evaluations of long-term symptom development in future analyses. These data 
will also be important to further clarify the predictive value of baseline imaging 
measures such as the 40 Hz ASSR. Moreover, as resources were focused on 
exploring the CHR group, follow-up assessments were only performed for this 
group. This means that CHR longitudinal changes cannot be compared to 
potential changes in FEP over time. However, for the current research questions 
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longitudinal changes in CHR in relation to baseline measures were the key focus 
for analyses.  
A majority of subjects were still within the first year of their participation in the 
study at the time of analysis, and future follow-up assessments will establish 
how many will convert to psychosis within three years. At the time of analysis, 
transition rates in the current sample were modest compared to numbers 
reported in early CHR studies (Lim et al., 2018; Mason et al., 2004; Yung et al., 
2007). However, the number of transitions seen here are similar to recent 
findings, reflecting an overall decline in transition rates in recent years 
(Hartmann et al., 2016; Lim et al., 2018; Yung et al., 2007). This decline could 
be due to factors such as earlier referrals to services and the presence of 
comorbidities (Lim et al., 2018).  
Impairments in selective attention are a characteristic of psychosis (Gold et al., 
2018), and one of the earliest emerging deficits evident in the CHR state (De 
Paula et al., 2015). This justified the inclusion of an attention task during the 
recording of 40 Hz ASSR data, as there is evidence for an effect of attention on 
ASSR measures (Hamm et al., 2015). Selective attention enhances ASSR measures 
in both controls and patients (Hamm et al., 2015). Hence, differential attention 
between study groups could confound results.  
Analyses demonstrated equal response speed across groups, suggesting that all 
individuals were paying attention to sounds presented. However, a few 
individuals in the FEP and CHR groups had increased error-rates (missed 
responses or responded to non-targets), making these groups perform 
significantly worse overall. Impaired target detection has previously been 
observed in ScZ samples, and could relate to an overall sensitivity to incoming 
stimuli, possibly linked to deficits in the inhibition of salience processing 
networks (Jimenez et al., 2016). Thus, the observed performance deficit could 
be associated with the same hyperarousal mechanisms hypothesized to give rise 
to increased ASSR measures in the sustained CHR group. 
A continuous discussion in psychosis research is the degree to which findings in 
chronic samples may be confounded by long-term use of antipsychotic 
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medication (Goff et al., 2017). Here, a wide range of medications were 
prescribed for psychotic and co-morbid symptoms in both the CHR and FEP 
group. Most previous ASSR studies have not focused on addressing this issue, but 
the reported presence of ASSR deficits in CHR (Koshiyama et al., 2018b; Tada et 
al., 2016), FEP (Koshiyama et al., 2018b; Spencer et al., 2008) and early onset 
ScZ (Wilson et al., 2008) indicate that long-term medication is unlikely to be a 
major contributor to the observed deficits. However, Hong et al. (2004) reported 
differential ASSR effects in patients on first and second generation 
antipsychotics and Rass et al. (2010) found that bipolar disorder patients 
medicated with any of a range of psychotropic medications had lower 40 Hz ASSR 
phase locking than unmedicated patients. Furthermore, in-vivo work has 
revealed ASSR alterations following pharmacological manipulations (Sivarao, 
2015; Vohs et al., 2012). Thus, medication was considered, but no statistical 
correction was performed, due to the variety of drugs and limited availability of 
information about exact dosages.  
Some MEG and 1H-MRS data were lost due to poor data quality. This was a 
problem particularly for the 1H-MRS measures. However, all analyses focusing on 
the primary group of interest (CHR) relative to controls had adequate statistical 
power for meaningful comparisons (>0.40 power). 
Finally, future work should further explore the beta frequency signal reported 
here to clarify whether it reflects a motor-inhibition evoked beta response. In 
addition, further investigations should aim to clarify the elevated cerebellar 
ASSRs in sustained CHR participants (Appendix 3), by exploring whether 
connectivity alterations are present between the cerebellum and/or thalamus 
and auditory cortex.  
8.9 Final Conclusion 
The search for early neural mechanisms involved in the emergence of CHR 
symptoms is essential to progress the understanding of early psychosis. The data 
presented in this thesis reveal the subtlety and complexity of such changes and 
highlight that multimodal approaches may help construct a framework for neural 
mechanisms contributing to emerging psychotic illness. 
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The findings indicate specifically that poor functional outcome in CHR, 
potentially representing a general vulnerability state, may be reflected by 
impaired RSMG 40 Hz power and ITPC, and reduced connectivity between RSMG 
and primary auditory areas. Furthermore, the analyses provide evidence of a 
robust beta frequency power deficit in CHR and FEP, strongly related to CHR 
functioning both at baseline and follow-up assessments. Thus, the current work 
demonstrates that ASSR measures provide a potential method for capturing 
alterations in the oscillatory domain, in both the beta and gamma range. Each 
should be studied further in future work and may provide candidate measures 
for machine learning projects attempting to assess individual risk levels. 
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Appendix 2 
 
Flow of YouR study at-risk participant recruitment from September 2014 to July 2018, for the 
auditory Steady State response task, recorded as part of the neuroimaging battery. 
 
 
YouR-study assessment timeline from the first face-to-face screening visit to at-risk 
participant follow-up assessments 
  
2892
•Entries on YouR study website (2853)
•Referrals (39)
499
•Participants undergoing screenings at the 
University of Edinburgh (85) or Glasgow (414)
154
•At-risk participants invited to further sessions
107
•At-risk participants undergoing brain scan 
paradigm 
93
•At-risk participants completing the auditory 
steady-state response experiment/sufficient 
data quality
Visit 1: 
Screening 
Assessment
Visit 2:
Further 
psychological 
assessments
Visit 3: 
Neuropsychological 
battery
Visit 4: 
Neuroimaging 
Paradigm
Visit 5-11: 
Follow-up 
assessments (Only 
at-risk)
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Appendix 3 
Supplementary longitudinal analyses. 
At the 12-month follow-up, individuals with sustained CHR symptoms had 
significantly higher 40 Hz ASSR spectral power in the right cerebellar areas 4-5 
(RCRBL45) than both controls and participants with resolved CHR symptoms 
(Table A). A significant group effect was also seen in ITPC data in the RCRBL45, 
but this effect was not significant in any of the post-hoc comparisons (Table B).  
Table A 40 Hz power in sustained and resolved CHR to controls 
Brain 
region 
Group Analysis Sustained CHR vs Control Resolved CHR vs Control Sustained vs Resolved 
CHR 
F p t  p d t    p d t    p d 
RSMG 0.55 0.55 -0.42 0.34 -0.11 -1.06 0.15 -0.25 0.32 0.35 0.14 
RHES 0.16 0.85 0.11 0.44 0.04 0.55 0.28 0.20 -0.28 0.37 -0.16 
RSTG 0.06 0.95 0.12 0.38 0.04 -0.25 0.42 -0.01 0.42 0.35 0.08 
RMTG 0.98 0.37 -0.04 0.46 -0.00 -1.28 0.10 -0.23 1.10 0.17 0.28 
RITG 0.04 0.97 0.27 0.37 0.09 -0.03 0.49 0.08 0.30 0.41 0.01 
RHIP 0.47 0.62 0.28 0.40 0.09 0.99 0.15 0.26 -0.40 0.33 -0.16 
LTHA 0.04 0.96 0.25 0.39 0.08 0.24 0.41 0.11 0.07 0.48 -0.03 
RTHA 0.27 0.76 0.68 0.24 0.22 0.28 0.39 0.07 0.55 0.29 0.174 
RCRBL45 3.06 0.05* 2.25 0.02* 0.70 0.69 0.24 0.22 2.21 0.01* 0.63 
P<0.05 = * (uncorr) 
 
Table B ITPC in sustained and resolved CHR compared to controls 
Brain 
region 
Group Analysis Sustained CHR vs Control Resolved CHR vs Control Sustained vs Resolved 
CHR 
F p t  p d t    p d t    p d 
LSMG 0.26 1.36 0.32 0.37 0.10 -1.55 0.06 -0.35 1.41 0.08 -0.45 
RSMG 0.29 1.26 -0.90 0.19 -0.27 -1.52 0.06 -0.34 0.17 0.43 -0.05 
LHES 0.23 1.58 1.01 0.15 0.31 -0.98 0.16 -0.22 1.93 0.03 -0.61 
RHES 0.17 1.81 -1.89 0.03 -0.58 -0.71 0.24 -0.16 -1.38 0.07 0.44 
LSTG 0.46 0.81 0.85 0.18 0.26 -0.54 0.29 -0.12 1.33 0.10 -0.42 
RSTG 0.71 0.36 -0.76 0.23 -0.23 -0.43 0.35 -0.10 -0.57 0.28 0.18 
LMTG 0.74 0.34 0.73 0.23 0.22 0.10 0.46 0.02 0.86 0.20 -0.27 
RMTG 0.62 0.48 -0.45 0.35 -0.14 -0.95 0.17 -0.21 0.23 0.41 -0.07 
LITG 0.21 1.57 1.63 0.06 0.50 0.55 0.29 0.12 1.56 0.07 -0.49 
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RITG 0.67 0.41 -0.31 0.41 -0.10 -0.90 0.18 -0.20 0.36 0.35 -0.11 
LHIP 0.45 0.78 0.09 0.44 0.03 -1.12 0.13 -0.25 0.93 0.19 -0.29 
RHIP 0.63 0.47 -0.16 0.47 -0.05 -0.98 0.16 -0.22 0.57 0.28 -0.18 
 
LTHA 0.67 0.42 0.05 0.46 0.01 -0.85 0.19 -0.19 0.75 0.23 -0.24 
RTHA 0.69 0.36 -0.03 0.49 -0.01 -0.84 0.19 -0.19 0.57 0.26 -0.18 
RCRBL45 0.95 0.05* 0.28 0.37 0.09 0.19 0.43 0.04 0.18 0.42 -0.06 
RCRBL10 0.85 0.15 0.00 0.47 0.00 -0.51 0.29 -0.11 0.44 0.32 -0.14 
P<0.05 = * (uncorr) 
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Figure A ASSR time-frequency plots for power ROIs - Grouped according to CHR status at 
12 months follow-up 
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Figure B ITPC plots grouped according to CHR status at 12 months follow-up  
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Table C Spectral power comparison in controls and GAF groups 
Brain 
region 
Group Analysis Low GAF vs HC High GAF vs HC Low vs High GAF 
F p t  p d t    p d t    p d 
Baseline 
RSMG 2.92 0.05* -2.39 0.01* 0.46 -0.88 0.20 0.20 1.11 0.13 -0.27 
RHES 1.01 0.40 -0.23 0.41 0.04 1.07 0.15 -0.27 1.35 0.10 -0.32 
RSTG 0.15 0.88 -0.06 0.47 0.01 0.39 0.35 -0.10 0.61 0.28 -0.14 
RMTG 0.59 0.57 -1.09 0.14 0.21 -0.47 0.32 0.11 0.40 0.36 -0.09 
RITG 0.02 0.97 0.04 0.48 -0.01 0.21 0.43 -0.06 0.19 0.45 -0.04 
RHIP 0.10 0.92 0.08 0.47 -0.03 0.44 0.33 -0.11 0.36 0.37 -0.08 
LTHA 1.96 0.15 0.56 0.29 -0.13 -1.44 0.08 0.33 -1.96 0.02* 0.45 
RTHA 0.63 0.55 -0.98 0.17 0.18 0.08 0.44 -0.04 0.92 0.18 -0.22 
RCRBL45 1.65 0.20 -0.05 0.50 -0.01 1.44 0.08 -0.38 1.84 0.03* -0.44 
12-month Follow-up 
RSMG 2.26 0.12 -0.31 0.38 0.09 -2.18 0.02* 0.55 1.65 0.05* -0.47 
RHES 0.37 0.67 -0.26 0.40 0.11 0.65 0.25 -0.18 -0.83 0.23 0.25 
RSTG 0.01 0.99 -0.12 0.50 0.03 -0.12 0.50 0.02 0.00 0.49 0.01 
RMTG 0.45 0.68 -0.79 0.23 0.19 -0.67 0.28 0.16 -0.17 0.47 0.05 
RITG 0.16 0.86 0.47 0.31 -0.12 -0.11 0.47 0.02 0.54 0.30 -0.15 
RHIP 1.56 0.21 1.48 0.07 -0.37 -0.32 0.39 0.07 1.55 0.06 -0.42 
LTHA 0.03 0.97 0.02 0.47 -0.02 0.23 0.39 -0.08 -0.18 0.43 0.06 
RTHA 0.03 0.97 0.21 0.44 -0.06 0.03 0.48 -0.03 0.17 0.43 -0.03 
RCRBL45 0.59 0.55 0.53 0.29 -0.14 1.07 0.15 -0.30 -0.51 0.30 0.16 
P<0.05 = * (uncorr) 
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Figure C ASSR time-frequency plots for power ROIs - Grouped according to GAF scores at 
baseline. 
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Figure D ASSR time-frequency plots for power ROIs - Grouped according to GAF scores at 
12 months follow-up  
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Figure E Plotted ITPC data grouped according to GAF scores at baseline  
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Figure F Plotted ITPC data grouped according to GAF scores at 12 months follow-up 
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Post-hoc tests from preliminary analyses comparing transitioned participants 
with non-converters and controls showed that both RSMG spectral power and 
ITPC in non-transitioned but not in transitioned CHR participants differed 
significantly from controls. Moreover, spectral power in transitioned CHR 
participants differed from those who did not transition in the right inferior 
temporal gyrus (RIFG) and right hippocampus (RHIP) (Table E). 
 
Table E 40 Hz Power in Transitioned CHR vs non-transitioned CHR and Healthy Controls 
Brain 
region 
Group Analysis Transitioned vs HC Non-transitioned  vs 
HC 
Transitioned vs Non-
transitioned 
F p t p d t  p d t p d 
RSMG 2.48 0.09 -0.54 0.33 0.28 -2.22 0.02* 0.40 0.19 0.37 -0.10 
RHES 0.26 0.78 0.71 0.23 -0.40 0.34 0.40 -0.07 0.58 0.24 -0.31 
RSTG 0.62 0.50 0.85 0.11 -0.45 -0.09 0.43 0.01 1.30 0.11 -0.66 
RMTG 0.78 0.43 0.07 0.31 -0.05 -1.19 0.11 0.21 0.57 0.23 -0.30 
RITG 1.78 0.18 1.66 0.06 -0.87 -0.28 0.37 0.04 1.92 0.05* -0.96 
RHIP 1.62 0.21 1.72 0.06 -0.89 0.01 0.49 -0.01 1.73 0.05* -0.86 
LTHA 0.04 0.97 0.29 0.35 -0.15 0.09 0.48 -0.04 0.23 0.41 -0.10 
RTHA 0.32 0.73 0.26 0.38 -0.16 -0.68 0.24 0.11 0.54 0.28 -0.28 
RCRBL45 0.42 0.66 0.72 0.21 -0.38 0.54 0.31 -0.12 0.73 0.26 -0.35 
P<0.05 = * (uncorr) 
 
Table F ITPC in Transitioned CHR vs non-transitioned CHR and Healthy Controls 
Brain 
region 
Group Analysis Transitioned vs HC Non-transitioned  vs 
HC 
Transitioned vs Non-
transitioned 
F p t p d t  p d t p d 
LSMG 0.46 0.62 0.18 0.38 -0.09 -0.87 0.18 0.16 0.52 0.28 -0.27 
RSMG 3.77 0.03* -0.35 0.43 0.18 -2.75 0.00* 0.50 0.61 0.25 -0.31 
LHES 0.43 0.67 0.67 0.24 -0.35 -0.34 0.35 0.06 0.97 0.17 -0.50 
RHES 0.56 0.56 0.25 0.37 -0.13 -0.96 0.17 0.17 0.59 0.29 -0.30 
LSTG 0.04 0.97 0.12 0.38 -0.06 -0.19 0.40 0.04 0.21 0.37 -0.11 
RSTG 1.40 0.23 1.19 0.12 -0.62 -0.65 0.24 0.12 1.72 0.06 -0.88 
LMTG 0.58 0.56 0.94 0.17 -0.49 0.17 0.43 -0.03 1.13 0.13 -0.58 
RMTG 1.07 0.32 0.61 0.24 -0.32 -1.11 0.13 0.20 1.14 0.14 -0.59 
LITG 0.92 0.40 -0.23 0.43 0.12 1.22 0.11 -0.22 -0.77 0.23 0.39 
RITG 0.96 0.37 0.62 0.25 -0.33 -1.01 0.15 0.18 1.15 0.13 -0.59 
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LHIP 0.73 0.47 0.20 0.38 -0.11 -1.11 0.13 0.20 0.62 0.21 -0.32 
RHIP 1.54 0.20 1.05 0.14 -0.55 -0.93 0.18 0.17 1.73 0.05 -0.89 
LTHA 2.10 0.12 0.83 0.20 -0.44 -1.53 0.07 0.28 1.74 0.06 -0.89 
RTHA 0.78 0.46 0.45 0.31 -0.24 -1.00 0.15 0.18 0.94 0.17 -0.48 
RCRBL45 0.62 0.53 0.68 0.22 -0.35 -0.58 0.27 0.11 1.13 0.13 -0.58 
RCRBL10 0.70 0.51 0.78 0.20 -0.41 -0.53 0.30 0.10 1.22 0.13 -0.62 
P<0.05 = * (uncorr) 
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Figure G ASSR time-frequency plots for power ROIs - Grouped according to CHR converters 
and  non-converters 
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Figure H 40 Hz ITPC data grouped according to psychosis conversion 
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